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 CHAPTER I 
 
INTRODUCTION 
 
The utilization of nanoscale tools in the development of clinically-relevant 
diagnostic assays and therapies, and the elucidation of complex biological mechanisms 
and mediators, will be facilitated by the development of surface engineering strategies 
which modulate cell and/or biomolecule-specific device targeting.  Nanoengineering of 
device interfaces permits the presentation of information at biologically-relevant length 
scales, and thus affords unprecedented control over various biomolecular interactions, 
such as ligand-receptor binding, opsonization, and cell-device contact.  Surface 
engineering strategies may also be applied to create nanodevices of enhanced 
functionality, via the construction of vehicles which permit the simultaneous packaging 
of multiple synthetic and biological materials with diverse physicochemical properties.    
This dissertation describes three diverse surface engineering strategies which are 
designed to expand the scope of application of nanotechnology in the imaging of cells 
and biomolecules in vitro and in vivo.  Targeting and multimodality are the two 
challenges in nanoscale surface engineering addressed.  Nanoscale surface modification 
technology was utilized to confer cell surface and intracellular substructure targeting 
capabilities upon nanostructures, and to facilitate multimodal nanotherapeutic and 
nanodiagnostic approaches.  These approaches were systematically evaluated in well-
characterized in vitro and in vivo models. 
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 The first Aim of this proposal was focused on the surface functionalization of 
quantum dot nanocrystals to enable multiplexed cellular and biomolecular detection in 
vivo with enhanced specificity.  In addition, cell subsets were internally-loaded with 
nanoparticulate imaging agents via a cell-penetrating peptide for the long-term tracking 
of cells in a mouse model of atherosclerosis ex vivo and in vivo.  In Aim 2, nanoscale 
various imaging agents and/or therapeutics were packaged together within a lipid matrix 
(solid lipid nanoparticles) to demonstrate the application of a novel multimodal 
nanocarrier for bioimaging and drug delivery applications.  Additionally, paracellular and 
subcellular translocation mechanisms of these solid lipid nanoparticles were investigated. 
 
Specific Aim 1: Develop surface engineering strategies for cell surface marker 
detection in vivo 
 
 
In this Aim, nanoparticle surfaces were engineered for the simultaneous color-
coded detection of multiple cell surface biomarkers within the same imaging specimen in 
vivo using fluorescence imaging.  Previous approaches to detect pathologically-
significant biomarkers in vivo have been impeded by rapid probe clearance, low signal to 
noise ratios, and an inability to simultaneously analyze multiple cell types and/or 
biomarkers within the same imaging session.  In this Aim, quantum dots (QD) were 
coated with engineered monoclonal Mab (Mab) and cell-penetrating peptide (CPP) 
coatings for the long-term multispectral imaging of cells and biomolecules ex vivo and in 
vivo with high targeting efficiency.  Mab conjugation was achieved by the use of a high 
molecular weight polyethylene glycol (PEG) bridge to evade physiological 
2
 nanoparticulate clearance mechanisms.  Furthermore, through biological and chemical 
modifications of the targeting Mab, specifically Fc-masking and PEGylation, Fc-
mediated probe clearance was reduced while maintaining high target specificity.  As a 
test bed for this application, cells and biomolecules involved in inflammation were 
targeted, and QD were used for spectrally-coding cell adhesion molecules (CAMs) and 
circulating neutrophils.  Imaging of inflammation is a technically-demanding task since 
nanoparticulate clearance mechanisms are pervasive and high-specificity imaging with 
low background is critical.  The specificity of QD-Mab was evaluated on isolated rat 
neutrophils and rat retinal endothelial cell cultures in vitro using fluorescence microscopy 
and flow cytometry.  The efficacy of this approach was evaluated in rat models of 
diabetes and ocular inflammation, using an in vivo fluorescence imaging system to detect 
multiple cell types and biomarkers with spectrally-distinct quantum dot fluorescence 
signatures, followed by ex vivo immunofluorescence correlation of in vivo observations.   
Following this application, quantum dot surfaces were then functionalized with a 
cell-penetrating peptide coating to enable its loading into cells ex vivo.  Loading cells 
with QD as opposed to labeling cell surface proteins may be preferable, as it potentially 
may enable long-term imaging of cells in vivo without membrane shedding of 
bioconjugates or perturbation of cell surface interactions.  This approach was utilized to 
investigate leukocyte subtype recruitment within lesions of the ApoE -/- atherosclerotic 
mouse model.   
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 Specific Aim 2: Develop entrapment-based surface engineering strategy to facilitate 
multimodal nanoparticulate applications  
 
 
Aim 2 was focused on the collective packaging of multiple synthetic and 
biological materials for the purpose of conferring multimodal functionality upon 
nanoscale carriers while concurrently conferring cell targeting capabilities.  
Multifunctional nanostructures have been sought after for designing combinative 
therapies, drugs with signal-emitting reporters, as well as cellular and biomolecular 
detection assays which exploit multiple imaging modalities.  In this Aim, a unique 
nanostructure referred to as functionalized multimodal solid lipid nanoparticles (SLN) 
was investigated for cell transport capabilities and efficacy as a multimodal carrier for 
bioimaging and drug delivery applications.  SLN consist of a biocompatible solid lipid 
matrix which during the nanoparticle synthesis process entraps materials of varying 
physicochemical properties, while bearing a variety of surface information on the SLN 
periphery.  This Aim was centered upon on the synthesis and characterization of SLN 
containing dyes, proteins, drugs, and the nanoparticulates iron oxide, gold, and QD.  Cell 
transport studies were conducted to determine if SLN have cell membrane translocation 
properties.         
4
 CHAPTER II 
 
BACKGROUND AND SIGNIFICANCE 
 
Potentials and Challenges of Nanoparticles for Medicine and Biology 
 
 The overall utility of nanotechnology in the detailed evaluation of biological 
mechanisms, as well the development of diagnostic and therapeutic tools in medicine, has 
yielded much enthusiasm.  In particular, the emergence of a variety of nanoparticles, 
often defined as objects with feature sizes below 100 nm, as well as techniques to 
modulate their surface properties, have enabled a number of applications in these fields.  
Successful applications of nanoscale surface engineering of nanoparticles in therapeutic 
development include liposomal and poly-lactide-co-glycolide (PLGA) formulations for 
targeted drug delivery and sustained drug release strategies (1-4), and the nanoscale 
surface modification of proteins for prolonged activity in vivo (5).  Superparamagnetic 
nanoparticles with biological coatings, such as dextrans, are already in clinical use as 
magnetic resonance contrast agents for the detection of a number of pathologies (6), and 
quantum dot nanocrystals have been utilized for a variety of studies in elucidating disease 
processes in vivo and in vitro, including cancer biology and cell signaling (7-10).  
Nanoparticle surfaces have been conjugated to receptor-specific ligands for the targeting 
of disease-specific cells, and with antibodies to detect proteins of interest, with the 
physicochemical properties of the nanoparticle permitting the monitoring of biology or 
disease using a number of analysis tools in medical imaging and molecular 
5
 characterization.  Collectively these applications are very promising and are primarily a 
consequence of decades of nanoscale surface engineering research and development.  
Further applications which extend the scope of such technologies are highly-desired and 
would yield valuable data concerning the pathogenesis, diagnosis, and/or treatment of 
disease, but will require additional nanoscale engineering advances over current 
techniques in order to be realized.   
 
Nanoscale Surface Modifications for Enhanced Cellular and Biomolecular 
Targeting: Proposed Work and Significance 
 
 
Three high-impact design challenges were addressed in this dissertation: high-
efficiency in vivo cell surface nanoparticulate targeting, intracellular delivery of 
nanoparticles, and strategies for the packaging of multifunctional nanoparticles.  In order 
to enhance the targeting specificity of nanoparticles to cell surface proteins, polymer and 
Mab biochemical modification techniques were employed to mask the nanoparticle from 
the immune system for long-term imaging, and to retain the antigen-binding affinity of 
the probe following ligand bioconjugation steps.  The objective of these strategies was to 
minimize nonspecific binding of the nanoparticle during the in vivo detection of 
molecular targets, so as to permit the real-time, simultaneous imaging of multiple 
biomarkers within the same imaging specimen, with low background or false-positive 
results.  The second challenge involved the translocation of nanoparticles across cell 
membranes.  By surface conjugation of the nanoparticle to cell penetrating peptides, the 
capability of loading nanoparticles within the cytoplasm was the objective.  This enabled 
tracking of cells in vivo or ex vivo without perturbing cell surface protein interactions 
6
 required for cell function, and also enhanced long-term imaging applications, since QD-
mAb conjugates could get dislodged from the cell surface due to routine cell surface 
protein shedding.  To address the third challenge, a general process was designed 
employing biocompatible functionalized solid lipids for constructing multifunctional 
nanoparticles containing diagnostic and therapeutic reagents for the delivery of drugs and 
bioimaging using diverse modalities (e.g. electron microscopy, fluorescence imaging, x-
ray).  The general aim of this strategy was to provide a targeted nanoparticle for usage in 
medicine and biology which permits extensive use of instrumentation while 
simultaneously permitting registration of the same biological target between each 
modality, while also potentially functioning as a biocompatible drug delivery device.                  
Three diverse schemes were proposed to address each nanoparticle surface 
engineering design problem, with the understanding that they could potentially be utilized 
not as individual approaches but in combination, and not explicitly using the prototype 
nanoparticles used for testing, but rather various classes and combinations of 
nanoparticles.   
 
Background and Significance: Aim 1- Develop surface engineering strategies for cell 
surface marker detection in vivo: Quantum Dot-Based, Multiplexed In Vivo Studies 
of Vascular Biomarker Expression and Leukocyte Trafficking in Inflammation 
 
 
Rationale 
It has become increasingly important in biology and medicine to consider the 
relative contribution of multiple cellular and molecular mediators to critical processes, 
such as angiogenesis and cancer progression, as opposed to traditional studies which 
7
 focused primarily on analyzing such mediators in singlet, or in a vacuum.  In order to 
simultaneously-monitor multiple participants in disease and other biological processes, 
molecular probes with near-absolute specificity, high signal to background ratios, and 
highly-distinct emission spectra (i.e. between molecular probes) must be developed.  
Quantum dot nanocrystals (QD) offer these potential features; their high fluorescence 
emission intensities, size-tunable emission spectra, and amenability to surface 
bioconjugation of ligands provide a means for simultaneously monitoring the expression 
of multiple biomarkers and/or cell subtypes via optical imaging.  However, in order to 
harness these superior optical properties, QD, as with other nanoparticles, must be 
carefully nanoengineered for maximum targeting efficiency.  The study of mediators of 
inflammation is an appropriate application for optimizing QD surface engineering 
strategies, as the cell types being targeted (e.g. macrophages, endothelial cells) are often 
problematic sites for nonspecific probe uptake.  In Aim 1 nanoparticulate masking 
strategies will be utilized which maximize target binding efficiency while reducing 
nonspecific clearance of the probe.    
 
Rationale for Multiplexed Imaging of Cellular and Biomolecular Mediators of 
Inflammation 
 
 
Undesirable provocation of the inflammatory response is a detrimental feature of 
numerous diseases such as diabetes, multiple sclerosis, atherosclerosis, and asthma (11-
13) and thus impacts a significant population.  Inflammation is a complex process 
involving numerous cell types and surface proteins characterized by leukocyte rolling and 
8
 tethering along endothelial cells followed by transmigration into tissue.  Treatment of 
inflammation-associated diseases can be challenging due to the fact that the extent and 
type of inflammation in each case can vary considerably. For example, the leukocyte 
subsets present, the molecular mediators participating in adhesion and emigration, and 
the resulting effects on tissue all vary with the type of inflammation.  Conventional 
therapies administered as anti-inflammatory measures such as non-steroidal anti-
inflammatory drugs (NSAIDs) and corticosteroids have mixed results in the clinic and are 
often characterized by significant side-effects. In light of the limitations of these 
generalized approaches, specifically-targeted therapeutic measures in development intend 
to inhibit key molecules to prevent transendothelial migration of leukocytes.  While not 
all specifically-targeted therapies have had equal success, those directed towards well-
studied molecules, such as Remicade (infliximab) which targets tissue necrosis factor 
(TNF) in Crohn’s disease and rheumatoid arthritis, have shown promising clinical 
efficacy in patients responding poorly to conventional regimens (10, 14).  It can be 
inferred that the success of clinical diagnostic procedures and therapeutic strategies 
which employ this molecular level approach is contingent upon a detailed understanding 
of the mechanisms and mediators involved in specific inflammatory processes.   
 
Current in vitro and ex vivo cellular and molecular profiling tools 
 
Decades of research in the pathogenesis of inflammatory disease have identified 
leukocyte subsets and their general functions, cell adhesion molecules (CAMs), and other 
protein families critical in the inflammatory cascade.  Biological assays used to elucidate 
9
 cellular and molecular function in inflammation include blotting techniques, which detect 
proteins, RNA, or DNA presence within a biological sample, and flow cytometry, a 
quantitative technique utilized to probe molecular expression, cell cycle phase and 
viability of cells.  Immunohistochemistry can be utilized to visualize a protein of interest 
in tissue sections.  Valuable information about the expression profiles and roles of 
proteins in inflammation have been extracted from experiments which use these assays.  
However, for many of these observations, in vivo corroboration has not been obtained.  
A second limitation of these approaches is that they provide endpoint data only. It 
is often necessary to culture cells, fix them and analyze each cell sample at a number of 
different time points.  However, real-time spatial and temporal information concerning 
these proteins is very difficult to obtain.  This data could be potentially valuable in 
determining if the co-expression of one protein next to another enhances its activity, or 
how the pattern of molecular expression cycles through the progression of a disease or in 
response to drug interventions.  In addition, such assays often involve complex isolation 
procedures.  Some cell cultures are sensitive or very difficult to maintain in vitro, which 
adds difficulty in analyzing a biomarker over a time course of days or weeks.  Standard 
flow cytometry is a powerful quantitative tool, and while it can be used to provide 
valuable information, such as an estimate of the number of particular receptors on a 
single cell, this analysis is performed using cells separated from the circulatory 
environment.  Thus, in vitro techniques may provide a means of generating hypotheses 
for in vivo function, but it is necessary that some in vivo technique be performed to 
validate the in vitro findings.   
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 Current in vivo cellular and molecular imaging tools 
 
The current understanding of the principal molecular and cellular players involved 
in inflammation is summarized in Figure 1. Given the above limitations with in vitro 
assays, several attempts to probe in vivo cellular and molecular activities in inflammation 
have been reported.  Radiolabeled monoclonal antibodies to ICAM-1 and VCAM-1 were 
administered in vivo (16, 17). While this represents an important step in multiplexed 
analysis of inflammatory markers, in order to assess Mab binding at the different 
timepoints, corrections due to background signal needed to be performed to estimate 
specific antigenic signal.  In addition to the signal to noise issues, these studies required 
compensations in signal calculations in order to distinguish each signal and minimize 
contributions from unbound Mab.  The spatial and temporal resolution of these 
radiolabeled Mab techniques are too limited for detailed studies of leukocyte-endothelial 
dynamics in inflammation.   
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Figure 1. Major inflammatory biomarkers and their   
functions (15). 
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 A technique with the spatial and temporal resolution to capture leukocyte motility 
through the circulation was established by Nishiwaki and colleagues using the fluorescent 
DNA-intercalating dye acridine orange (AO) in conjunction with scanning laser 
ophthalmoscopy (SLO) (18).  While spatial and temporal resolution is adequate, AO is 
internalized by all nucleated cells in the circulation.  Thus, endothelial cells and all 
leukocyte subsets fluoresce with AO signal, presenting a challenge in determining cell 
adhesions, and making it impossible to probe molecular expression.  Furthermore, AO is 
phototoxic to lysosomes and a suspected carcinogen (19), has a low quantum efficiency, 
and is prone to fading and cell washout.  Thus, this technique is not appropriate for in 
vivo imaging applications where multiple species are to be detected or for long periods of 
time.  Nevertheless, it is the most common method of observing labeled leukocytes in the 
circulation for determination of extravasation and velocity.   
A third method has been used to characterize VCAM-1 expression in vivo using 
multimodal fluorescent Cy5.5-conjugated Mab and peptide conjugates by Weissleder and 
colleagues (20, 21).  Both conjugates, most notably the peptide conjugates, exhibited a 
high affinity for VCAM-1 in both intravital confocal microscopy and magnetic resonance 
studies on atherosclerotic lesions and in TNF-α induced inflamed murine ear.  While this 
method is a significant achievement in the development of in vivo molecular profiling 
techniques, its utility in multispecies real-time imaging applications may be limited.  
First, one of the applications was hampered by nonspecific IgG control Mab uptake at 
certain time periods in inflamed murine ear, thus calling into question the specificity of 
the Mab-based technique.  While the peptide-Cy5.5 conjugate was specifically taken up 
by the cells, performing the same technique for detection of other biomarkers would 
13
 require time-consuming phage display rounds which may not yield suitable, specific 
candidates.  In addition, while the use of a magnetic resonance contrast-enhancing probe 
in detecting VCAM-1 may be a useful tool for whole-body detection applications, its 
potential in applications requiring the detection of multiple proteins is limited to available 
contrast agents.  Also, the use of cross-linked iron oxide nanoparticles (CLIO) has been 
associated with aggregation problems (22), which could limit their in vivo utility, as 
nonspecific signal may be detected by aggregation of nearby conjugates.  The dye Cy5.5 
was used to detect VCAM-1 using fluorescence imaging which opens the possibility of 
this technique for monitoring multiple proteins. However, as in the radiolabeled Mab 
technique, different conjugates would be required to detect other proteins, which would 
necessitate an additional excitation laser for each fluorophore.  In addition, organic dyes 
can often have spectrally-overlapping characteristics making specific detection without 
noise a challenge. 
 
A QD-based in vivo imaging technique for the simultaneous detection of cellular 
and molecular inflammatory mediators 
 
 
 The proposed design differs from previous in vivo approaches to study 
inflammation primarily by the harnessing of unique QD optical properties, as well as 
novel surface engineering strategies which are aimed toward enhancing QD targeting 
efficiency.  QD-Mab conjugates are used to specifically label molecular targets in vivo.  
QDs, or semiconducting nanocrystals, with their nanoscale size providing a quantum 
confinement effect, are the only tracers which can make a multi-spectral imaging system 
achievable.  These properties include higher quantum efficiency relative to conventional 
14
 dyes, resistance to fading, narrow and size-tunable emission spectra excitable by only one 
wavelength, and amenability to surface engineering of proteins and polymers for 
optimum stability and targeting (23).  No conventional fluorescent probes currently 
implemented in in vivo imaging techniques are capable of exhibiting all of these features. 
 Current techniques used to observe detailed cellular and molecular interactions in 
inflammation are not suitable for imaging multiple cell types, concurrently with multiple 
proteins, continuously in real-time with sufficient spatial and temporal resolution.  A QD-
based in vivo retinal fluorescence imaging technique has been designed which will enable 
noninvasive studies of dynamic leukocyte-endothelial interactions and molecular 
expression at high sensitivities and signal to noise ratios.  This multispectral approach 
will allow the in vivo distinction of up to four different cell types or proteins in the same 
imaging specimen at sub-micron resolutions.  Continuous imaging at millisecond 
intervals will be performed to capture high-velocity cell motility through major vessels as 
well as the microcirculation.   
 Size-tunable QD nanocrystals will be used to specifically-label multiple proteins 
expressed on leukocytes or endothelial cells.  It is possible to detect each protein 
simultaneously in the retinal circulation due to the distinct spectral signatures encoded by 
the QD bioconjugates.  QD emission peaks are narrow and intense, minimizing spectral 
overlap while exhibiting high signal to background ratios.  QDs are amenable to 
conjugation of antibodies or peptides to their surface, as well as surface engineering of 
polymers designed to stabilize them or improve bioconjugation efficiency(24).  Only one 
excitation source is necessary to visualize all nanocrystals, in contrast to methods using 
fluorophores which require a separate excitation wavelength for each fluorophore.   
15
  The proposed retinal imaging approach is based on an inverted fluorescence 
microscope equipped with xenon flashlamp and metal halide excitation lamps.  This 
apparatus was originally developed as part of an optical technique to track vascular 
permeability changes in the retina (25).  This technique has been used to track acridine 
orange labeled leukocytes in a rat retina.  An example of a video frame from one of these 
sequences is shown in Figure 2.  In this frame the moving AO labeled cells are captured 
as well-defined white dots (arrows) by the 4 ms flashlamp illumination.  These results 
suggested that this platform in combination with brighter, specific probes would enable 
us to noninvasively monitor cells and proteins in inflammatory disease in the retina.   
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Figure 2. In vivo tracking of acridine orange labeled 
cells (arrows) in a rat retina illuminated with a 
flashlamp. 
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 Nanoparticulate surface engineering strategies for enhanced in vivo half-life and 
targeting specificity: PEGylation, site-specific bioconjugation of proteins, and Mab 
fragmentation 
 
 
 
 The success of this quantum dot-based multispectral imaging approach is highly-
dependent on the probe’s affinity and specificity for the target of interest.  In utilizing 
quantum dots or other nanoparticles for the in vivo detection of cells and biomolecules in 
disease, several physiological factors must be addressed in surface engineering processes.  
First, the body has several tissues, primarily the liver and spleen, which actively retain 
nanoparticles as part of their role in the reticuloendothelial system (RES) (22, 26).  The 
major nanoparticulate modification employed to evade RES uptake for as long as 
possible has been PEGylation.  Polyethylene glycol (PEG) is well-known for its ability to 
diminish nanocarrier clearance by the reticuloendothelial system and inhibiting protein 
surface adsorption.  This is a consequence of the hydrophilic exclusion volume exerted 
by the freely mobile polymer chain of the carrier surface.  This is analogous to having a 
surface whereby a hydrophilic tail whips several angstroms from side to side, essentially 
whipping away hydrophobic molecules which might normally bind to the surface, an 
occurrence which might induce immune clearance via opsonization.  This strategy has 
been recently utilized for the protection of therapeutic proteins, as reinforced by the 
increasing number of PEGylated drugs in the clinic, such as PEGASYS (interferon alfa-
2b, Roche) and Exubera (inhaled insulin, Pfizer).  In addition, PEGylation has been 
reported to reduce nonspecific binding of quantum dot nanocrystals to cell surfaces in 
vitro (27), and more importantly, to reduce RES uptake in vivo (26, 28).  
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  The next challenge to be considered when designing a nanoparticulate targeting 
system in vivo involves the development of a surface modification strategy which retains 
the full functionality of the targeting moiety.  In many targeting paradigms, the surface 
ligand may be a biomolecule which is not recognized as foreign by the body, such as 
folate and transferrin.  However, in a large fraction of nanoparticulate targeting methods, 
antibodies, primarily immunoglobulin G (IgG) proteins are employed.  Whole IgG 
contain two F(ab) regions, which contain the antigen-binding site, as well as a Fc 
fragment, a species-conserved sequence which is responsible for immune recognition of 
the Mab.  Fc-mediated opsonization and clearance through phagocytes with Fc receptors, 
such as macrophages, are potential sources of nanoparticulate clearance as well, unless 
the Fc fragment can be shielded from such recognition.  Two general methods have been 
reported which aim to combat this clearance mechanism; however, it must be noted that 
these studies have only examined Mab clearance itself, rather than nanoparticle-Mab 
complex clearance.  The first method is to enzymatically-digest the IgG molecule at a 
specific site, so as to separate the active F(ab) or F(ab)2 fragment from the Fc fragment, 
as can be accomplished with pepsin or papain/ficin, respectively (5, 29, 30).  By utilizing 
digestion schemes that yield a divalent (F(ab)2) Mab fragment, a higher affinity Mab is 
derived relative to the monovalent (F(ab)) form.  However, if the Mab is to be covalently 
cross-linked to nanoparticle surfaces, a significant problem further compromising Mab 
affinity would result by conjugating the F(ab)2 form.  Nanoparticles are cross-linked to 
antibodies (whether in their fragmented or whole form) using amine residues, which are 
usually critical for antigen-binding activity.  When the Mab to be conjugated to a 
nanoparticle is in its whole (Fc + F(ab)2) form, antibodies which are cross-linked via the 
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 Fc region (which contains many lysine amino acids bearing amine groups) maintain their 
antigen-binding affinity (i.e. antigen-binding region amines are not modified).  However, 
if the Fc fragment is absent, then there is no alternative but to cross-link amines used for 
antigen-binding to the nanoparticle.  Nonspecific amine-cross-linking has thus been 
implicated in the loss of function of antibodies, especially in the case of Mab F(ab)2 
conjugation (5, 31).  In contrast, the F(ab) fragmentation reaction (using pepsin) is 
capable of yielding an Mab fragment without an Fc region which bears a single, site-
specific unpaired cysteine residue (normally used to link F(ab) fragments by disulfide 
bridges) (29).  This residue is often the only cysteine in the entire IgG, and is located in 
the hinge region of the Mab which is not involved in antigen-binding.  Using specific 
sulfhydryl-reactive chemistries, nanoparticles can be site-specifically conjugated to F(ab), 
such that Fc-mediated nanoparticulate clearance is eliminated, and antigen-binding 
affinity of the F(ab) is not obliterated by nonspecific amine chemistries as in the divalent 
case.  However, as a result of this tradeoff for site-specific conjugation (to avoid 
nanoparticle cross-linking induced deactivation of the Mab), only the inherently lower 
affinity, monovalent form of Mab is attached on the nanoparticle surface.  A final 
concern with this first method of Mab engineering is that enzymatic digestion of 
antibodies is a complex process, with the procedure being significantly sensitive to the 
host species of the Mab.  For example, Mouse IgG subclass 2 antibodies can be digested 
by papain, whereas IgG subclass 1 antibodies do not cleave sufficiently in response to the 
enzyme, requiring a completely different enzyme, ficin (Pierce, Rockland, IL), to 
accomplish the task.  Empirical testing of optimal procedures for each Mab can be very 
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 costly and time-consuming, and there is no guarantee of successful, high-efficiency 
digestion.     
To circumvent the various problems brought by Mab fragmentation techniques, 
recombinant protein engineering strategies have emerged recently, whereby vectors are 
engineered to generate Mab fragments with site-specific linker sites (31, 32).  
Furthermore, by utilization of PEG linkers with divalent cysteine-reactive arms, Mab 
fragments (specifically scFv, or single-chain Mab fragments) can be “glued” together to 
create an Mab construct with similar affinity to a F(ab)2.  While this may be an optimal 
method for the site-specific PEGylation of antibodies for prolonged circulation time with 
preserved target affinity, it has not been applied to nanoparticulate surface engineering, 
nor is it clear that such a strategy could be applied without extensive optimization.  
Furthermore, Mab production using this strategy would be potentially very time-
consuming and costly, especially in the case where multiple such antibodies were to be 
produced. 
In Aim 1 a strategy for masking the Fc region of the Mab will be tested, by 
adsorbing Fc-specific F(ab)2 fragments to the QD-Mab surfaces.  We hypothesize that the 
steric hindrance imposed by the Fc-blocking Mab would inhibit Fc-mediated clearance 
mechanisms in the body, such as complement fixation and Fc receptor binding.  Should 
this strategy prove successful in reducing nanoparticulate clearance, it would constitute a 
time-saving, inexpensive Mab engineering method that could be applied to nanoparticle-
Mab constructs and antibodies alike to reduce immune reactions for improved in vivo 
targeting.       
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 Advantages and potential applications of QD-based retinal imaging platform 
 
 The unique features of this technique are high signal intensity, the ability to 
noninvasively detect both cells and cell surface markers simultaneously in vivo with high 
spatial and temporal resolution, the need for only one excitation source in the visible 
spectrum, and the optical accessibility to perform continuous imaging for the collection 
of real-time data.  Currently, no other system currently available has combined all of 
these features for in vivo imaging applications.  In addition, the surface engineering 
strategies proposed in Aim 1 are likely to enhance the specificity of the circulating 
bioconjugates, thus minimizing noise, and due to the engineering of site-specific cross-
linking sites on the Mab, the QD probes should have very high affinity for their epitopes.      
The capability to image multiple proteins and cells simultaneously on any time 
scale with striking clarity would be a major advancement in the field of in vivo molecular 
imaging.  Specifically, the utility of this approach will become increasingly important in 
the design of diagnostic assays and therapeutic strategies, in which the monitoring and/or 
targeting of multiple suspected mediators of inflammation is critical to an improved 
prognosis.  In addition to elucidating the key cells and proteins in inflammation, this 
strategy certainly can be extended, for example, to the tracking of homing precursor cells 
and proteins in angiogenesis, for which the corneal pocket is a widely-accepted model 
(33), as well as molecular profiling in a number of ocular diseases ranging from 
glaucoma, macular degeneration, and diabetic retinopathy, devastating diseases which 
impact a large population and necessitate in vivo therapeutic targets and early diagnostic 
indicators.  Flow cytometric analysis of any circulating cell type via microscopic analysis 
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 of the retinal circulation is feasible with this technology, which might facilitate the 
development of imaging applications which seek out circulating metastatic cells to 
monitor tumor progression.   
From a surface engineering standpoint, it is likely that Mab engineering would be 
equally effective with other classes of Mab-conjugated nanoparticles, such as gold 
nanoparticles for ablative targeting of diseased tissue, iron oxide nanoparticles for cancer 
imaging, or Mab-conjugated liposomes.  The PEGylation chemistry is also readily 
applied to most nanoparticles which are to be employed for in vivo targeting; in addition, 
even non-targeted nanoparticles used for vascular imaging, or for passive tumor 
accumulation in drug delivery applications employing passive retention in the leaky 
vasculature which supplies it, would most likely benefit from increased circulation time 
for prolonged velocity calculations or maximal drug retention, for example.         
 
Background and Significance: Aim 2 - Develop entrapment-based surface 
engineering strategy to facilitate multimodal nanoparticulate applications: Solid 
Lipid Nanoparticles for Bioimaging and Drug Delivery 
 
 
Rationale 
 
Given the novel properties conferred upon nanoscale devices of unimodal 
functionality, it has quickly become relevant that composite structures consisting of 
nanoparticulates of various functionalities can be delivered within the same package, 
given the proper surface engineering strategy.  Multimodal nanoscale devices would 
permit the usage of multiple imaging modalities in biology and medicine to extensively 
characterize disease processes with the feature of co-registration, for example, by using in 
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 vivo MRI in conjunction with fluorescence microscopy in histological analysis to 
correlate with in vivo findings.  By packaging diagnostic and therapeutic reagents within 
the same vehicle, detailed pharmacokinetic and pharmacodynamic studies would also be 
enabled, for example, by conducting biodistribution studies of candidate drugs as 
assessed by optical or magnetic resonance reporter nanoparticles.      
 The suitable multimodal nanoparticle platform would consist of a biocompatible, 
well-tolerated biomaterial, either natural or synthetic, which is amenable to the 
encapsulation or entrapment of nanoscale compounds of varying physical and chemical 
properties.  Specifically, the carrier, whether having a hollow core and membranous 
bilayer, as liposomes, or having a glassy, porous interior, such as some polymeric 
structures, should ideally be capable of bearing hydrophobic and hydrophilic, charged or 
neutral, or high (MDa) and low molecular weight (>500 Da) compounds.  While the 
internal modularity must be accommodating, equally important is the nanoparticle 
surface.  By surface-tuning the nanoparticle surface with bioactive ligands such as 
targeting antibodies or CPPs, the ultrafunctional construct would behave as one 
nanoparticle in a biological environment.  Should the carrier be capable of holding 
multiple encapsulated probes, high signal to noise ratio imaging and the delivery of 
therapies with maximum treatment efficiency can be carried out relative to single 
nanoparticles.   
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 Current Techniques for the Design of Multimodal Nanoparticles 
 
  The first multimodal applications utilizing nanoparticles generally consisted of 
single probes bearing dual functionalities, an example being gold nanoshells, the 
thickness and core radius of which can be tuned to scatter and absorb photons at distinct 
NIR-range wavelengths for deep tissue penetration.  This feature, combined with the 
engineering of bioactive functionalities on the nanoshell surface, together form a HER2-
targeted, photothermosensitive optical contrast agent(34-36).  A number of multimodal 
strategies are in development by specialized drug delivery companies, utilizing pumps, 
microchips, and various biosensors (ALZA, Epic Therapeutics, Emisphere Technology, 
Alkermes).  Recent device innovations for bioimaging and drug delivery reported in the 
literature attest to the high efficacy of multimodal approaches.  Liposomes were 
engineered to bear both quantum dots and the T1 magnetic resonance contrast agent 
Gadolinium for dual-modality imaging at levels sufficient to detect tumor angiogenesis 
(37, 38).  In a magnetooptical nanoparticulate application, Cy5 dye conjugated with 
dextran cross-linked iron oxide nanoparticles were utilized to detect atherosclerotic 
plaques via inflammatory biomarkers, using both MRI and in vivo optical imaging(20, 
21).  In an innovative combinative therapeutic approach for combating tumors, an anti-
angiogenic agent was layered above a sustained release chemotherapeutic agent to 
achieve a temporally-controlled “nanocell (39).”  Thus, both lipid-based and polymeric-
based approaches have been demonstrated to be promising platforms for multimodal 
systems, in addition to biologically (e.g. dextran)- engineered approaches.   
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 Solid Lipid Nanoparticle-Based Multimodal Nanoparticles: Potential Advantages 
 
 The aforementioned works are only a few examples demonstrating the diversity 
of multimodal approaches that are possible for detailed studies of biological processes 
and disease in living systems.  However, as this field is in its infancy, there are as 
expected some drawbacks which require consideration should this area progress further 
in potential.  First, many multimodal approaches seek to complex only a few 
nanoparticles together, to create bimodal point sources, such as Cy5-iron oxide 
nanoparticle constructs (21).  While initial studies demonstrate that signal output is 
sufficient for the detection of disease in animal models, an approach adapted for hi-
fidelity imaging of disease in humans might benefit from a multimodal carrier engineered 
to bear multiple cargoes, perhaps 10-100 nanoparticles within one carrier.  Indeed, in the 
case of T2 relaxing agents, a high density of the reagent at the target site would provide 
excellent signal over background, a welcome advantage for the detection of 
hepatocellular carcinomas for which the nanoparticle is currently utilized (40).  In 
addition, it is important to consider a major common denominator of the aforementioned 
nanoparticulate systems which hinder their transition from laboratory testing to clinical 
implementation: regulatory issues and potential for scaling-up of production.  For 
example, PLGA nanoparticles, recalling their ability to be internalized nonspecifically 
into endosomes followed by triggered escape, have the potential to degrade within cell 
bodies, a process which due to the carrier alone has been associated with cytotoxicity.  
Furthermore, it has been a highly-difficult task to scale up PLGA nanoparticle production 
lines, thus limiting this polymer application to biomedical implants, such as Zoladex, as 
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 well as large microparticulate forms which are too large for intracellular transport.  In 
addition to regulatory concerns and production difficulties is the issue of cost.  
Liposomes, for example, are very expensive to make, a fact which hinders the majority of 
candidate liposomal formulations in the pharmaceutical industry.  As individual 
liposomal formulations are costly, it is unlikely that production of liposomes bearing 
multiple cargoes would be economically feasible, unless it posed a very high-impact 
detection and/or treatment reagent.  A major contributor to the cost of nanoparticulates 
like these involve the time-consuming steps and multiple resources required for synthesis.  
Evaporation, cooling, centrifugation, emulsion, and mixing steps to generate pure 
nanoparticles with acceptable loading efficiencies can be tedious and are not only costly 
but add to the challenge of scaling-up production.  Next, while each nanoparticulate 
system has its own advantages supporting their potential candidacy for multimodal 
systems, there are still a host of disadvantages when evaluating the physicochemical 
properties of the carriers themselves.  PLGA, for instance, has been associated with 
intraparticle cargo degradation, due to the internal acidic environment created by ester 
hydrolysis of the polymer surface, as demonstrated with a drop in fluorescence of FITC-
Albumin with PLGA microspheres (41).  Liposomes are associated with a variety of 
physical stability issues, making long-term storage and regular drug administration a 
challenge.  While there are countless potential applications of liposomal formulations in 
the literature, the expectations have clearly not matched its potential, having been first 
invented in 1913 and the main focus of hundreds of R&D funding initiatives. 
 In light of these observations, a nanoparticulate system for the development of 
multimodal systems for bioimaging and drug delivery for the purpose of enhanced 
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 cellular/biomolecular detection should ideally have the following characteristics: 
potential for scale-up of production, a capacity to accommodate compounds of varying 
physicochemical properties (size, charge, solubility, e.g.), amenability to presentation of 
multiple surface functionalities (polymers, ligands, etc.), should be a solid candidate for 
regulatory agency approval by using GRAS (generally recognized as safe) standards 
among others, and lastly, should be as stable as possible under varying storage conditions 
and administration regimens (intravenous, intraocular, etc.).   
 The hypothesis of Aim 2 is that an approach not described for multimodal 
nanomedical or nanobiological systems, dubbed functionalized solid lipid nanoparticles 
(fSLN), is a solid starting material strategy which could address some or all of the 
expectations for a successful multifunctional system.  A class of solid lipids were 
identified which could be formulated into nanoparticles ranging in average size from 35-
800nm depending on process parameters.  Nanoparticulate formation is accomplished by 
the solvent-assisted formation of a microemulsion.  The solid lipid, a dry pellet, is 
dissolved with a solvent composition of tunable polarity, such that the affinity of this 
organic solution for water is adjusted.  Upon the addition of an aqueous phase to the 
solvent mixture, the hydrophobic packing of the lipid upon exposure to water provides 
for instantaneous formation of a nanoscale particle, the size of which is determined by 
solvent polarity.  Higher solvent polarity permits rapid phase inversion as water 
miscibility is higher, whereas lower solvent polarity likely extends the nanoparticle 
packing time, allowing for larger-sized nanoparticles to form.  The instantaneous lipid 
packing which occurs upon organic-aqueous phase inversion is thought to readily entrap 
any species dissolved in either phase.       
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 Summary 
 
The three surface engineering strategies proposed here represent an investigation 
into the improvement of nanoparticulate probe functionality, to facilitate the development 
of diverse and powerful applications in biology and medicine.  The dissertation focused 
specifically on two challenging problems, the enhancement of nanoscale device in vivo 
targeting, and the development of multifunctional devices.  The result of this research 
was a framework enabling nanodevice targeting to specific destinations within tissues or 
cells, for the purpose of high-resolution bioimaging using multiple imaging modalities. 
 The first manuscript describes efforts to perform multiplexed in vivo retinal 
vascular imaging using quantum dots functionalized with modified, Fc-blocked 
antibodies, in rat models of diabetes and ocular inflammation.  This work was published 
in Bioconjugate Chemistry in Fall 2007 (42).  The second manuscript extends the strategy 
of using quantum dots to image multiple cell types in pathology by incorporating cell-
penetrating peptide-coated quantum dot nanocrystals to image monocytes and T 
lymphocyte recruitment to atherosclerotic lesions.  This work was submitted to the 
Journal of Lipid Research in April 2008.  Chapters V and VI describe the synthesis and 
characterization of solid lipid nanoparticles (SLN), unique endothelial barrier 
translocation properties conferred upon SLN via surface engineering, and cell membrane 
translocation properties of multimodal SLN constructs.  Chapter V was published in 
IEEE Transactions on NanoBioscience in March 2008 (43). 
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 Abstract  
Quantum dot-antibody bioconjugates (QD-mAb) were synthesized incorporating 
PEG crosslinkers and Fc-shielding mAb fragments to increase in vivo circulation times 
and targeting efficiency.  Microscopy of endothelial cell cultures incubated with QD-
mAb directed against cell adhesion molecules (CAMs), when shielded to reduce Fc-
mediated interactions, were more specific for their molecular targets.  In vitro flow 
cytometry indicated that surface engineered QD-mAb were capable of labeling leukocyte 
subsets with minimal Fc-mediated binding.  Nontargeted QD-mAb nanoparticles with Fc-
blockade featured 64% (endothelial cells) and 53% (leukocytes) lower nonspecific 
binding than non Fc-blocked nanoparticles.  Spectrally-distinct QD-mAb targeted to the 
cell adhesion molecules (CAMs) PECAM-1, ICAM-1, and VCAM-1 on the retinal 
endothelium in a rat model of diabetes were imaged in vivo using fluorescence 
angiography.  Endogenously-labeled circulating and adherent leukocyte subsets were 
imaged in rat models of diabetes and uveitis using QD-mAb targeted to RP-1 and CD45.  
Diabetic rats exhibited increased fluorescence in the retinal vasculature from QD 
bioconjugates to ICAM-1 and VCAM-1 but not PECAM-1.  Both animal models 
exhibited leukocyte rolling and leukostasis in capillaries.  Examination of retinal whole-
mounts prepared after in vivo imaging confirmed the fluorescence patterns seen in vivo.  
Comparison of the timecourse of retinal fluorescence from Fc-shielded and non-Fc-
shielded bioconjugates indicated nonspecific uptake and increased clearance of the non-
Fc-shielded QD-mAb.  This combination of QD surface design elements offers a 
promising new in vivo approach to specifically label vascular cells and biomolecules of 
interest. 
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 Introduction 
 
Inflammation is a complex process involving numerous cell types and surface 
proteins.  It is characterized by leukocyte rolling and tethering along endothelial cells 
followed by transmigration into tissue, where their immunodefensive functions, such as 
phagocytosis, are elicited (1, 2).  Undesirable provocation of the inflammatory response 
is thought to be a detrimental feature of numerous diseases such as diabetes, 
atherosclerosis, and asthma (3-6).  Treatment of inflammatory disease is challenging due 
to uncertainties associated with the roles of many of the cellular and biomolecular 
mediators.  However, one developing strategy hinders inflammation by blockade of cell 
surface receptors either on the endothelium or on circulating leukocytes (7-9). 
Detailed information about molecular mediators of inflammation might be 
acquired through in vivo imaging methods, since they can provide real-time data 
concerning the spatial and temporal dynamics of cellular activities and molecular 
expression throughout the time course of the disease.  However, disadvantages of current 
imaging techniques include limited optical accessibility to tissue, invasiveness (10, 11), 
low or unstable signal intensity due to the use of organic fluorophores (12-14), or low 
spatial and temporal resolution achieved by the use of radiolabeled antibodies (15).  No 
available technique provides a framework for the simultaneous imaging of multiple 
molecular participants on moving leukocytes and stationary endothelium and leukocytes 
in real time.   
Imaging inflammation is a difficult task, as the cell types of interest have one or 
more of the Fcγ receptor family (CD16, CD32, and CD64) which bind to Fc fragments of 
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 Immunoglobulin G (IgG) antibodies with variable affinity (16).  Binding of bioconjugates 
to these receptors can yield false-positive results when attempting to detect vascular cell 
surface targets.  In addition, it is well-known that nanoparticulate probes are subject to 
rapid uptake by the tissues of the reticuloendothelial system, such as liver and spleen 
(17).  These immunodefensive mechanisms either serve to rapidly clear the probe from 
the circulation, or to nonspecifically bind the probe.  However, the many advantages 
afforded by nanoparticles as bioconjugates, particularly quantum dots (QD), which 
feature size-tunable visible-IR emission spectra, the need for only one excitation source, 
and high quantum efficiency, warrant new methods to facilitate their continued 
application (18, 19).  Recent work has indicated that the surface functionalization of PEG 
chains on the quantum dot surface can substantially reduce nonspecificity and clearance 
problems (20, 21).  In addition, many studies have established QD amenability to 
bioconjugation and ease of encapsulation in water-soluble coatings (22), and its 
incorporation within targeted in vivo imaging applications (20, 23, 24).    
In this study, we selected spectrally-distinct quantum dot (QD) nanocrystals to 
enable high-resolution, multispecies imaging using a previously developed, non-invasive 
in vivo retinal vascular imaging system (25).  In this application, which pursues the 
detection of vascular targets, mitigation of nonspecific uptake and clearance mechanisms 
are essential.  To address this, monoclonal antibodies (mAb) targeting leukocytes, 
neutrophils (26) or the cell adhesion molecules PECAM-1, ICAM-1, and VCAM-1 were 
site-specifically conjugated to PEG-Maleimide-activated QD surfaces via 2-MEA to 
preserve mAb orientation and binding affinity (27).  QD-mAb were then adsorbed with 
Fc-blocking F(ab)2 fragments to reduce nonspecific immunorecognition.  When 
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 incubated with endothelial cells or leukocytes in vitro, the shielded probes were found to 
be more specific for their targets relative to controls.  In vivo retinal imaging of 
streptozotocin (STZ)-treated diabetic rats using QD-mAb revealed upregulation of 
ICAM-1 and VCAM-1 but not PECAM-1.  Imaging of a rat model of Endotoxin-Induced 
Uveitis (EIU) showed the expected increase in stagnant leukocytes in the 
microcirculation.  The high photostability of QD permitted post-experimental histological 
observations which confirmed the in vivo results.  Real-time imaging of QD-IgG1 
conjugates indicated rapid clearance of conjugates lacking Fc-blocking F(ab)2 fragments 
from the circulation.  The distinct spectral emission characteristics of the QD enabled the 
simultaneous imaging of up to four biomarkers or cell types within the same animal with 
high specificity.   
 
Experimental Procedures 
 
Synthesis and Characterization of Shielded Quantum Dot-Antibody Conjugates 
 QD nanocrystals with approximately 80 NH2 groups/nanoparticle (ITK-NH2, 
Invitrogen Corp.) were surface-functionalized with a heterobifunctional PEG-based 
cross-linker (NHS-PEG-MAL, Nektar Therapeutics) to couple reduced antibodies to the 
surface, followed by Fc-shielding F(ab)2 surface adsorption as shown in Scheme 1.  (1) 1 
uM of QD-ITK-NH2 (1.2 x 1014 nanoparticles in 200 uL solution) were maleimide-
activated by incubation with a 20-fold molar excess of NHS-PEG-MAL (MW: 5218) for 
2 hours in PBS with 10 mM EDTA, pH = 7.4 (PBS-EDTA) at room temperature.  Excess 
NHS-PEG-MAL was removed using two exchanges of PBS-EDTA on a 100K MWCO  
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Scheme 1. Schematic of Fc-shielded QD-mAb design. (1) Maleimide activation of QD-
NH2 surface using NHS-PEG(5000)-MAL (N-hydroxysuccinimide-polyethylene glycol-
maleimide) crosslinker. (2) Selective hinge region reduction of whole IgG into two 
functional half IgG (r IgG) with hinge region MAL-reactive sites using 2-
mercaptoethylamine (2-MEA). (3) Reaction of r IgG with MAL-activated QD. Reaction 
is site-specific, preserving activity at antigen-binding sites (*).  (4) Adsorption of Fc-
specific F(ab)2 against purified QD-r IgG bioconjugates. 
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 Amicon Ultra-4 column.  The solution was analyzed qualitatively for the presence of 
large aggregates (> 200 nm) using fluorescence microscopy, and was filtered through a 
100 nm syringe filter if aggregates were observed. (2) mAb (Table 1) were buffer-
exchanged in 500 μg amounts into PBS-EDTA, with two exchanges on a 100K MWCO 
spin column device (Amicon Ultra-4, Millipore) according to manufacturer-supplied 
instructions.  The retentate was resuspended to 10 mg/mL concentration in PBS-EDTA.  
The antibodies were then reduced specifically in the hinge region to create two 
monovalent IgG (r IgG) bearing 1-2 free sulfhydryl groups using 2-mercaptoethylamine 
(2-MEA, Pierce) (28) according to manufacturer's instructions.  Briefly, 6 mg of 2-MEA 
was dissolved in 100 μL of PBS-EDTA, and 1 μL of this solution was added to each 10 
μL of mAb solution.  The mixture was reacted for 120 min. at 37°C on a slow rocking 
platform.  Excess 2-MEA was removed from mAb using a NAP-5 desalting column (GE 
Healthcare) pre-equilibrated with degassed PBS-EDTA buffer according to 
manufacturer's instructions.  The presence of free sulfhydryl groups generated from 2-
MEA reduction was confirmed using Ellman’s reagent (Pierce) on a Nanodrop ND-1000 
spectrophotometer according to manufacturer's instructions.  (3) The QD retentate from 
(1) was then added to the 2-MEA reduced and purified r IgG mixtures and incubated 
overnight at 4°C.  The following day, the reaction was terminated with 1 mg/mL L-
cysteine (Sigma) to quench remaining maleimide groups. The QD-r IgG conjugates were 
purified by gel filtration chromatography according to manufacturer's instructions 
(Superdex 200, GE Healthcare).  Fractions were eluted with PBS into 96-well 
microplates and evaluated by a UV-Vis and fluorescence spectrophotometry (Nanodrop 
ND-1000 and ND-3300) or a fluorescence microplate spectrophotometer (Biotek Synergy 
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 HT) in order to identify appropriate QD-mAb fractions and to evaluate conjugation 
efficiency.  In 6 separate conjugations of r IgG2a to QD655, the average conjugation 
efficiency measured by UV-Vis absorbance spectrophotometry on pooled QD-bound and 
unbound r IgG fractions was 59.33 ± 11.34%.  This corresponds to 18 r IgG/QD.  (4) The 
bioconjugate fraction was incubated with goat anti-mouse IgG (Fc-specific) blocking 
F(ab)2 (Sigma) at molar concentrations equal to primary antibody concentrations for 1 
hour at room temperature, and the resulting mixture was filtered through a 0.22 μm 
syringe filter and stored at 4ºC until use.  On the day of animal imaging, bioconjugates 
were briefly spun in an Eppendorf 5415R microcentrifuge for 10 min. at 10,000g to 
remove QD-mAb aggregates, reserving the supernatant for use.  The supernatant was 
examined by fluorescence microscopy to ensure the absence of QD aggregates (> 200 
nm).  
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 Flow Cytometry 
 Whole blood was collected in 2 x 3mL aliquots from male Long-Evans rats into 
BD VACUTAINER tubes spray-lined with K3EDTA.  Erythrocytes were lysed by 
incubation with BD PharMLyse at a 20:1 ratio of lysis buffer to whole blood for 15 min. 
in the dark at room temperature to obtain a diffuse red suspension of white blood cells.  
The solution was then centrifuged at 400 x g in an Allegra X-22R unit with swinging 
bucket rotor (Beckman) at room temperature.  The leukocyte pellet was rinsed in 500 μL 
PBS (pH = 7.2) containing 0.5% BSA, and 0.1% sodium azide (staining buffer) to reduce 
shedding of membrane antigens.  Each pellet was rinsed twice with staining buffer.  The 
cells were resuspended to a 1x106 leukocytes/mL concentration, and were incubated for 
45 minutes with one of the following in staining buffer: 50 nM each of QD585-anti-RP-1 
conjugate, QD585-anti-CD45 conjugate, Fc-blocked QD585-isotype control IgG1, 
maleimide-activated and L-Cysteine quenched QD585, Fc-blocked QD585-isotype 
control IgG2a, non Fc-blocked QD585-IgG2a isotype control, or 1 ug Phycoerythrin (PE)-
anti-RP-1 conjugate (BD Pharmingen).  A separate unlabeled fraction was also retained 
for analysis.  All samples were immediately analyzed (n = 20,000 gated events) using a 
BD LSR II multicolor flow cytometer equipped with a 488 nm Ar laser.  Rat leukocyte 
subtypes could be readily resolved by forward and side scatter profiles as previously 
described (29).  Bandpass emission filters were set at 585/42nm to analyze QD or PE-
labeled cells.  Analysis was conducted using Flowjo 7.0 (Treestar Software).   
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 Cell Culture and Immunofluorescence Microscopy 
 YPEN-1 (CRL-2222, ATCC) rat prostate endothelial cells were cultured to 
confluency on Lab-Tek II 8-well chambered coverslips with media containing Minimum 
essential medium (Eagle) with 2 mM L-glutamine and Earle's BSS adjusted to contain 
1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium 
pyruvate, supplemented with 0.03 mg/ml heparin; fetal bovine serum, 5%.  YPEN-1 were 
stimulated with 30 ng/mL TNF-α in media overnight as previously described (30) to 
upregulate cell adhesion molecules, or incubated with media alone as a control.  The next 
day, YPEN-1 were rinsed with 1 wash of media and incubated with 10 nM amounts of 
QD bioconjugates for 1hr. at 37°C as follows: QD655-anti-PECAM, QD655-anti-ICAM, 
QD655-anti-VCAM, QD655 (reactive maleimide group quenched with 1 mg/mL L-
Cysteine), and QD-isotype control IgG1 in Fc-blocked forms as described above or as 
synthesized without the Fc-blocking step.  Cells were then rinsed 6 times in Dulbecco’s 
PBS containing Ca and Mg, pH = 7.4, and incubated with 4% paraformaldehyde in PBS 
for 15 min at 25°C, followed by rinsing three times, 5 minutes each, with PBS with 50 
mM glycine.  Fixed cells were imaged using a Nikon TE2000U inverted fluorescence 
microscope with filter settings as shown in Error! Reference source not found..  These 
experiments were performed in triplicate.  Images were acquired using a Hammamatsu 
C7780 12-bit color CCD in conjunction with Image Pro Plus 5.1 (Media Cybernetics). 
 
Preparation of Animal Subjects 
 All experimental procedures were approved by the Vanderbilt University 
Institutional Animal Care and Use Committee. Diabetes was induced in Long-Evans rats 
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 by intraperitoneal injection of 65mg/kg streptozotocin (STZ, Sigma) in 0.1 mM sodium 
citrate, pH = 4.5, with the same number of rats remaining untreated as experimental 
controls (n = 6 per group).  Elevated blood sugar (> 250mg/dl) was confirmed in STZ 
treated animals.  Endotoxin-Induced Uveitis (EIU) was initiated in Long-Evans rats by 
intraperitoneal injection of 200 μg lipopolysaccharide.  Controls were age-matched 
untreated rats (n = 6 LPS, n = 3 control).  Animals were anesthetized with 
intraperitoneally-administered 15/85% ketazine/xylazine prior to imaging.  Tail vein 
catheterization was performed for injection of QD-mAb.  Both eyes were dilated with 1 
drop each of 2.5% phenylephrine hydrochloride and 1% tropicamide ophthalmic 
solutions (Alcon).  The right eye was placed on the plano-concave lens previously filled 
with 2% methyl cellulose (Aqua Poly-Mount, Polysciences).     
 
In vivo Retinal Imaging 
 Our imaging design is based on a previously published technique (25), in which 
an inverted fluorescence microscope (TE2000U Eclipse, Nikon) with 4X and 10X 
objectives and a plano-concave -6 D lens (Edmund Scientific) on the microscope stage 
were utilized to image the rat retinal circulation.  In this study this technique was 
modified to include a high sensitivity Andor Bioimaging iXon 885 EMCCD camera 
(Andor Bioimaging), Hamamatsu C7780 color camera, Exfo X-cite 120 metal halide 
lamp (Exfo Life Sciences), and a pulsed xenon arc flashlamp excitation source (FX 4400, 
Perkin Elmer) triggered by a function generator configured for square wave output at 20 
Hz (Tektronix).  The metal halide lamp and flashlamp were utilized for the imaging of 
stationary endothelial targets and circulating leukocytes, respectively.  Following 
measurements of pre-injection tissue autofluorescence levels in each QD-specific 
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 emission channel, QD-mAb were injected via the tail vein catheter.  Injectate consisted of 
200 uL of a 500 nM solution in PBS-EDTA.  Initial digital sequences were acquired 
using exposures ranging from 20 to 200 ms (depending on the QD and the filter set, 
Table 1) at 110 ms intervals.  Subsequent sequences were acquired at approximately 30 
min. intervals for 2.5 hrs.  In four animals, a QD-IgG1 isotype control was used as a 
negative control.  Animals were sacrificed with 150mg/kg sodium pentobarbital 
administered via tail vein catheter.   
 
Immunofluorescence Microscopy of Retinal Tissue  
 Following euthanization of animals, both eyes were enucleated. Retinal flat 
mounts were prepared of the right eye, which was the eye imaged by our in vivo retinal 
imaging system.  Eyes were fixed in 4% paraformaldehyde in PBS overnight and flat-
mounted on a microscope slide mounted with fluorescence mounting media.  The left eye 
was fixed in 4% paraformaldehyde and paraffin embedded for sectioning.  Sections and 
flat mounts were analyzed by fluorescence microscopy (Nikon TE 2000U) using the 
same filters as those used in in vivo imaging (Table 1). 
 
Image Analysis 
 For analysis of QD-mAb binding to YPEN-1, fluorescence micrographs acquired 
under identical settings and conditions (matched cell densities in field of view) were 
measured in the Red CCD channel (the chip with which QD655 emission is captured) for 
fluorescence intensity using Image Pro Plus 5.1.  From this data the mean Red channel 
fluorescence intensity was obtained and standard deviation determined.  Background 
correction was performed on image intensities by subtracting the mean Red CCD channel 
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 intensity obtained from the same density of unlabeled YPEN-1.  Intensities were 
analyzed for statistical significance using an unpaired 2-tailed t-test (SigmaStat 3.0, 
SYTAT).  Background-corrected data was then plotted using SigmaPlot 9.0 (SYSTAT).  
Statistical significance was interpreted by P < 0.05.   
For in vivo image quantification of leukostasis, the area of image analysis of rat 
fundi was a circle of two optic disk diameters from the center, allowing for counts of 
stagnant leukocytes and observations of leukocyte trafficking and cell adhesion molecule 
expression within major arteries and veins as well as the microcirculation.  A leukocyte 
was assumed to be stagnant if no displacement larger than 1 cell diameter was observed 
within 60 s of continuous imaging.  The number of stagnant QD-labeled cells was 
quantified for STZ, EIU, and wild-type retinas post-acquisition from digital video using 
Andor iQ 1.6, and compared using an unpaired 2-tailed t-test in SigmaStat 3.0.   
Quantitative analysis of Fc-blocked and non Fc-blocked QD-IgG1 bioconjugates 
was performed by analyzing 60 consecutive digital frames of wild-type rat retina before 
and after systemic injection of 500 nM (200 uL) of each probe.  An observation area of 2 
optic disc diameters from center was utilized for the analysis.  Using Andor iQ 1.6 image 
analysis software, the mean fluorescence intensity of 60 consecutive frames was plotted 
as a function of time.  Data was plotted using SigmaPlot 9.0.   
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 Results 
 
In Vitro Studies 
 In cell culture studies, the QD655-mAb Fc-shielded conjugates specifically 
labeled CAMs on TNF-α-stimulated YPEN-1 rat endothelium (TNF+) (Figure 1A-D, 
Figure 2B, 2E).  In order to simulate the in vivo environment, no traditional 
immunofluorescence blocking steps (e.g. serum, Fc receptor blocking mAbs) were 
utilized.  Under TNF+ conditions, a statistically-significant increase in Fc-blocked 
QD655-anti-VCAM binding to YPEN-1 (Figure 1B, 1D) was observed, whereas TNF+ 
conditions did not significantly affect QD655-anti-PECAM binding (Figure 1A).  These 
observations were consistent with previous reports (31, 32).  QD655-anti-ICAM 
bioconjugates bound TNF+ YPEN-1 by over 10-fold as compared to untreated cells 
(Figure 2E).  A strong reduction in nonspecific binding was observed when comparing 
binding of Fc-blocked and non Fc-blocked QD655-anti-ICAM bioconjugates (Figure 
2A-B, 2E).  A reduction in nonspecific binding was also observed when comparing 
measured intensities of YPEN-1 labeled with Fc-blocked or non Fc-blocked QD655-
isotype control IgG1 nanoparticles (Figure 2C-E), suggesting that the Fc fragment is 
responsible for a substantial percentage of QD-mAb nonspecific binding.  
Immunofluorescence analysis of YPEN-1 indicated that non Fc-blocked QD655-mAb 
constructs were aggregated in focal locations along cell membranes, shown by 
arrowheads (Figure 2A-C).  This observation may be due to two features: the  
upregulation of Fcγ receptors on endothelial cells following TNF-α stimulation, and the 
patching and capping effect observed previously for Fc receptor-ligand combinations 
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 (33).  Specifically, patching and capping refers to the accumulation of surface bound 
IgG-Fc receptor pairs at distinct, punctate locations at the membrane to form clumps of 
Fc receptor-IgG pairs.  This incidence of cap formation was less evident in TNF+ YPEN-
1 cells incubated with Fc-blocked bioconjugates (Figure 2B).  Maleimide-quenched QD 
which were not conjugated to Mab (Figure 1C) did not bind appreciably to cell surfaces.  
These data collectively suggest that nonspecific binding of unshielded probe was likely 
due to the binding of mAb Fc fragment to endothelial Fc receptors. 
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Figure 1. Evaluation of Fc-blocked QD-mAb conjugate specificity toward TNF-α 
stimulated (TNF+) or untreated (TNF-, image insets) rat endothelial cells (YPEN-1).  (A-
C) Fluorescence micrographs of QD655-anti-PECAM (A), QD655-anti-VCAM (B), and 
QD655 (C).  Insets show incubation of TNF- YPEN-1 with matched bioconjugates.  (D) 
Mean image intensities from immunofluorescence analysis of TNF+/- YPEN-1 incubated 
with QD655-mAb bioconjugates (reported as mean + S.D., n=3 images per sample).  
Intensities for each TNF+ and TNF- pair were compared by t-test for statistical 
significance (P < 0.05 indicated by asterisk). 
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Figure 2. Comparison of Fc-blocked and non Fc-blocked QD655-mAb conjugate 
specificity toward TNF-α-stimulated YPEN-1 (TNF+).  (A-B) TNF+ YPEN-1 incubated 
with non Fc-blocked (A) and Fc-blocked (B) QD655-anti-ICAM bioconjugates 
(magnification 100X).  Arrowheads indicate possible Fc receptor capping, which was 
substantially reduced when using Fc-blocked conjugates.  (C-D) TNF+ YPEN-1 
incubated with non Fc-blocked (C) and Fc-blocked (D) QD655-IgG1 isotype control 
bioconjugates, with capping sites labeled with arrowheads (magnification 400X).  (E) 
Mean image intensity analysis reveals lower nonspecific binding of bioconjugates 
featuring Fc blockade (reported as mean + S.D., n = 3 images per sample).  Intensities for 
each matched Fc-blocked and and non Fc-blocked bioconjugate were compared by t-test 
for statistical significance (P < 0.05 indicated by asterisks).   
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 Fc-blocked QD585-anti-RP-1 (neutrophils) and QD585-anti-CD45 (leukocyte 
common antigen) were shown to retain bioactivity and specificity in vitro (Figure 3).  
QD585-anti-RP-1 conjugates were shown to specifically bind to neutrophils and not other 
leukocyte subsets (Figure 3A), and QD585-anti-CD45 were shown to label the three 
main subclasses of leukocytes as shown by flow cytometric analysis of erythrocyte-lysed 
whole blood (Figure 3B, 3D).  QD-anti-RP-1 was observed to have over 4-fold 
enhancement in fluorescence over PE-RP-1 (1003 vs. 233), a positive control antibody 
coupled to phycoerythrin (Figure 3C).  QD585-IgG2a (matching the isotype of QD585-
anti-RP-1), when Fc-blocked with a anti-Fc F(ab)2 fragment, featured 53% lower mean 
fluorescence levels than that due to the non-Fc-blocked conjugate (Figure 3C), indicative 
of reduced nonspecific binding of Fc-blocked bioconjugates.  Fc-blocked QD585-anti-
CD45 conjugates used to label leukocytes yielded a mean fluorescence of 1430, over 17-
fold greater than cells labeled with Fc-blocked QD-IgG1 isotype control (82) and 22-fold 
greater than unlabeled cells (65) (Figure 3D). 
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Figure 3. FACS analysis of leukocytes labeled with QD-mAb bioconjugates in vitro. (A) 
QD585-anti-RP-1 (Fc-blocked) specific labeling of neutrophils in peripheral blood.  (B) 
QD585-anti-CD45 (Fc-blocked) labeling of all leukocyte subsets, with arrow B-D 
indicating fluorescence histogram of gated leukocytes (D). (C) Gated neutrophil 
populations from rat peripheral blood (arrow A-C shows a gated neutrophil population 
used for analysis of 1 sample), (488nm Ar laser excitation, Phycoerythrin (PE) emission 
filter (585/42nm)), with mean fluorescence intensity of each sample indicated in bold.  
Light Blue: PE-anti-RP-1 dye-labeled positive control mAb, Purple: QD585-anti-RP-1 
(Fc-blocked), Blue: QD585 quenched with L-Cysteine, Brown: QD-Ms-IgG2a isotype 
non-Fc blocked, Green: QD-Ms-IgG2a isotype Fc blocked, Red: Unlabeled rat peripheral 
blood. (D) Rat leukocytes labeled with QD585-anti-CD45 (Red, gated leukocytes from 
(B)), QD585-Ms IgG1 Fc blocked isotype control (Blue), or unlabeled (Green).  
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 In vivo Imaging 
Intravenous injection of QD bioconjugates targeted to ICAM-1 or VCAM-1 
resulted in a maximum increase in vascular fluorescence in streptozotocin (STZ)-treated 
diabetic rats within 30 and 90 minutes, respectively (Figure 4).  This increase in 
fluorescence was observed in major vessels as well as the microcirculation.  Control rat 
retinas did not exhibit the same fluorescence intensity with either the ICAM (Figure 4A-
C) or VCAM (Figure 4D-F) conjugates.  Injection of QD anti-PECAM produced 
increases in fluorescence which were similar in both STZ-treated and untreated animals 
(Figure 4G-I).  Injection of QD-IgG1, a nonspecific control, did not result in 
fluorescence signal accumulation in the retinal vasculature to any appreciable degree 
throughout the duration of imaging up to 2.5 hrs (Figure 4J-L).  
Intravenous injection of QD585-anti-RP-1 conjugates enabled the fluorescence 
detection and long-term tracking of neutrophils in STZ-treated diabetic animals as shown 
in Figure 5A-D. Using a pulsed xenon flashlamp, we visualized individual free flowing 
leukocytes (Figure 5A-B), leukocyte rolling along endothelial walls (Figure 5C), and 
leukostasis (Figure 5D) in major vessels as well as capillaries.  Individual neutrophils 
were resolved in all vessels including arteries, and an increase in stagnant neutrophils in 
the microcirculation was observed in the STZ-treated group (5.83 ± 2.86, n = 6) vs. 
untreated animals (0.50 ± 0.55, n = 6) (P < 0.01).  Fluorescence micrographs of stagnant 
neutrophils in flat-mounted STZ-treated rat retinas confirmed in vivo observations 
(Figure 5G).  
Injection of the QD655-anti-CD45 bioconjugate in LPS-treated EIU rat models 
revealed a significant number of stagnant leukocytes in the microcirculation relative to  
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Figure 4. Representative frames from in vivo digital videos of STZ treated and untreated 
rat retinas. Pre-injection digital videos using the appropriate fluorescence filters for the 
spectrally-distinct biomarkers of interest (left column; A,D,G,J) were acquired prior to 
bioconjugate injection. QD585-anti-ICAM, QD655-anti-VCAM, QD525-anti-PECAM, 
and QD565-Ms IgG1 were systemically injected in STZ-treated rats. Untreated control rat 
fundi (middle column; B,E,H,K) and STZ-treated rat fundi (right column; C,F,I,L) were 
imaged either 30 min (ICAM)  or 90 min (VCAM, PECAM, IgG1) post-injection under 
identical acquisition settings used for background autofluorescence measurements for 
each biomarker channel.  Fluorescence enhancement due to target binding in untreated 
controls (B,E,H,K) was primarily observed for PECAM (H). The retinal vasculature of 
STZ-treated rats (C,F,I,L) showed a marked increase in fluorescence due to binding of 
QD-mAb conjugates to ICAM (C) and VCAM (F), with at least 5-fold increases in 
fluorescence intensity over background measured for labeled vasculature.  Injection of 
conjugates to PECAM (I) produced similar levels of fluorescence under both conditions 
(H,I). Fluorescence signal from nonspecific IgG1 mAb bioconjugates (J-L) was not 
detected in either control or STZ retinas.  Images shown were acquired at imaging 
intervals resulting in optimal signal to noise ratio.   
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Figure 5. In vivo imaging of endogenously QD-mAb-labeled leukocyte trafficking in two 
rat models of inflammation.  The CCD acquired images with exposure times ranging 
from 50 to 200ms with 110 ms between exposures.  Flowing of QD585-RP-1 labeled 
cells in vessels (A-B) or leukocyte rolling (C) in STZ model as detected by two pulses of 
a xenon flashlamp at 50 ms intervals within 30 minutes of probe injection.  Leukostasis 
was frequently observed in the STZ-treated rat model (D in right panel). Stagnant 
neutrophil appears as a hyperfluorescent dot in the microcirculation. Stagnant neutrophils 
were continuously visible in the retinal vasculature for over one hour of in vivo imaging. 
Stagnant leukocytes labeled in vivo with QD655-anti-CD45 were present at high densities 
in EIU rat models (E) relative to untreated controls (F).  Stagnant neutrophils labeled in 
STZ-streated diabetic animals were visible in post-mortem retinal flat-mounts (G). 
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 untreated animals (Figure 5E-F).  The number of stagnant leukocytes in LPS-treated rat 
retinas (20.33 ± 8.73, n = 6) was elevated over control retinas (2.17 ± 1.17, n = 3) in vivo 
(P < 0.01). 
Ten seconds after tail vein injection, comparison of the retinal fluorescence from 
Fc-shielded and non-Fc-shielded bioconjugates showed significantly less fluorescence 
from the non-shielded bioconjugate (Figure 6).  Tracers injected intravenously into a tail 
vein travel through the hepatic circulation, heart and lungs before the remainder reaches 
the eye.  Our data indicate that non Fc-blocked nonspecific QD-IgG1 is cleared rapidly 
within 2 hours of circulation, returning retinal fluorescence levels to pre-injection values 
(Figure 6E-H, J).  For Fc-blocked nonspecific QD-IgG1, an apparent bolus is observed 
within 12 seconds of injection (Figure 6B), and fluorescence levels by 2 hours have not 
returned to background values (Figure 6A-D, I).  These results suggest that Fc blockade 
substantially enhances the circulation lifetime of the QD-mAb due to reduced uptake and 
clearance.   
 
Ex vivo imaging of retinal tissue 
 Immunofluorescence analysis of flat-mounted retinas showed correlation of in 
vivo features, such as enhanced CAM expression areas within the microcirculation, with 
ex vivo microscopy (Figure 7A-B).  Analysis of post-mortem retinal tissue also indicated 
low nonspecific binding of Fc-shielded bioconjugates (Figure 7C-D) within blood 
vessels.  The microcirculation in a flat mount from an EIU rat featured leukocyte 
adhesions and extravasations similar to those observed in vivo (not shown), and similar to 
the result shown for the STZ-treated rat (Figure 5G).  
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Figure 6. Comparison of Fc-blocked (A-D, I) and non Fc-blocked (E-H, J) QD-IgG1 
mAb bioconjugates in vivo.  (A) Pre-injection autofluorescence in QD655 emission 
channel.  (B-D) Fc-blocked QD655-IgG1 in retina observed 12 s post-injection (B) where 
the first-pass of bolus through retinal circulation is observed, 1 hr. post-injection (C), and 
2 hrs. post-injection, by which time Fc-blocked QD655-induced fluorescence is still 
above background levels as measured in (I, dashed line).  (E) Autofluorescence levels in 
QD565 channel.  (F-H) non Fc-blocked QD565-IgG1 bolus was not qualitatively visible 
at 12 s post-injection (F), and subsequent image acquisitions at 1 hr (G) and 2 hr (H) 
revealed eventual return of image intensity to pre-injection levels (J, solid line), 
suggesting a relatively rapid clearance and/or uptake of non Fc-blocked QD-mAb.   
59
  
 
 
 
 
Figure 7. In vivo microcirculatory VCAM-1 expression (A), can be confirmed using 
immunofluorescence analysis post-mortem (B), as shown for QD655-anti-VCAM-1 
labeled vasculature. While QD655-VCAM-1 (Fc-blocked) conjugates were shown to 
specifically stain vasculature in retinal histological sections (C), no background staining 
due to QD-IgG1 (Fc-blocked) was observed above background autofluorescence levels 
(D). 
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 Discussion 
 
 Fc-blocked QD-mAb were found to be specific for CAM and leukocyte targets, as 
shown by immunofluorescence (Figure 1-2), flow cytometry (Figure 3), and in vivo and 
ex vivo retinal imaging (Figure 4-7).  QD-IgG that were nonspecific in reactivity did not 
bind to retinal vasculature (Figure 6), which suggests that Fc-blocked QD-antibody 
bioconjugates feature reduced nonspecific binding tendencies while retaining the native 
binding affinity conferred by the mAb.  Our technique, employing PEGylation, 2-MEA 
reduction and Fc-blockade by Fc-specific F(ab)2 is a rapid, cost-effective method for the 
site-specific bioconjugation and immune-shielding of mAb on nanoparticle surfaces.  The 
2-MEA reduction process was found to work equally well on mouse IgG1 and IgG2a 
subclasses using the same protocol.  As an alternative to removal of the Fc fragment from 
the antibody, we choose instead to adsorb it with an antibody fragment which itself has 
no Fc region.  Non-targeted QD-IgG conjugates adsorbed with an Fc-blocking F(ab)2 
were less susceptible to nonspecific binding to leukocyte and endothelial cell surfaces 
compared to the same conjugates without Fc-blockade (Figure 1-3).  This may be the 
result of steric inhibition conferred upon the bioconjugate by the F(ab)2 which reduces Fc 
receptor access to its Fc fragment binding site on the IgG.  Fc-blockade of CAM-targeted 
QD did not affect their binding affinities toward endothelial cell proteins in vitro or in 
vivo (Figure 1-2, 4).  Fc-blockade by itself also may potentially enhance the circulation 
half-life of QD-mAb when employed in conjunction with PEG.  Fc-blocked, non-targeted 
QD-IgG were present in the retinal circulation in much higher fluorescence levels relative 
than the same dose of non-Fc-blocked constructs (Figure 6), suggesting that Fc-blockade 
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 of IgG may substantially reduce first-pass nonspecific clearance of probes due to liver 
and spleen immunorecognition.  Therefore, our probe design features target selectivity 
with a reduced tendency for nonspecific binding. 
 Analogues of our strategy exist for reduction of nonspecific binding of 
bioconjugates for in vitro applications, and we have applied these in vitro techniques for 
the first time to in vivo imaging.  For example, the commercial reagent FcBlock (anti-
CD16, anti-CD32, BD Biosciences) has long been utilized to functionally block Fc 
receptors on hematopoietic and endothelial cells prior to immunofluorescence (34) or 
flow cytometric (35) analysis for the reduction of background staining using cell surface 
protein antibodies.  Direct blockade of the Fc fragment of antibodies rather than Fc 
receptors occurs often in biology.  Blockade of the antibody Fc domain with 
streptococcal proteins has been found to reduce Fc-mediated nonspecific binding (36).  
Herpes Simplex Virus type 1 (HSV-1), when bound by an IgG, uses its Fcγ receptors to 
occupy the Fc fragment of the same IgG, thus preventing Fc-mediated immunodefensive 
mechanisms (37).  By adsorption of the QD-IgG conjugate with an Fc-targeted F(ab)2, it 
is likely that the adsorbed fragment makes the Fc binding site of the targeting antibody 
sufficiently inaccessible to immune surveillance, thus enhancing specificity and 
circulation time.     
Other strategies to reduce Fc-mediated immune recognition of antibodies or 
antibody-based bioconjugates are reported in the literature. Specifically, antibody 
fragmentation techniques using papain, pepsin, or ficin require several reaction steps and 
much reagent quantity and time optimization for each antibody species and subclass, and 
generally do not yield a biomolecule with a site-specific crosslinking site suitable for 
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 nanoparticle conjugation.  Instead, primary amines which reside in the antigen-binding 
site of the antibody could be crosslinked to the nanoparticle, obliterating its antigen 
binding affinity following bioconjugation.  Protein engineering techniques now provide 
for a means of producing antibody fragments with engineered hinge region cysteines 
(Fab’) which allow for site-specific nanoparticle conjugation while preserving the 
antigen-binding region (38, 39).  However, this process is time-consuming and costly, 
and may not be suitable in applications where multiple IgGs are to be conjugated to 
nanoparticles for multiplexed imaging on a small scale, or where IgG targets are quickly 
examined and replaced for purposes of drug discovery or biology.  Our process provides 
for the site-specific conjugation of antibodies to nanoparticles, without IgG subclass-
specific optimization, with similar benefits of immune system evasion afforded by 
antibody fragmentation techniques.  
Our in vivo imaging results are consistent with studies of ICAM and VCAM 
expression in diabetic and non-diabetic tissue, in which their upregulation is implicated in 
an inflammatory cascade that causes various complications of the disease (6, 40, 41).  QD 
fluorescence due to ICAM and VCAM expression is apparent on major vessels as well as 
the microcirculation in disease models, which appears as an out of focus fluorescent 
background behind the major vessels (Figure 4A-F).  QD targeted against PECAM, a 
panendothelial marker, produced increases in fluorescence which were similar in both 
STZ-treated and untreated animals (Figure 4G-I), thus suggesting its utility as an internal 
control or vascular counterstain in this imaging application.  Our technique was found to 
be suitable for the long-term imaging of stagnant leukocytes commonly observed in both 
the STZ-treated rat model of diabetes (6, 9) and the LPS-treated rat model of EIU (42).   
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 Photobleaching is a problem with current techniques which probe leukocyte 
dynamics in vivo, such as acridine orange fluorography (43, 44).  Thus, long-term 
imaging of leukocytes is hindered.  Using QD-based fluorography, we were able to 
continuously observe entrapped leukocytes in the circulation over an hour of continuous 
illumination without bleaching (Figure 5).  Therefore, our QD-based imaging technique 
constitutes a potential alternative to current methods of imaging leukocytes due to the 
ability to simultaneously image multiple leukocyte subsets and stationary biomarkers 
with one excitation source with high specificity.    
Our imaging technique provides non-invasive optical access to the in vivo retinal 
vasculature and continuous monitoring of vascular events. Spatial resolution on the order 
of a cell is achieved with this technique.  QD have superior optical properties, such as 
high quantum efficiency and photostability, as well as distinct size-tunable emission 
wavelengths with the need for only one excitation source.  By harnesseing these QD 
properties while immune-shielding the nanoparticle surface, it was readily possible to 
image three CAMs and one leukocyte subset within the same animal, without spectral 
overlap, using one blue excitation source to sufficiently illuminate QD-tagged species 
within the circulation.  This feature enables detailed multiplexed studies of disease and 
biological processes.  We used this approach to simultaneously observe the molecular 
expression of three different biomarkers, while also observing leukocyte-endothelial 
interactions.  Other applications of this imaging strategy could readily be applied to 
studies in which multiple cellular and biomolecular vascular functions remain to be 
elucidated such as cancer, ocular angiogenesis, and atherosclerosis.  While qualitative 
information was primarily presented in this initial application of our technique, we 
64
 foresee the calculation of additional parameters including rolling velocities for various 
subtypes, relative fluorescence intensities of specific biomolecules along vascular walls, 
density of entrapped leukocytes, and important features of the inflammatory process in 
vivo. 
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Abstract 
 
The progression of atherosclerosis has been associated with leukocyte infiltration 
within lesions.  We describe a technique for the ex vivo imaging of cellular recruitment in 
atherogenesis which utilizes quantum dots (QD) to color-code different cell types within 
lesion areas.  Spectrally-distinct QD were coated with the cell-penetrating peptide 
maurocalcine to cytoplasmically-label immunomagnetically-isolated monocytes and T 
lymphocytes.  QD-maurocalcine bioconjugates labeled both cell types with high 
efficiencies, preserved cell viability, and did not perturb native monocyte adhesion to 
inflamed endothelium in vitro.  QD-labeled cells were reinfused in ApoE -/- mice and 
age-matched controls for up to 4 weeks to investigate the incorporation of cells within 
aortic lesion areas, as determined by oil Red O (ORO) and immunofluorescence staining 
ex vivo.  QD-labeled cells were visible in atherosclerotic plaques within 2 days of 
injection.  Reinfused monocytes colocalized with CD68 immunofluorescence staining, 
whereas T lymphocytes were observed in distinct regions.  Both cell types colocalized 
with areas of subsequent ORO staining.  Our method for tracking leukocytes in lesions 
enables high signal to noise ratio imaging of multiple cell types and biomarkers 
simultaneously within the same specimen.  It also has great utility in monitoring the role 
of circulating leukocytes in plaque development and progression.   
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Introduction 
 
Atherosclerosis is a complex disease exacerbated by multiple cellular and 
molecular participants.  A key contributor toward atherogenesis is the dysfunction of 
vascular endothelium, which presents molecular cues promoting leukocyte infiltration 
into arterial intima (1).  Leukocytes which localize within atherosclerotic plaques include 
monocytes (2, 3), and lymphocytes, primarily of the CD4+ subset (4, 5).  Monocytes 
migrate toward lesions and accumulate lipids in a process that transforms them into 
macrophage foam cells (6).  These lipid-laden macrophages secrete reactive oxygen 
species and proteinases which induce a positive-feedback monocyte recruitment cascade, 
eventually leading to plaque instability and rupture (7).  Lymphocytes also contribute to 
the progression of atherosclerosis via the secretion of the proinflammatory cytokine 
interferon gamma (IFN-γ), which has various roles in contributing to leukocyte 
recruitment to plaques and eventual plaque instability (4, 8-10).  Other cell types, such as 
neutrophils (11) and dendritic cells (12, 13), also play a role in potentiating 
atherosclerotic complications via their activation proximal to inflammatory plaque 
surfaces.  Therefore, techniques to visualize the spatial and temporal dynamics of these 
cellular mediators are needed to understand their role in the different stages of 
atherosclerosis.     
Advances in the pathobiology of atherosclerosis have identified a number of key 
cellular and molecular mediators involved in early and late stages of disease (14, 15).  
Furthermore, innovations in both  imaging instrumentation and in vivo imaging reagents 
complement these therapeutic and diagnostic targets for developing strategies to visualize 
73
     
vascular disease in vivo (16, 17).  Macrophages in lesions have been imaged in vivo using 
magnetic resonance imaging (18, 19), optical imaging (20, 21), and positron emission 
tomography (22), by either intracellular targeting or cell surface biomarker targeting.  
Recently, we investigated a strategy for the color-coding of circulating leukocytes and 
cell surface biomolecules with fluorescing semiconducting nanocrystals, or quantum dots 
(QD), for multiplexed in vivo vascular imaging in rodent models of diabetic and ocular 
inflammation (23).  The size-tunable emission spectra of QD enable the simultaneous in 
vivo and ex vivo tracking of multiple cells and biomarkers within the vasculature of the 
same animal with only one excitation source.  Furthermore, QD are amenable to 
bioconjugation of ligands for cell targeting, and feature high quantum yields and 
photostability for long-term imaging applications (24, 25). 
In this report, we demonstrate the utility of a method for applying the optical 
properties of QD for ex vivo imaging of atherosclerotic cellular components.  The 
technique uses QD coated with the cell penetrating peptide maurocalcine (26) to 
fluorescently-label cytoplasmic compartments of lymphocytes and monocytes with 
different emission wavelengths so they can be simultaneously-detected in tissue.  This 
approach was used to visualize leukocyte subtype recruitment to aortic valve leaflet 
lesions in an ApoE -/- mouse model of atherosclerosis (27), and has important 
implications for the multiplexed imaging of cells and biomolecules in vascular disease in 
vivo. 
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Methods 
 
Immunomagnetic isolation of leukocytes 
 All animal procedures were approved by the Instituional Animal Care and Use 
Committee at Vanderbilt University.  Spleens from wild-type and ApoE -/- mice aged 
from 7 months to 1 year were collected in RPMI 1640 supplemented with 10% fetal 
bovine serum (FBS) and 1% streptomycin-Fungizone.  Splenocytes were prepared by 
disrupting the spleen with a syringe plunger on a nylon mesh filter.  Collected cells were 
washed once in RPMI medium.  Lymphocytes were isolated using Lympholyte M density 
gradient medium (Cedarlane Laboratories, Burlington, NC) according to manufacturer’s 
instructions.  Monocytes and T lymphocytes were isolated using anti-CD11b-coated 
paramagnetic microbeads (Miltenyi Biotec, Auburn, CA, # 130-049-601) and biotin-anti-
T cell receptor antibody- (TCR β chain, BD Biosciences, San Jose, CA) coated 
paramagnetic microbeads (Miltenyi Biotec # 130-091-256) for monocytes and T 
lymphocytes, respectively.   Each population was tested for purity by flow cytometry.  In 
all cases (n = 4) the purity was >90%.   Data was analyzed using FlowJo 7.2 (Treestar 
Software, Ashland, OR) and a FACSCalibur flow cytometer (BD Biosciences).      
 
Quantum dot-labeling of leukocytes 
 QD coated with 6-8 streptavidins/nanoparticle emitting at 585 nm and 655 nm 
(QD585 and QD655) were purchased from Invitrogen Corporation (Carlsbad, CA).  
Biotinylated maurocalcine peptide was synthesized by Biomatik Corporation according 
to previously-published protocols (26).  A 35-fold molar excess of peptide was mixed 
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with 1 molar equivalent of QD585 or QD655 in 100 mM PBS, pH = 7.4, for 30 min. at 
room temperature.  QD-maurocalcine was then separated from excess peptide using size-
exclusion chromatography over a Superdex 200 column according to manufacturer 
instructions (GE Healthcare, UK).  Elution fractions were measured using a BioTek 
Synergy HT microplate spectrophotometer (BioTek, Vermont, USA) configured for QD 
fluorescence at 585 nm or 655 nm, and peptide fluorescence as measured by 
fluorescamine assay (Sigma Chemical, St. Louis, MO).  This process typically yielded 
QD with 12-17 peptides per nanocrystal. 
For each cell labeling experiment, 1 X 106 cells/mL were stained with 100 nM 
QD-maurocalcine in PBS, pH = 7.4, at 37°C for 30 min.  Cells were rinsed with PBS via 
centrifugation at 200 X g for 10 min.  Cell viability and labeling efficiency were 
determined by the LIVE/DEAD single color fixable green kit according to manufacturer 
instructions (Invitrogen) on a FACSCalibur flow cytometer.  Unlabeled cells subjected to 
the same rinsing and centrifugation steps served as controls. 
 
Monocyte adhesion assay 
bEnd.3 mouse endothelium was a gift from Dr. Jack Virostko.  Cells were 
cultured in DMEM supplemented with 10% fetal bovine serum to confluency on 24-well 
tissue culture grade microplates.  Cells were then treated with 500 ng/mL Salmonella 
Typhimurium lipopolysaccharide (LPS, Sigma) or untreated in complete media overnight.  
Monocytes (1 X 106 cells/mL) were incubated with 1 μM calcein-AM (Invitrogen) for 30 
min.  100,000 monocytes of this suspension were either incubated in PBS or PBS 
containing 100 nM QD-maurocalcine for 30 min at 37°C.  After rinsing with PBS, cells 
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were plated onto LPS-stimulated or unreated bEnd.3 monolayers and incubated for 1 hr. 
at 37°C.  At the end of the experiment, monolayers were rinsed three times with PBS to 
remove non-adherent cells, and the microplate was measured for calcein-AM 
fluorescence (490 nm excitation/525 nm emission).  Results were compared by t-test and 
plotted using Sigmaplot 9 (SYSTAT, San Jose, CA). 
 
Analysis of QD-labeled leukocytes in ApoE -/- mouse aorta 
 
ApoE -/- and wild-type mice ranging from 7 months to 1 year were injected with 
1 X 106 QD-maurocalcine-labeled monocytes or T lymphocytes via the retroorbital route.  
Animals were euthanized 2, 3, 5, and 28 days post-injection, and proximal aorta and 
whole aorta were harvested and sectioned as described previously (28).  5 μm frozen 
sections were stained for immunofluorescence with Alexa Fluor 488-conjugated anti-
CD68 and mounted in VECTASHIELD with DAPI (Vector Laboratories, Burlingame, 
CA).  Sections were analyzed by fluorescence microscopy on a Nikon TE2000U Eclipse 
inverted microscope (Nikon Instruments, Melville, NY) using DAPI, Alexa Fluor 488, 
QD585, and QD655 cubes in conjunction with a Hamamatsu C7780 cooled CCD camera 
(Hamamatsu Corp., Bridgewater, NJ).  Image analysis was conducted using Image Pro 
Plus 5.1 (Media Cybernetics, Bethesda, MD). 
 
Ex vivo imaging 
En face aortas from ApoE -/- and wild-type mice were imaged for QD 
fluorescence using an IVIS 200 fluorescence imaging system configured for spectrally-
distinct detection of QD585 and QD655 using bandpass emission filters (Caliper Life 
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Sciences, Hopkinton, MA).  Following QD imaging, aortas were stained with Oil Red O 
and the percentage of atherosclerotic lesions (ORO positive area)  was quantified in using 
a previously described technique (29).  The IVIS 200 was then used to image ORO-
stained areas via analysis of dye-induced near-infrared fluorescence (30, 31) with QD 
fluorescence subtracted from the image.  ORO-stained lesions were pseudocolored so that 
areas of QD585-lymphocytes, QD655-monocytes, and ORO could be colocalized within 
the same tissue. 
 
Results 
 
Loading of leukocytes with QD-maurocalcine bioconjugates 
The attachment of maurocalcine cell penetration peptides to QD enabled their 
highly-efficient loading into T lymphocytes and monocytes ex vivo, with no appreciable 
effects on cell viability and function.  Immunomagnetic isolation procedures using anti- 
TCR and anti-CD11b beads yielded distinct T lymphocyte or monocyte subpopulations 
as demonstrated by double-staining experiments (Figure 1A).  Labeling of these 
populations separately with QD585-maurocalcine and QD655-maurocalcine was more 
efficient than labeling with QD alone (Figure 1B-C). 
Flow cytometric viability assays did not reveal substantial differences in cell 
viability between populations incubated with QD-maurocalcine or unlabeled populations, 
for either cell type (Figure 2A).  Furthermore, monocytes labeled with QD homed to 
LPS-stimulated bEnd.3 mouse endothelium at a comparable rate to monocytes loaded 
only with C-AM dye (Figure 2B). 
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Figure 1. FACS analysis of CD11b and TCR-biotin immunomagnetically-purified 
leukocyte subsets (A), and QD-maurocalcine labeling of T lymphocytes with QD585 (B) 
and monocytes with QD655 (C).  (A) Immunomagnetic purification yields two distinct 
populations, a CD11b+/CD68+ population, and a CD11b+/CD68- population.  T 
lymphocytes express low levels of CD11b and expression of CD68 is absent, whereas 
monocytes express both markers at relatively higher levels.  (B-C) Both leukocyte 
subsets efficiently-internalize QD-maurocalcine (red) while excluding QD without 
peptide (green).  
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Figure 2. Cell viability analysis (A) and monocyte adhesion assay on bEnd.3 mouse 
endothelial monolayers in vitro (B).  *- P < 0.05, n = 3. 
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Localization of QD-labeled leukocyte subsets in atherosclerotic lesions 
QD-labeled monocytes were observed in atherosclerotic lesions as early as two 
days post-injection and as late as four weeks (latest time point observed) in ApoE -/- 
mice.  Figure 3 shows QD-labeled monocytes within aortic root lesions of 7 month 
(Figure 3A-D) and one year old (Figure 3E-H) ApoE -/- mice, and their colocalization 
with CD68-positive cells and the nuclear stain DAPI.  In both mice, infused monocytes 
appeared to have infiltrated squamous endothelium to reside in deep regions of the lesion, 
where other, presumably pre-existing macrophages were present.  However, the extent of 
accumulation of both resident and ex vivo reinfused monocytes/macrophages in early 
lesions was noticeably lower than the extent of accumulation in 1 yr. old ApoE -/- mouse 
lesions.  Observations of lesions from mice of similar age were consistent with our 
finding that monocyte accumulation in lesions was proportional to the extent of lesion 
progression as determined by size and ORO staining.  Lesions from mice not injected 
with QD-labeled cells or not labeled with CD68 did not exhibit appreciable 
autofluorescence.   
QD-labeled T lymphocytes were observed in ApoE -/- mice aortic lesions as early 
as two days and as late as four weeks (latest timepoint tested) post-injection of cells.  
Figure 4 shows fluorescence micrographs of lesions from the youngest animals (7 
months) and the oldest animals (1 year) tested.  A stark contrast in cellular accumulation 
between the two age groups was evident with both QD and immunofluorescence labeling 
methods.  T lymphocytes appeared in regions of plaques either adjacent to resident 
macrophages or distinct from macrophages.  QD585-labeled cells were detected in either  
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Figure 3. Representative fluorescence micrographs of QD-labeled monocyte 
accumulation in aortic root tissue lesion of 7 month old (A-D) and 12 month old (E-H) 
ApoE -/- mice, 5 days post-injection of 1 X 106 QD655-labeled monocytes.  (D, H) Areas 
of colocalization between QD-labeled monocytes and Alexa Fluor 488-anti-CD68  are 
indicated with arrowheads (Magnification 50X).  Inset in (H) shows magnified region 
(100X) showing increased colocalization of infused monocytes with resident 
macrophages.   
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Figure 4. Fluorescence micrographs of QD-labeled T lymphocyte recruitment to aortic 
root lesions.  (A) Arrowheads indicate regions of cellular infiltration (yellow).  
Magnification 50X.  (B) Arrowheads indicate lymphocytes in regions colocalized with 
CD68 (green), or in distinct areas. 
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deep regions of lesions as small clusters (~5-8 cells) of lymphocytes in 
CD68-rich areas (Figure 4A), or areas of low CD68 expression near smooth muscle 
cells (Figure 4B).   
The time allotted for QD-labeled leukocyte circulation post-injection did not 
affect relative levels of leukocyte accumulation in lesions, as 4 week post-injection 
timepoints featured similar accumulation of leukocytes as 2-5 day post-injection 
age-matched animals (not shown).  Generally, QD was not observed to fade within 
the coverslipped specimen within a month following sample preparation, nor did 
extended circulation time of QD-labeled cells adversely affect photostability and 
photointensity of QD within lesions.  Lesion autofluorescence in the QD585 channel 
was negligible.   
Correlation of leukocyte accumulation with ORO staining by en face analysis 
Macroscopic fluorescence imaging of en face preparations of mouse aortas 
revealed QD585 and QD655 accumulation in ORO-stained lipid regions throughout the 
aortic stem (Figure 5).  No cells were observed in wild-type aortas, indicating that QD-
labeled cells homed specifically to lesions.  Furthermore, QD fluorescence was 
proportional to lesion surface area as determined by ORO-positive staining.  The near 
infrared fluorescence spectra of ORO did not overlap with that of QD655 and QD585, 
due to the use of distinct bandpass emission filters and the serial nature of sample 
preparation, whereby QD images were acquired prior to ORO staining to allow for digital 
image background correction. 
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Figure 5. Ex vivo imaging of en face aorta preparations using macroscopic fluorescence 
imaging of ORO (A), QD585-T lymphocytes (B), and QD655-monocytes (C). 
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Discussion 
 
QD are versatile reagents for imaging disease in preclinical models, due to the 
flexibility of ligands (nucleic acids, antibodies, peptides) they can accommodate, high 
photostability and emission intensity, and size-tunable emission wavelengths, and 
imaging of multiple QD within tissue requires only one excitation wavelength  (32).  QD 
have been loaded into (cytoplasm) or onto (cell surface) multiple cell types for imaging 
of dynamic processes in vivo, including tracking of cancer metastasis (33) and leukocyte-
endothelial interactions during inflammatory vascular disease (23).  The multispectral 
imaging capabilities enabled by QD make them attractive reagents for visualizing 
dynamic processes consisting of multiple cellular and biomolecular mediators in vivo. 
In this work, we have adapted QD for monitoring atherogenesis in ApoE -/- mouse 
models ex vivo, with particular attention given to the potential utility of this approach for 
in vivo imaging of cellular accumulation within atheroma.  Furthermore, leukocytes 
capable of homing to lesions, namely monocytes, which differentiate into macrophages 
within the lesion, can be genetically-engineered to induce regression of lesions (34).  
Therefore, a technique to monitor their biodistribution in vivo and ex vivo is particularly 
desirable.  Flow cytometric analysis indicate that QD-maurocalcine bioconjugates were 
internalized efficiently within leukocyte subtypes (Figures 1B-C), with no significant 
effects on cell viability (Figure 2A) and homing to inflammatory endothelium (Figure 
2B) observed.  These in vitro studies collectively indicate that QD are at least on the short 
term suitable for studies of leukocyte function in vascular disease.  Homing of both cell 
types to lesions were observed (Figures 3-4), with varying degrees of penetration and 
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colocalization with resident macrophages.  Therefore, QD may be a useful tool to study 
differential localization on a spatial or temporal scale for several cell types within the 
same tissue. The multiplexing capability afforded by the use of spectrally-distinct QD 
makes the simultaneous detection of multiple cell types a possibility, even with the use of 
conventional immuno-fluorescence markers, in this case Alexa Fluor 488 anti-CD68 and 
the nuclear stain DAPI, without spectral bleed-through.  Although organic dyes were 
used in conjunction with QD-labeled cells in this application, QD-antibody conjugates 
could be substituted in order to multiplex immunofluorescence analysis as well. 
Macroscopic imaging of QD within en face aorta preparations indicate both the 
specificity of QD-labeled leukocytes toward lesions, as well as the high signal to noise 
ratio of QD in tissue (Figure 5B-C).  We selected QD configured for emission above 
green (< 540 nm) wavelengths for this study, due to the substantial amount of tissue 
autofluorescence within lesions in this range of the spectrum.  The selection of yellow-
red wavelengths provide for high signal to noise ratio imaging of atherosclerotic lesions 
without auto-fluorescence.  QD are optimally-excited using ultraviolet to blue excitation 
wavelengths.  Since ORO fluorescence is excited at ~650 nm, with peak emission in the 
range 670-700 nm (Figure 5A), macroscopic fluorescence imaging of ORO, QD585 
(lymphocytes), and QD655 (monocytes) could be simultaneously performed in the same 
tissue, since the QD selected do not emit appreciable fluorescence when excited at 650 
nm.  Therefore, QD emission wavelengths can be selected for optimal multispecies 
imaging, and can also be integrated within conventional lesion analysis tools which use 
fluorescent dyes or immunohistochemical stains. 
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Several observations support the utility of QD for in vivo imaging applications 
involving vascular disease.  The aorta is not directly accessible to optical imaging 
instrumentation, due to its deep location.  However, given the high intensity and stability 
provided by QD in the aorta (Figure 5), we believe that optical imaging of 
atherosclerotic lesions in vivo is feasible.  QD can be designed to emit in the near infrared 
emission windows for optimal in vivo imaging of tissues without the scattering and 
absorption limitations imposed by imaging of shorter wavelengths (35).  Furthermore, 
although the UV-blue excitation light required to optimally excite QD would only have 
limited penetration in tissue due to scattering and absorption phenomena, two-photon 
excitation instruments have been designed for exciting QD optimally while at the same 
time overcoming these limitations (36).  The prospect of using QD-antibody and QD-
peptide bioconjugates for labeling cell surface biomarkers or the cytoplasm of specific 
subtypes of cells, combined with in vivo imaging instrumentation, should facilitate efforts 
toward the molecular profiling of atherosclerosis in vivo for developing diagnostic assays 
and disease-customized therapeutic interventions for clinical usage. 
 
Conclusion 
 
We have demonstrated a technique for monitoring the recruitment of leukocyte 
subsets to atherosclerotic lesions.  The optical properties of QD can be harnessed to 
permit high signal to noise ratio imaging of multiple cell types without spectral overlap, 
and can also be used simultaneously with conventional immunofluorescence and 
immunohistochemical reagents used in the study of atherosclerosis.  Given the 
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implication of multiple cell types in the initiation and progression of atheroma, QD 
should be utilized to study these cell types within the same specimen in order to 
understand the interconnectedness of atherosclerotic mediators.   Future efforts of this 
technique will include molecular profiling of atheroma in vivo including the monitoring 
of inflammatory biomarker expression in early and late stages of disease, and the 
assessment of therapeutic response via the tracking of genetically-engineered monocytes 
infused systemically in order to promote lesion regression in vivo. 
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Abstract 
 
The objectives of this study were to synthesize and characterize functionalized 
solid lipid nanoparticles (fSLN), to investigate their interaction with endothelial cell 
monolayers, and to evaluate their transendothelial transport capabilities.  fSLN bearing 
tetramethylrhodamine isothiocyanate-labeled bovine serum albumin (TRITC-BSA) and 
Coumarin 6 were prepared using a single-step phase inversion process that afforded 
concurrent surface modification with a variety of macromolecules such as polystyrene 
sulfonate (PSS), poly-L-lysine (PLL), heparin (Hep), polyacrylic acid (PAA), polyvinyl 
alcohol (PVA), and polyethylene glycol (PEG).  TRITC-BSA/Coumarin 6 encapsulated 
in fSLN with composite surface functionality (PSS-PLL and PSS-PLL-Hep) were also 
investigated.  Size and surface charge of fSLN were analyzed using dynamic light 
scattering and transmission electron microscopy.  Transport across bovine aortic 
endothelial cell (BAEC) monolayers was assessed spectrophotometrically using a 
transwell assay, and fSLN localization at the level of the cell and permeable support was 
analyzed using fluorescence microscopy.  fSLN with tunable size and surface 
functionality were successfully produced, and had significant effects on cell localization 
and transport.  Specifically, fSLN with PSS-PLL-Hep composite surface 
functionalization was capable of translocating 53.2 ± 8.7 ug of TRITC-BSA within 4 
hours, with fSLN-PEG, fSLN-PAA and fSLN-PSS exhibiting near-complete apical, 
paracellular, and cytosolic localization, respectively.  Coumarin 6 was released by fSLN 
as indicated by dye labeling of BAEC membranes.  We have developed a rapid process 
for the production of fSLN bearing low and high molecular weight payloads of varying 
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physicochemical properties.  These findings have implications for drug delivery and 
bioimaging applications, since due to tunable surface chemistry, fSLN internalization 
and/or translocation across intact endothelial cell monolayers is possible. 
 
Introduction 
 
 Endothelial barrier function governs the transport of information such as 
macromolecules and solutes from the blood to the tissues.  The pathways through which 
this transport may occur have been identified to be paracellular (between cells) or 
transcellular (through cells) (1).  Endothelial cells maintain a tight barrier 
compartmentalizing blood and tissue through multi-protein junction complexes (2), and 
utilize various machinery such as caveolae (3) to shepherd desired materials across or 
between the cell.  Most processes involving the transport of macromolecules, such as 
clathrin-dependent endocytosis, direct cargoes to intracellular compartments, such as 
endosomes and lysosomes, as opposed to exocytosis at the basolateral membrane, and 
thus are not considered processes for translocation of compounds across endothelial 
barriers (4).  Some small molecules, due to their small size (<500 Da) and/or 
lipophilicity, are capable of translocation across endothelial barriers, including the tight 
blood-brain barrier (5).  However, it has been a significant challenge in pharmaceutical 
research to deliver imaging agents or therapeutics of varying physicochemical 
characteristics (e.g. high molecular weight, hydrophilic) across endothelial barriers with 
the same efficiency.   
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 We have developed a strategy for the single-step encapsulation and surface 
functionalization of solid lipid nanoparticles (fSLN), based on a combined adaptation of 
the solvent-injection process by Schubert et al. (6) and a previously-described process in 
our laboratory for the development of functionalized polymeric nanoparticles (7).  In our 
process, low and high molecular weight compounds of varying hydrophilicity and charge 
are entrapped within a coco-glyceride based, solid lipid matrix, with concurrent 
modification of the fSLN surface through incorporation of functional moieties in the 
aqueous phase.  In this study, we investigated whether synthesizing fSLN with tunable 
surface functionalities of varying hydrophilic-lipophilic balance (i.e. negative, positive, 
bioactive) could impart endothelial barrier translocation properties.  We demonstrate that 
fSLN can be engineered to achieve various cell interactions, and to transport compounds 
normally not capable of transcytosis across endothelial monolayers. 
 
Materials and Methods 
 
Materials 
 Softisan 100 was a gift from Sasol GmbH.  Coumarin 6 (laser grade) was from 
Acros Organics.  3 μm pore size permeable cell culture supports (Transwell®) were from 
Corning.  TRITC-BSA (1 mol TRITC/mol BSA), paraformaldehyde, Dulbecco’s minimal 
essential medium (DMEM), fetal bovine serum (FBS), 1-methyl-2-pyrrolidone (NMP, 
anhydrous), dimethylformamide (DMF, ACS Grade), tetrahydrofuran (THF, ACS 
Grade), acetone (anhydrous), poly (styrene-4 sodium sulfonate) (MW = 70,000, (PSS)), 
poly (acrylic acid) (MW = 10000, (PAA)), poly (L-lysine hydrochloride) (MW = 22,100,  
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(PLL)), poly (vinyl alcohol) (MW = 13,000, (PVA)), porcine heparin sodium salt (MW = 
4000-6000, (Hep)), and hydroxyl-terminated poly (ethylene glycol) (MW = 10,000, 
(PEG)) were from Sigma.  Float-a-Lyzer dialysis membranes (cellulose ester, 100K 
MWCO) were from Spectrum Laboratories.  VECTASHIELD aqueous mounting 
medium for fluorescence microscopy was from Vector Labs.  BAEC were a gift of Dr. 
Keith Gooch, and were used at passages 3-4.  BAEC were cultured in DMEM containing 
10% FBS and 1% penicillin/streptomycin/fungizone prior to transport experiments.  
BAEC cultures were free of fibroblast contamination.          
 
Methods 
Synthesis of Functionalized Solid Lipid Nanoparticles 
fSLN bearing various surface functionalities were prepared using a modified 
phase inversion process (Table 1).  0.1% (w/v) Softisan 100 and 0.01% (w/v) Coumarin 
6 were dissolved in a 1 mL organic phase consisting of the solvent pairs DMF/Acetone, 
THF/Acetone, or NMP/Acetone.  Solvent ratios were adjusted stoichiometrically to 
achieve solvent compositions of varying solvent polarity-polarizability indices (SPP) as 
measured by Catalan (Equation 1) (8, 9).  To this 1 mL of an aqueous phase consisting 
of 0.1% (w/v) TRITC-BSA and 0.001% (w/v) of one of the surface functionalization 
moieties (e.g. PSS, PLL) was added to yield the fSLN.  Residual solvents and freely 
soluble functionalization moiety were removed by dialysis against 1 L double distilled 
deionized water (ddH2O, Millipore) in Float-a-Lyzer dialysis membranes for four hours, 
with three complete changes of ddH2O.  Further modification of fSLN with composite 
functional surfaces, to synthesize fSLN-PSS-PLL, fSLN-PSS-PLL-Hep and fSLN-PLL-
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Hep were prepared by electrostatic layer-by-layer (LBL) assembly (10).  Specifically, 
fSLN-PSS, following dialysis, were incubated with 1% (w/v) PLL in ddH2O under 
constant stirring for 5 minutes, and then dialyzed in a similar manner as described above.  
fSLN bearing composite surface functionality was then achieved by incubating SLN-
PSS-PLL or SLN-PLL in 1% (w/v) Hep in ddH2O under constant stirring for 5 minutes, 
followed by 100K MWCO dialysis to generate fSLN bearing PSS-PLL-Hep and PLL-
Hep, respectively.  
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Table 1. Specific fSLN formulations prepared and their general properties. 
 
 
                           (1) 
Equation 1. Solvent Polarity-Polarizability Index Calculation for binary solvent systems, 
where Vx = volume of compound X, SPPY = SPP index value for solvent Y, as 
determined by Catalan (8). 
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fSLN Size and Zeta Potential Characterization 
 The size distribution and zeta potential (ζ) of the fSLN suspensions were 
determined in triplicate using a Beckman-Coulter DELSA 440SX Zetasizer. 
Additionally, ζ was mapped as a function of pH to determine the isoelectric point (11) of 
the fSLN surface.  Briefly, 200 μL of SLN suspension was suspended in a total of 2 mL 
ddH2O adjusted to the desired pH with 2 N HCl or 2 N NaOH as needed prior to ζ 
measurement.  Size distribution was monitored for several months post-fSLN synthesis to 
ascertain the effect of storage (4°C) on size.   
Low-Voltage Transmission Electron Microscopy (LVTEM)   
 fSLN-PSS were imaged using LVEM5 (DeLong Instruments).  fSLN were air-
dried onto 3 mm grids and then imaged at 5kV under 10-5 mbar vacuum.  The image was 
captured using an attached CCD camera (Proscan 1300 x 1030 pixels) and processed 
using a ProDIA Image Processing Software. 
In vitro Transendothelial Transport Studies 
P3 or P4 BAEC were plated onto polycarbonate inserts at a nominal density of 
50,000 cells/cm2 and the inserts were assembled in wells of a 12-well tissue culture 
microplate.  BAEC incubated at in a humidified incubator at 37°C and 5% CO2, until 
confluent (2-3 days).   
Prior to in vitro transport studies, the receiver compartments of the 12-well plates 
were filled with 400 μl Ringers’ solution supplemented with 10% FBS and the 
monolayers were bathed with 200 μl Ringers’ solution supplemented with 10% FBS.  
Next, 200 μL of the fSLN suspension in Ringers’ was added to the upper compartment, 
and the cells were incubated for 4 hours at 37°C.  Ringers’ supplemented with 10% FBS 
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containing 0.1% TRITC-BSA served as controls in order to verify integrity of the 
monolayer during the transport studies.  We initially verified that exposure to Ringers for 
4 hours did not affect BAEC monolayer integrity as assessed by the absence of visible 
discontinuities in the cell monolayer in micrographs.  Experiments were performed in 
triplicate.  SLN produced using the NMP/Acetone binary solvent system was selected for 
transport studies due to their size reproducibility even under slight variations in SPP.   
In selected wells, 1 mg/mL Texas Red-Dextran (MW = 10 kDa, neutral, 
Invitrogen) was incubated with BAEC monolayers seeded on Transwell inserts for 1 hr. 
in Ringers’/FBS, then rinsed 3 times with PBS and fixed.  In addition, Texas Red-dextran 
was incubated with BAEC 1 hour following BAEC incubation with fSLN-PSS-PLL-Hep, 
in order to assess effects on the paracellular permeability of the BAEC monolayer.  In 
these cases, the receiver compartment was replaced with fresh Ringers’/FBS solution to 
remove interfering fluorescence from fSLN.  Permeability coefficients were calculated 
based on dextran concentrations as previously-described (12).           
Following incubation, the media covering the cells was removed carefully using 
micropipette and rinsed three times with Ringers followed by fixation with 4% 
paraformaldehyde for 10 minutes.  The Transwell inserts were removed and mounted on 
a glass slide using VECTASHIELD/DAPI.  The 12-well microplates were then analyzed 
in a Biotek Synergy HT microplate fluorescence spectrophotometer configured for 
TRITC, Coumarin 6, and Texas Red-specific channels to measure SLN translocation 
across the BAEC monolayer.  For formulations indicating high translocation via 
microplate spectrophotometry (more than 15% fluorescence intensity above BAEC not 
incubated with fSLN), the concentration of TRITC-BSA in the receiver compartment 
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solution was determined via fluorescence spectrophotometry.  The solution was exposed 
to 40ºC temperature to melt solid lipid, and filtered through an Amicon-4 spin column 
centrifugation device with 10K MWCO in order to concentrate TRITC-BSA and remove 
free lipid.  Concentration was measured using a Nanodrop ND-3300 fluorescence 
spectrophotometer calibrated by a TRITC-BSA standard curve in Ringers’/10% FBS 
solution prepared by the same heating/concentration preparation steps.  Texas Red-
Dextran in the receiver compartment was measured by fluorescence spectrophotometry 
using a standard curve.         
Visualization of fSLN in BAEC Monolayers  
 The mounted Transwell supports were imaged using a Nikon TE2000U inverted 
fluorescence microscope equipped with a motorized computer-controlled z-focus device 
(Ludl, Inc.) using TRITC and FITC filters for TRITC BSA and Coumarin 6 respectively.  
Using Image Pro Plus 5.1 in conjunction with ScopePro 5.0 (Media Cybernetics), 2-D 
slices of BAEC in each channel were acquired by sequentially exposing a field of view 
under TRITC and FITC filters to generate a co-registered image showing fSLN and 
Coumarin 6 localization in the same frame.  The z-stacks were deblurred using a 
constrained, iterative algorithm (Inverse Filter, Sharpstack 5.2.2) calibrated to imaging 
objective settings (Plan Apo 40X oil immersion), and combined to construct cross-
sections that restrict out-of-focus haze from slices not within the X-Y plane of interest.  
Cross sections were generated from high-resolution TIFFs using Andor iQ 1.5 image 
analysis software (Andor Bioimaging).   
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 For evaluation of fSLN-PSS localization within BAEC in culture, cells were 
seeded to confluency in 6-well microplates and imaged via fluorescence microscopy 
using phase contrast and TRITC settings.     
Cytotoxicity of BAEC exposed to fSLN 
 BAEC seeded to confluency on 6-well microplates were incubated with fSLN-
PSS or fSLN-PSS-PLL-Hep suspensions for four hours in Ringers’/FBS.  Cells were 
rinsed three times and detached with 0.25% trypsin, and resuspended into ice-cold 
PBS/EDTA pH = 7.4.  Cells were then incubated with LIVE/DEAD single color fixable 
(green) viability kit (Invitrogen) according to manufacturer instructions, and assayed for 
viable/dead cells using a BD FACSCalibur flow cytometer equipped with 488 nm laser.  
The dead cell proportion, showing a log-scale enhancement in green (FL1) fluorescence, 
was quantified using FlowJo 7.2.2 (TreeStar software) in order to express %viability of 
BAEC populations as compared to Ringers’/FBS exposure alone.  A minimum of 20,000 
cells were assayed per sample.   
 
Results 
 
Size and Surface Charge Characterization 
 In our process, by varying the SPP of the organic phase, fSLN diameter was 
tunable.   The organic phase was composed of acetone and a highly polar secondary 
phase (NMP, THF, or DMF).  Increasing the polarity of this phase (higher SPP) resulted 
in a reduction in fSLN mean diameter (Figure 1).  While the THF-Acetone system 
offered fSLN over a much wider range than the other systems investigated, the NMP-
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Acetone system afforded the particles with highest size reproducibility with variance in 
SPP.  This suggests that the range of NMP-Acetone volume fractions studied all have 
high miscibility with water, favoring rapid phase inversion and lipid packing, which 
subsequently promotes the formation of fSLN of smaller size.  fSLN prepared by our 
process appeared to be fairly monodispersed as satellite populations above and below the 
size of the major population peak were wither minimal or absent.      
 All three solvent systems were capable of producing stable nanoparticles, as 
indicated by lack of coagulation/turbidity in solution over a month of storage, except for 
the case of fSLN-PLL, which noticeably coagulated in suspension within 24 hours post-
synthesis.  The spherical morphology of the fSLN was confirmed by low-voltage TEM 
(Figure 2).  Following storage at 4°C for one month, fSLN-PSS (SPP = 93.44) exhibited 
a small change (4.54%, n = 3) in mean diameter as measured by dynamic light scattering.   
The incorporation of the prescribed functional group in the aqueous phase onto 
the SLN surface was verified by measuring the pIe of the fSLN surface.  This was 
performed by mapping the ζ of the fSLN as function of pH.  pIe corresponded reasonably 
well with that for the pKa of the ionizable group in the functional moiety (Figure 3).  
Thus, entrapment of the functional moiety on the SLN surface was achieved at 
concentrations sufficient to impart its charge characteristics. 
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Figure 1. fSLN-PSS Diameter as a function of solvent polarity-polarizability index (SPP) 
for three different binary solvent systems of varying solvent composition (n=3).  All 
solvent pairs consisted of Acetone and one of NMP, DMF, or THF.  Diameter was not 
affected by the incorporation of other surface functionalities (data not shown).  SLN 
diameter is expressed as a peak (>80%) value from size distribution analysis using multi-
angle dynamic light scattering.  
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Figure 2. LVTEM of fSLN-PSS synthesized using the NMP/Acetone binary solvent 
system.  Compacted nanoparticles (black regions) with spherical morphology are 
apparent.  Air-drying artifacts distort nanoparticle size measured by dynamic light 
scattering.   
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Surface Charge Characterization of Composite fSLN 
The impartation of composite layered surface functionalities (PSS-PLL, PSS-
PLL-Hep, PLL-Hep) was verified by measuring the ζ, of fSLN at physiological pH (7.4), 
which for fSLN-PSS-PLL and fSLN-PSS-PLL-Hep was 8.72 ± 3.22 mV and 2.82 ± 1.71 
mV, respectively.  ζ  for fSLN-PSS at pH = 7.4 was -42.40 ± 5.78 mV (Figure 3), 
collectively suggesting that fSLN-PSS-PLL-Hep surfaces are composed of both PLL and 
Hep. 
In vitro Transendothelial Transport Studies 
 Of all formulations tested, fSLN bearing the composite layered functionality of 
PSS-PLL-Hep afforded the most translocation of BSA (fluorescence intensity 
corresponding to 53.2 ± 8.7 μg as determined by fluorescence spectrophotometry, Figure 
4).  The relative amount of TRITC-BSA translocated across BAEC in the PSS-PLL-Hep 
system was 22-fold greater than the second most efficient system, fSLN-PLL-Hep, and 
about 160-fold greater than TRITC-BSA/Ringers’ control.  Previous studies reported a 
baseline flux of < 0.05 pmol BSA/hr for intact BAEC monolayers, a rate three orders of 
magnitude lower than observed for the fSLN-PSS-PLL-Hep system in this study (13).  
fSLN-PEG and fSLN-PVA systems did not transport detectable levels of TRITC-BSA in 
the receiver compartment.  Furthermore, Coumarin 6 was not detected in the receiver 
compartments for any formulation tested. 
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Figure 3.  Zeta potential (ζ) as a function of pH for various functionalized SLN (n = 3, 
reported as mean ± S.D.).  The isoelectric point (11) of the sample (point at which ζ = 0 
mV) corresponds closely with the pKa of the surface functionality’s ionizable group (PSS 
= sulfonic acid ( pKa = 2.1), PAA = acrylic acid (pKa = 4), PLL = amine (10.5), Hep = 
uronic acid (3.13), PEG = hydroxyl (5))   
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Figure 4. Fluorescence spectrophotometry of fSLN/TRITC-BSA transport across BAEC 
monolayers for a variety of surface functionalities (n = 3, reported as mean ± S.D.).  
Fluorescence intensity of fSLN-PSS-PLL-HEP-associated receiver compartment was 
measured to correspond to 53.2 ± 8.7 μg of TRITC-BSA.  Other fSLN species were 
below thresholds of TRITC detection in receiver compartments.   
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Endothelial monolayer integrity following fSLN-PSS-PLL-Hep translocation was 
measured using a dextran permeability assay.  Dextran is known to translocate BAEC 
monolayers via a paracellular route, and thus has been used to measure the integrity of 
endothelial barriers and their tight junctions (14).  Prior to incubation with fSLN, 
permeability of Texas Red-dextran (MW = 10,000) across BAEC monolayers after 1 hr. 
was 9.1 X 10-6 ± 3.5 X 10-7 cm/s.  Following 4 hr. incubation with fSLN-PSS-PLL-Hep, 
the 1 hr. dextran permeability was 9.6 X 10-6 ± 4.3 X 10-7 cm/s (n = 3).  These data were 
similar, and also consistent with previous studies of dextran permeation across intact 
monolayers (15).  Thus, endothelial integrity at this timepoint was not compromised with 
regard to the paracellular transport pathway.  In addition, fSLN-PSS-PLL-Hep were 
detectable by fluorescence microscopy in the receiver compartment, indicating that fSLN 
can be transported across monolayers intact, while maintaining stability in serum (Figure 
5). 
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Figure 5. fSLN-PSS-PLL-Hep observed by fluorescence microscopy in receiver 
compartments following transendothelial transport assays.   
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Fluorescence Microscopy of BAEC Incubated with Functionalized SLN 
 Fixed BAEC monolayers were imaged using fluorescence microscopy to assess 
localization and extent of transport within monolayers.  Representative fluorescence 
micrographs from the six most efficacious fSLN formulations are shown in Figure 6.  
Our data suggests that the chemical composition of the SLN surface dictates various 
aspects of fSLN interaction with BAEC monolayers including compartment of 
localization (intracellular versus apical cell surface), and transport pathway (paracellular 
versus transcellular).   
Among the negatively charged fSLN, fSLN-PSS exhibited intracellular 
localization, with a diffuse cytoplasmic distribution, but without passage through 
endothelium (Figure 6F).  To confirm this distribution, fSLN-PSS incubated with BAEC 
on tissue culture polystyrene were also imaged for greater clarity by fluorescence 
microscopy, and fSLN distribution within cell cytoplasm was similar (Figure 7).  fSLN-
Hep was internalized within BAEC, but appeared to be sequestered in the cytoplasm and 
not translocated, as indicated by a lack of fluorescence at the support membrane level 
(Figure 6C).  fSLN-PAA particles, however appeared to primarily localize along cell-
cell junctions (Figure 6D).  These results suggest that impact of charge in cellular 
interaction in this system might be secondary to other considerations such 
physicochemical characteristics of the surface functional moiety.   
Among the fSLN with composite surface functionality, fSLN-PLL-Hep (Figure 
6B) was distributed primarily along paracellular regions and/or at the apical surface.  
Furthermore, no accumulation of these particles at the level of the Transwell membrane 
insert was observed, suggesting a lack of translocation.  This is significantly different  
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Figure 6. Fluorescence microscopy of permeable supports with fixed BAEC monolayers 
following in vitro SLN transendothelial transport studies.  Each of the 6 display items 
consist of a 2-D view of the monolayer at the middle of the cell (16) and a cross-sectional 
view of the same monolayer processed via deblurring and reconstruction from a 3-D 
stack through the insert (bottom).  TRITC-BSA is red, and Coumarin 6 is green; a 
mixture of the two is orange in color.  Images are representative of experiments 
performed in triplicate.  SLN formulations displayed are (A) fSLN-PSS-PLL-Hep, (B) 
fSLN-PLL-Hep, (C) fSLN-Hep, (D) fSLN-PAA (arrowheads show localization along cell 
borders), (E) fSLN-PEG, and (F) fSLN-PSS.  (fSLN-PSS-PLL data not shown)  
(Magnification 400X) 
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Figure 7. Fluorescence micrographs of BAEC incubated with fSLN-PSS.  All cells in 
view are efficiently and diffusely labeled with TRITC-BSA containing nanoparticles 
(pseudocolored red).  (Magnification 100X) 
115
from the fSLN-Hep system, which also possesses a net negative surface charge, and once 
again alludes to fSLN-cell interactions that are more complex and driven by 
physicochemical considerations.  Similarly, no appreciable translocation was observed in 
fSLN-PSS-PLL (data not shown), although its positively charged surface is more 
favorably disposed toward interacting with negatively charged cell surfaces.  These 
observations are consistent with transendothelial transport studies (Figure 4).  In 
contrast, fSLN-PSS-PLL-Hep (Figure 6A) was primarily localized to paracellular 
transport regions, also known as tight junctions, although in some cases larger SLN were 
restricted to the apical cell surface without entry.  As shown in the cross-sectional image 
derived from 3-D image processing (Figure 6A), fSLN-PSS-PLL-Hep bearing TRITC-
BSA were transported to the level of the permeable support (bottom layer of image).  
This level of monolayer permeation was not observed for any other species tested.  In the 
transport studies this system yielded the highest fluorescence in the receiver compartment 
as well (Figure 4).  No translocation was observed in the fSLN-PEG (Figure 6E) and 
fSLN-PVA system (fSLN-PVA data not shown).  These fSLN remained primarily 
associated with the plasma membrane near the apical surface as highly compacted 
nanoparticle aggregates, with no detected populations at support boundaries.  Since the 
samples were thoroughly washed prior to fixing, these interactions represent stable cell 
surface incorporation.  In all inserts, it was observed that Coumarin 6 was partitioned 
effectively in the cell membrane.  This could be due to either leakage of the small 
molecule through the fSLN, or additionally, partitioning of the dye within cell 
membranes upon initial fSLN contact with BAEC.  Further investigation is necessary to 
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determine the primary mechanism of small molecule release, as this study would be 
important for investigating fSLN as drug delivery formulations. 
Cytotoxicity Analysis  
 The toxicity profile of fSLN was assessed using a membrane integrity dye in 
conjunction with flow cytometry, and was found to be similar to Ringers’/FBS exposure 
alone (Figure 8).  These results, in conjunction with dextran permeability studies, 
demonstrate that fSLN constitute a biocompatible approach for the translocation of 
compounds across endothelium.     
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Figure 8. Flow cytometric toxicity analysis.  BAEC were incubated with fSLN-PSS or 
fSLN-PSS-PLL-Hep for 4 hrs. in culture.  Viability of fSLN-labeled cells was similar to 
BAEC incubated in Ringers’/FBS.  Data reported as %viable (mean ± S.D., n = 3) BAEC 
from a sample of 20,000 assayed cells. 
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Discussion 
 
The ability to deliver of therapeutics and imaging agents of diverse 
physicochemical properties across endothelial barriers has key implications in the 
diagnosis and treatment of high-impact diseases such as cancer, atherosclerosis, and 
diabetes.  In general, current methods for traversing endothelium may not be suitable for 
high molecular weight compounds, or may expose the underlying tissue to the 
unrestricted influx of compounds as a result of prolonged barrier perturbation.  In our 
approach, we have selected a solid lipid, the hydrogenated coco-glyceride Softisan 100, 
as a biocompatible starting material for the delivery of compounds across endothelial 
barriers, as it is a component of many topical formulations for the purpose of imparting 
enhanced spreading and permeation characteristics (17, 18).   
The physicochemical characteristic of fSLN surfaces appears to be the dominant 
parameter in dictating their destination within or across endothelial cells.  Among the 
various fSLN studied, fSLN bearing the composite surface derived from PSS, PLL and 
Hep afforded the most efficacious transport across BAEC monolayers.  Since this 
efficiency of translocation was not observed for individual components of this 
formulation (i.e. fSLN-PSS, fSLN-PSS-PLL, fSLN-PLL-Hep), it is apparent that all three 
moieties are necessary to achieve high molecular weight payload translocation.  A 
possible mechanism involving diminished cellular membrane interaction due to the 
presence of the negatively-charged PSS and some specific interactions with cell junctions 
through tight-junction proteins with affinity for heparin may be involved, with the PLL 
layer serving as a molecular bridge between the PSS and Hep regions on the fSLN 
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surface.  This mechanism seems reasonable based on the experimental observations and 
what is known about heparin.  Heparin is a highly bioactive polysaccharide involved in 
critical endothelial cell functions.  Heparin is present in many configurations which serve 
to elicit distinct responses from endothelial cells, which also have specific heparin-
binding sites (19-21).  Furthermore, heparin is involved in the transcytosis of 
biomolecules across endothelium (16).  However, in our studies, fSLN-Hep, while 
appearing to be stable nanoparticles, were not capable of transcytosis. This observation is 
consistent with the proposed mechanism wherein the relatively hydrophobic, but 
negatively charged PSS has a role in favoring interaction with tight junctions.  Further 
studies are warranted to ascertain if the ultrastructure of Hep are altered by the presence 
of strongly-charged polyelectrolytes in conjunction with a neutral solid lipid.    
Some of the cell interaction characteristics of the fSLN warrant further attention.  
fSLN-PSS were observed to efficiently and homogenously penetrate cell membranes into 
cytoplasmic space.  A lack of aggregation of the particles suggests that the cytoplasmic 
distribution may not entirely involve the endosomal pathway.  As discussed earlier, PSS 
may inhibit solid lipid interactions with cell surface domains, in turn facilitating direct 
membrane fusion.  fSLN-PAA was observed to possess a very high affinity for the cell-
cell boundaries.  However, this site-specific aggregation did not appear to facilitate 
transendothelial transport.  Coating of fSLN with PEG resulted in localization of 
nanoparticles exclusively to cell surfaces.  The exclusion volume created by the gyration 
of PEG tethers on the fSLN surface may prevent lipid-lipid interactions entirely.  Our 
preliminary efforts to probe the effects of fSLN on endothelial barrier integrity and 
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cytotoxicity suggest that lipid nanoparticles do not adversely effect cell viability or 
barrier properties, as indicated by flow cytometric and dextran permeability assays. 
Our initial studies concerning the synthesis, characterization, and in vitro 
transendothelial transport properties of fSLN warrant their future investigation as 
versatile drug or bioimaging probe carriers for vascular disease.  Our process provides for 
the rapid, single-step encapsulation of physicochemically-diverse compounds within 
stable solid lipid matrices, which can concurrently be engineered at their biological 
interface to exhibit novel properties, such as transcellular or intracellular penetration.  We 
anticipate its further investigation as a multimodal delivery system for bioimaging, drug 
delivery, and/or gene therapy. 
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Introduction 
 
 The efficient intracellular targeting of both clinical imaging and therapeutic 
agents poses a significant challenge in medicine and biology.  Optimal systems for this 
purpose should feature biocompatibility, the capability to deliver physicochemically-
diverse payloads such as nanoparticles or proteins, evasion of the endo-lysosomal 
pathway of internalization, and an amenability to surface functionalization for tuning of 
interfacial characteristics.  Here we report on the application of multimodal 
functionalized solid lipid nanoparticles (fSLN) for efficient delivery into the cytosol with 
low toxicity.  fSLN were capable of encapsulating various nanoparticulate and 
chemotherapeutic payloads.  Delivery of fSLN into the cytosol was achieved after pre-
incubation of endothelial cells and cell lines at 4°C, and without colocalization with 
endosomes.  fSLN-labeled cells could be imaged, depending on the payload, by magnetic 
resonance imaging, fluorescence imaging, and/or light microscopy, and paclitaxel-loaded 
fSLN were capable of inducing cell cycle arrest.  fSLN are a novel vehicle for the 
delivery of diverse payloads into cells without endosomal sequestration or chemical 
modification of the encapsulated payload itself.                      
 Current approaches directed toward the goal of intracellular drug targeting and/or 
imaging include the use of cationic peptides (1, 2) or polymers (3), and nanoparticulate 
formulations such as ligand-conjugated liposomes (4), dendrimers (5) or cholesterol-
based carriers (6, 7).  Many of these strategies are limited by cytotoxicity at modest 
doses, reliance on endocytosis, adverse modification of the drug/imaging agent, and a 
decrease in delivery efficiency with increasing payload size.  We therefore sought to 
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develop a biocompatible delivery paradigm which would enable the rapid intracellular 
delivery of a diverse range of imaging agents and therapies without compromising their 
functions.   
Highly-biocompatible solid lipids, or “hard fats,” have been utilized extensively 
in dermatological and cosmetic applications for the ability to promote permeation and of 
topically-applied compounds (8-10).  However, studies to elucidate the nature of their 
contact with cell membranes on the microscale have not been carried out with great 
detail.  We hypothesized that some solid lipids may have intimate interactions with 
plasma membranes such that the translocation of co-formulated species, such as drugs or 
nanoparticles, is enabled.  We conducted studies to determine whether solid lipids could 
be formulated into nanoscale pharmaceutical or contrast agent carriers.  A discrete class 
of solid lipids, hydrogenated coco-glycerides, were identified by our laboratory which 
could be formulated into nanoparticles ranging from approximately 80-900 nm (11).     
fSLN synthesis using these solid lipids is accomplished by the solvent-assisted 
formation of a microemulsion (11, 12).  In this process, the lipid is dissolved within an 
organic solvent system of tunable polarity, such that the affinity of the solution for water 
is controllable.  Upon the addition of an aqueous phase to the solvent mixture, the 
hydrophobic packing of the lipid upon exposure to water provides for instantaneous 
formation of a nanoscale particle, the size of which is determined by the polarity of the 
organic phase.  Higher solvent polarity permits rapid phase inversion as water miscibility 
is higher, whereas lower solvent polarity extends the nanoparticle packing time, allowing 
for larger-sized nanoparticles to form.  By adding hydrophobic species within the solvent 
phase and hydrophilic species within the aqueous phase, we have successfully 
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encapsulated diverse species, such as albumin and the fluorescent dye Coumarin 6 (11).  
The high loading efficiency of our lipid entrapment process translates to high signal to 
noise ratios compared relative to individual, non-encapsulated species, and permits the 
delivery of higher concentrations of therapies or imaging agents in discrete packets.  SLN 
can be engineered to bear multiple surface functionalities, permitting their usage as 
conventional nanoparticles for site-specific targeting by means of charge or biomolecule-
assisted conjugation (11).  Cationic, neutral, anionic, and bioactive interfaces have been 
constructed on fSLN surfaces via layer-by-layer assembly.  The process of formulating 
SLN requires no surfactants or emulsifying agents, and all solvents are removed by 
extensive dialysis following SLN formulation.  In past work, it was observed that 
negatively-charged fSLN bearing a polystyrene sulfonate (PSS) polymer surface, as 
opposed to other surfaces exhibiting cationic charges, exhibited interactions with bovine 
aortic endothelial cell (BAEC) membranes which facilitated internalization (11).  In this 
report, we expand upon previous studies to widen the scope of constructs that can be 
encapsulated within fSLN for evaluation as a multimodal device, and to investigate the 
mechanism and dynamics of fSLN internalization within cells.    
 
Methods 
 
Synthesis and characterization of fSLN 
 fSLN were synthesized using a modified phase inversion technique as previously-
described (11).  In this process, a 500 μL aqueous phase is prepared consisting of 
hydrophilic moieties for encapsulation, along with the stabilizing polymer PSS (0.1%, 
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MW = 70,000, Sigma), confers sufficient dispersion and water solubility upon resulting 
fSLN.  This phase is combined with a 500 μL anhydrous organic phase consisting of N-
methyl pyrrolidone:acetone = 70:20, with the remainder of volume consisting of 
hydrophobic encapsulants in DMSO.  Hydrophilic encapsulants studied were 1 mg of 20 
nm fluorescein isothiocyanate (FITC)-dextran-coated superparamagnetic iron oxide 
nanoparticles (SPIO, Micromod Partikletechnologie GmbH), and/or 1 μM 1.4 nm 
streptavidin-Alexa Fluor 594-conjugated gold colloids (Nanoprobes, Inc.).  Hydrophobic 
species encapsulated included 1 μM quantum dot nanocrystals (Evident Technologies) 
dialyzed into DMSO, and/or 1 μM paclitaxel (Sigma) in DMSO.  fSLN-QD-SPIO were 
produced by incorporating 1 mg and 1 μM doses of SPIO and QD, respectively, in the 
reaction mixture, in order to investigate multimodality.  fSLN were concentrated as 
necessary using a Pall Nanosep spin column filtration device, MWCO = 10K using 
distilled water or PBS.  Unencapsulated (free) SPIO or QD were phase-separated and 
removed by Pasteur pipette.  Organic solvents or low molecular weight compounds (gold, 
paclitaxel) were removed by dialysis into double-distilled water or PBS using 25K 
regenerated cellulose dialysis columns for 2 hrs. followed by overnight dialysis in 100K 
MWCO columns (Spectrum Laboratories).   
The fluorescence (intrinsic or dye-labeled) of all encapsulants enabled the 
determination of encapsulation efficiency by fluorescence spectrophotometry using a 
Nanodrop ND-3300 and fitting to standard curves of encapsulants.  fSLN bearing no 
payload was processed under identical parameters and used as a control.  Encapsulation 
efficiency was determined for fSLN-QD, fSLN-SPIO, fSLN-paclitaxel and fSLN-gold by 
determining the ratio of encapsulated species to total species originally present in the 
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reaction mixture prior to phase inversion.  Samples were analyzed in triplicate.  fSLN 
were further characterized by dynamic light scattering analysis on a Beckman-Coulter 
DELSA 440SX particle zetasizer, and by fluorescence microscopy using a Nikon 
TE2000U inverted fluorescence microscope equipped with dye and QD-matched 
excitation and bandpass emission filters.  Transmission electron microscopy (TEM) was 
performed on a Phillips CM-12 at 80 keV.  fSLN were pipetted 1:1 with a solution of 
pure ethanol on Formvar grids and dried.   Staining with 5% phosphotungstic acid was 
performed to stain solid lipid in negative relief.       
 
Flow cytometry and fluorescence microscopy  
 Bovine aortic endothelial cells were cultured at passages 4-6 in DMEM with 10% 
FBS and 1% pencillin-streptomycin at 37°C, 5% CO2.  The human cervix carcinoma cell 
line, HeLa (American Tissue Type Culture Collection # CCL-2), and a mammary 
carcinoma line, 4T1 (gift of Dr. Jack Virostko, Vanderbilt Institute of Imaging Science), 
were cultured in the same medium and under the same conditions. 
HeLa cells were cultured in 6-well microplates or 4-well chambered slides (Lab-
Tek II, Nalge Nunc) to 80% confluency.  For flow cytometric analysis of fSLN-QD 
uptake, cells were incubated with the fSLN equivalent of 100 nM QD emitting at 580 nm 
for 30 min at 37°C.  To block endocytosis, cells were pre-incubated at 45 min. at 4°C and 
then incubated with fSLN-QD at the same temperature for 30 min.  Following incubation 
cells were rinsed three times in HBSS, pH = 7.4.  These incubation steps were also 
repeated with Qtracker QD-loading reagent (Invitrogen) according to manufacturer’s 
instructions.  Cells were detached with 0.25% trypsin-EDTA, which also served to 
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remove surface-bound fSLN.  Cells were pelleted at 400 X g, 5 min., and rinsed once and 
resuspended in HBSS for flow cytometry.  Cells were analyzed on a LSR II flow 
cytometer (BD Biosciences) equipped with a UV laser and a 585/42 nm bandpass 
emission filter to detect QD.  Unlabeled cells were used as a control.  This experiment 
was performed in triplicate.     
For cell cycle analysis, HeLa were incubated with 10 nM fSLN-paclitaxel, drug 
alone (in DMSO), or empty fSLN for 24 hrs.  Cells were then rinsed thrice in HBSS, 
trypsinized, and fixed with ice-cold 70% ethanol for 2 hrs. at -20°C.  The cells were 
rinsed in HBSS and pelleted.  The pellet was resuspended in 1 mL of 50 μg/mL 
propidium iodide and 50 μL of 10 μg/mL RNAse A (Sigma) for 12 hr. at 4°C and 
analyzed on a FACSCalibur flow cytometer (BD Biosciences).  Data was analyzed using 
FlowJo 7.2 (Treestar Software).  For cell cycle analysis, the distribution of cell cycle for 
each population was determined using the Watson pragmatic fitting module incorporated 
in the software.  10,000 cells of each population were analyzed.  To determine cell 
viability, cells were stained with the LIVE/DEAD single color fixable green kit 
(Invitrogen) and analyzed according to manufacturer instructions. 
For fluorescence microscopy, HeLa were incubated with 10 nM fSLN-QD were 
fixed in 4% paraformaldehyde in PBS, quenched with 100 mM glycine in PBS, and 
coverslipped using Cytoseal 60 (Richard-Allan Scientific).  Samples were imaged using a 
Nikon TE2000U inverted fluorescence microscope.  For imaging of fSLN bearing Alexa 
Fluor 594-conjugated gold colloids, cells were incubated with 100 nM fSLN-gold or gold 
colloids alone as a control for 30 min. at 37°C.  Cells were rinsed thrice in HBSS, and 
imaged using the same procedure. 
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For qualitative light microscopic analysis of fSLN-QD-SPIO uptake in HeLa 
cells, cells on chambered slides were incubated with the fSLN equivalent of 0.25 mg 
SPIO nanoparticles for 60 min at 37°C.  0.25 mg dextran-coated SPIO was incubated for 
60 min. for comparison with fSLN-SPIO and 24 hrs. as a positive control.  Cells were 
then rinsed and fixed.  Samples were stained using Perls’ Prussian Blue stain according to 
manufacturer instructions (Sigma).  Cells incubated with fSLN-gold or fSLN-gold-SPIO 
(using dosage for fSLN-gold) were stained with the gold colloid detection reagent 
GoldEnhance for qualitative light microscopic analysis (following the Prussian Blue stain 
in multimodal samples).       
 
Magneto-optical fSLN imaging      
For magnetic resonance imaging, four samples containing a pellet of 1 X 105 cells 
(in Eppendorf tubes) were placed in a custom-built holder and aligned so that the pellet 
(400 X g, 5 min.) of each sample was in approximately the same plane. Samples were 
then imaged at bore temperature (20 ˚C) using a 7.0-T, 16-cm bore Varian Inova 
spectrometer (Varian Inc., Palo Alto, CA). A 63-mm inner diameter quadrature volume 
coil (Doty Scientific, Columbia, SC) was used for RF transmission and reception.  
 For each set, a single 2-mm slice just above the pellet was chosen from T2-
weighted scout images for subsequent imaging. T2 measurements were then made using a 
single-slice, multiple spin-echo sequence (13) with an echo spacing (∆TE) = 7 ms, 
repetition time (TR) = 2 s, number of echoes (NE) = 16, field of view = 40 × 40 mm2, 
acquisition matrix = 64 × 64, in-plane resolution = 625 ×  625 μm2, acquisition 
bandwidth = 51.8 kHz, and number of averages (NEX) = 2. Spoiler gradients were placed 
132
about each 90x180y90x broadband composite refocusing pulse (14) in an alternating and 
descending fashion (13) in order to remove signal from unwanted coherence pathways. 
The spoiler gradients were calculated so as to cause a minimum phase dispersion of π/2 
across one slice thickness, which was found to be sufficiently large to remove stimulated 
echo artifacts within the decay curve. 
 T1 measurements were made in the same slice using the multiple flip angle 
approach (15), in which a total of four gradient echo images were acquired using 
excitation flip angles (θ) of 5, 10, 20, or 40˚. Additional imaging parameters included TE 
= 2.6 ms, repetition time (TR) = 50 ms, prescan dummy scans = 100 (to ensure steady-
state was reached prior to acquisition), field of view = 40 × 40 mm2, acquisition matrix = 
64 × 64, in-plane resolution = 625 ×  625 μm2, acquisition bandwidth = 50 kHz, and 
number of averages (NEX) = 8. 
The multiple-spin echo data, (TE)M⊥ , were used to generate T2 maps by fitting 
data from each voxel to  
 
 2TE /0(TE) e
TM M −⊥ =  (1) 
 
where M0 represents the equilibrium magnetization and TE the echo times used during 
acquisition. The multiple flip angle data, ( )M θ⊥ , were used to generate T1 maps by 
fitting data from each voxel to  
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where TR and θ represent the repetition time and excitation flip angles used during 
acquisition, respectively. All fitting was performed using the nonlinear Levenberg-
Marquardt optimization algorithm (16).   
Following magnetic resonance imaging, cell pellets and a gradient of fSLN-QD-
SPIO suspensions were imaged using an IVIS 200 fluorescence imaging system (Caliper 
Life Sciences) with filters appropriate for QD, using background subtraction to remove 
autofluorescence.  Empty fSLN incubated with cells were used as a control.    
 
Results and Discussion 
 
 fSLN-PSS were capable of encapsulating quantum dot nanocrystals (2.4 nm, 
Figure 1), gold colloids (1.4 nm), iron oxide nanoparticles (SPIO, 20 nm), and/or the 
anticancer drug paclitaxel (Table 1).  The encapsulation of hydrophobic compounds was 
relatively more efficient.  The mean size of fSLN-QD as determined by dynamic light 
scattering analysis was 111 ± 8.6 nm for >65% of the distribution of particles.  The 
remaining distribution of nanoparticles post fSLN synthesis was typically a lipid 
aggregate easily removed by 0.8/0.2 μm series syringe filtration.  Using the same process 
parameters, less than 10% differences in hydrodynamic radius between fSLN bearing 
varying cargoes, including multimodal nanoparticles (QD-SPIO), were observed by 
dynamic light scattering analysis.  These observations suggest that the hydrophobic lipid 
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packing which occurs upon phase inversion produces similarly-sized nanoparticles, 
regardless of the encapsulated species.   
 
Table 1. Encapsulation Efficiencies for fSLN formulations 
fSLN formulation Encapsulation Efficiency (%, n = 3) 
fSLN-QD 40.23 ± 7.18 
fSLN-Gold 46.34 ± 8.57 
fSLN-Paclitaxel 65.73 ± 7.41 
fSLN-SPIO 22.11 ± 3.37 
 
 
 
Figure 1. Fluorescence spectroscopy and transmission electron microscopy of fSLN.  (A) 
fSLN-QD-PSS (orange) can be surface functionalized with PLL (green, FITC-labeled) 
without alteration in QD fluorescence emission profiles.  (B-C) Low magnification 
(66000X) and high magnification (176000X)  TEM of fSLN-QD-PSS.  
 
 
Within a 30 min. incubation period, fSLN internalized within HeLa cell 
membranes as determined by flow cytometric analysis (Figure 2A).  Internalization of 
fSLN was only slightly reduced at 4°C cell pre-incubation rather than blocked, 
suggesting that fSLN can enter cytoplasmic space without complete dependence on 
active transport.  The slight reduction in internalization could be due to decreased plasma 
membrane fluidity, which would reduce lipid-lipid interactions between the nanoparticle 
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and cell membrane.  In contrast, the quantum dot endosomal-loading agent, Qtracker, 
which translocates nanocrystals across membranes via cationic oligoarginine peptides 
(17), did not internalize within cells appreciably at 4°C (Figure 2A).  Co-incubation of 
cells with Qtracker and fSLN bearing 580 nm-emitting quantum dots revealed distinct 
localization within the cytoplasm (Figure 2B).  These data collectively reveal that fSLN 
may be capable of membrane translocation to the cytosol without inclusion and 
sequestration in endosomal compartments, making subcellular targeting possible.  Our 
approach achieves nanoparticulate internalization within cells without cationicity, which 
may complex electrostatically with negatively-charged cell surface proteins within the 
cell and possibly alter their function or availability within the cell.  Viability of HeLa 
treated with fSLN-QD for 2 hrs. was 88 ± 3 %, comparable to untreated cells (92 ± 2 %) 
and empty fSLN-treated cells (90 ± 5 %).        
 fSLN successfully delivered gold colloids within HeLa cells as determined by 
light and fluorescence microscopy (Figure 2C).  Colloids exhibited a diffuse cytoplasmic 
and cell membrane localization when delivered by fSLN, but did not translocate cell 
membranes efficiently without lipids (Figure 2D).  fSLN may therefore be a useful 
carrier for gold colloids in photothermal ablation applications (18, 19), or as a computed 
tomography x-ray (20) or electron microscopic contrast agent (21).   
SPIO were also effectively delivered into HeLa cells within 1 hr post-incubation 
(Figure 2E).  However, when dextran-coated SPIO were incubated with HeLa cells for 
the same interval, little internalization was indicated by Prussian Blue staining (Figure 
2F).  Thus, fSLN enable rapid translocation of compounds incapable of penetrating cell 
membranes alone.                   
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Figure 2. Flow cytometric, fluorescence, and light microscopic characterization of 
multimodal fSLN internalization in HeLa cells.  (A) fSLN translocation into HeLa is 
largely energy-independent.  (B) 200X magnification of distinct localization of fSLN-
QD580 (red) and endosome-marking Qtracker cationic peptide-based conjugates, which 
aggregate in the endosomes (green).  (C-D) Alexa Fluor 594-labeled gold colloid 
internalization in DAPI-labeled HeLa.  (C) fSLN-gold, (D) gold colloids alone at 
equivalent concentration.  Inset (C) Goldenhance light microscopic enhancement of gold 
colloids in HeLa cells (charcoal regions).  Magnification 50X.  (E-F) Prussian blue 
staining of fSLN-SPIO (E) and SPIO given at equivalent dose and incubation time (60 
min.) in HeLa cells, counterstained with nuclear fast red.  Magnification 50X.    
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fSLN efficiently delivered SLN-paclitaxel into HeLa cells for induction of cell 
cycle arrest in G2 phase (Table 2), comparable to free drug.  Nanoparticles bearing dye-
labeled paclitaxel were visible in the cytosol within 30 min. of incubation (Figure 3).  24 
hrs. post-incubation, a marked increase in the percentage of cycling cells in the G2 phase 
was observed, consistent with literature reporting the timecourse of paclitaxel-induced 
mitotic arrest (22).  Therefore, fSLN can potentially be utilized as a drug delivery vehicle 
in conjunction with imaging agents to visualize uptake and/or biodistribution.  Future 
studies are warranted to investigate relative drug formulation efficacy when combined 
with nanoparticles.          
 
 
 
Figure 3. Fluorescence micrograph (magnification 100X) of HeLa stained with Oregon 
Green 488-loaded fSLN. 
 
 
Table 2. Efficacy of 10 nM fSLN-paclitaxel compared to 
drug alone in arresting G2/M phase in HeLa cells following 24 hr. incubation 
Sample %G1 %G2
Untreated 37.08 23.52
fSLN 35.07 22.12
fSLN-paclitaxel 21.88 49.57
Paclitaxel 17.99 45.61
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 The multimodality of fSLN was specifically-investigated by translocating 
quantum dots and iron oxide nanoparticles within the same fSLN vehicle across 4T1 
mammary carcinoma cells.  This tumor cell line was selected due to its highly-metastatic 
potential.  Imaging modalities to track tumor cell extravasation and metastasis with the 
aid of contrast agents are therefore a likely application for fSLN targeting.  Within the 
same cell pellet following rinsing and trypsinization steps to detach cell surface-bound 
proteins which might adsorb fSLN nonspecifically, both magnetic resonance contrast, in 
the form of shortening of T2 relaxation, as well as optical contrast via QD fluorescence, 
was achieved (Table 3-4, Figure 4).  Loading of fSLN-SPIO-QD was achieved within 
one hour, whereas to achieve the same T2-weighted contrast using conventional, dextran-
coated SPIO, a 24 hr. overnight loading period was required (Table 4).  Incubation of 
dextran-coated SPIO with 4T1 cells for 1 hr. without fSLN did not result in significant 
uptake, similar to HeLa cells.  Negative enhancement of T2-weighted images was 
proportional to fSLN-SPIO-QD loading concentration, but fSLN-QD did not affect T2 
relaxation as compared to unlabeled cells (Table 4).  QD fluorescence in fSLN-SPIO-QD 
was reduced compared to fSLN-QD but remained detectable by optical imaging (Figure 
4A), suggesting that a balance between magnetic resonance contrast and optical contrast 
can be achieved by judicious selection of starting concentrations of each reagent in fSLN 
synthesis.  fSLN should therefore be considered as a useful device for the safe, rapid 
loading of multimodal nanostructures into cells.     
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Table 3. Relaxation measurements acquired (mean ± SD) for determination of relaxivity.       
Amount corresponds to mg of SPIO in each cell pellet.  
fSLN-QD-SPIO (mg) 0.031  0.095  0.117  0.247  
T1 (ms) 1287.3 ± 78.2 1008.5 ± 98.9 816.1 ± 43.1 747.0 ± 43.7 
T2 (ms) 67.8 ± 2.9 43.1 ± 5.1 37.4 ± 8.8 26.0 ± 6.5 
 
 
Table 4. Relaxation measurements acquired for 4T1 cell pellets  
Sample Untreated SPIO 24 hr. fSLN-QD-SPIO fSLN-QD 
T1 (ms) 2108.9 ± 90.31223.9 ± 72.1 806.4 ± 121.9 2393.9 ± 83.1 
T2 (ms) 127.1 ± 1.9 78.4 ± 8.0 65.7 ± 16.0 117.9 ± 4.0 
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Figure 4. Multimodal imaging of 4T1 using fSLN-SPIO-QD.  (A) SPIO do not 
significantly quench QD emission and fluorescence is proportional to fSLN 
concentration.  (B) T2 shortening in 4T1 cell pellets is a function of fSLN-SPIO-QD 
concentration.  (C) T1 and T2 maps of fSLN-QD-SPIO in 4T1 cell pellets corresponding 
to Table 3.  (D) T1 and T2 maps of fSLN-QD-SPIO, SPIO (24 hr. incubation), untreated, 
and fSLN-QD-treated 4T1 cell pellets corresponding to Table 4. 
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Multimodality and high loading volume are unique features of fSLN.  The 
incorporation of diverse imaging agents and therapeutics within a single, targeted 
package should expand the scope of clinical approaches.  For example, lower-resolution 
but noninvasive imaging modalities such as MRI could be combined with optical imaging 
for guidance in tissue biopsies and histological immunofluorescence analysis.  
Furthermore, the encapsulation of many nanoparticles within one functional nanoscale 
carrier should enable signal to noise amplification strategies for detection of proteins for 
in vitro diagnostics using flow cytometry, or in vivo imaging using optical imaging, as 
example applications whereby detection of biomolecules in low abundance is critical to 
diagnosis.  Furthermore, the entrapment of high concentrations of cytotoxic drugs within 
nanoscale packets should result in enhanced therapeutic efficacy if the carrier can be 
appropriately site-directed.   
Current strategies for translocating compounds of varying physicochemical 
properties (e.g. hydrophilicity, molecular weight, charge) across membranes have largely 
been limited to the use of cationic transfection reagents such as polymers or peptides.  In 
this work we demonstrate for the first time that an anionically-charged, biocompatible 
nanoparticle composed of a solid lipid matrix is capable of rapidly delivering various 
imaging agents and therapeutics into cells.  Negatively-charged compounds are typically 
incapable of penetrating plasma membranes without dependence on receptor-mediated or 
other types of endocytosis, making our findings a novel result and expanding the range of 
currently-limited techniques for delivering compounds to subcellular destinations.  Given 
the wide range of encapsulants tested in this work, it is likely that other therapeutics and 
contrast agents are also compatible with the encapsulation process, including Gadolinium 
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chelates and radiotracers.  We hypothesize that the negative charge of fSLN afforded by 
PSS surface entrapment electrostatically-perturbs interactions of the nanoparticle with 
cell surface proteins, thereby favoring lipid-lipid interactions.  The negative charge of 
fSLN, besides its potential role in promoting energy-independent nanoparticle  
translocation, may also be favorable for preserving cell viability and function as a result 
of reducing the likelihood of cytoplasmic protein adsorption to the fSLN surface.  
However, charge alone may not be responsible for the membrane translocation 
capabilities of fSLN, as PAA-coated fSLN did not translocate across membranes but 
rather were localizaed among cell borders (11).  Our process additionally features size-
tunability and amenability to surface functionalization of targeting ligands, making fSLN 
a versatile candidate for a wide range of pharmaceutics and imaging agents.   
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CHAPTER VII 
 
0BCONCLUSIONS AND FUTURE WORK 
 
 This dissertation is composed of four manuscripts which define a framework for 
incorporating nanoscale surface engineering for enhanced functionality in bioimaging 
and drug delivery.  The main functional advances in nanotechnology made possible by 
this work relate to enhanced targeting (cell surface and intracellular) capabilities, and the 
development of multifunctional devices.  Chapters III and IV were concerned with the 
goal of improving nanoparticle imaging agent targeting for long-term in vivo imaging of 
disease.  In chapter III, insight into the imaging of diabetes and ocular inflammation 
(uveitis) was provided using a noninvasive retinal imaging technique in conjunction with 
quantum dot-antibody conjugates (QD-Mab) that were engineered for high specificity 
and circulation lifetime.  While only QD-Mab were the imaging agent in these studies, it 
is likely that most other imaging agents would benefit from the immune-shielding 
techniques used in this Aim, such as iron oxide nanoparticles, microbubbles, or gold 
nanoparticles for magnetic resonance, ultrasound, or x-ray contrast agents, respectively.  
Future work will be focused on molecular expression of various inflammatory molecules 
using this technique in diabetes and atherosclerosis.  In addition, studies are currently 
underway to elucidate the role of Fc-blockade in reducing liver and splenic macrophage 
uptake of QD-Mab in vitro and in vivo.  The implications of this study may be significant 
for the design of Mab-based therapeutics, many of which are currently in clinical usage.  
In chapter IV, QD were coated with a cell-penetrating peptide (CPP), to confer 
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cytoplasmic loading capabilities upon QD, which themselves are not capable of crossing 
cell membranes.  By retaining QD in subcellular space, labeled cells can interact with 
other cells or biomolecules without potential steric hindrance from QD-Mab conjugates, 
and QD cannot be shed from the membrane surface as part of normal membrane 
shuffling/recycling functions, for long-term imaging applications such as the imaging of 
cancer metastasis.  Future work is directed toward the elucidation of mechanism of CPP 
internalization into cells, and whether internalization can occur independently of 
endocytic mechanisms.  Should the CPP evade the endosomal pathway, subsequent work 
will be directed toward the targeting of QD-CPP toward subcellular destinations for 
bioimaging and targeted therapeutics.   
 Chapters V and VI explore features of functionalized solid lipid nanoparticles 
(fSLN) relevant for imaging and drug delivery as proposed in Aim 2.  Surface 
engineering approaches for the impartation of multiple functionalities into one device, 
and for the conferring of targeting capabilities upon the device.  In Chapter V, it was 
observed that fSLN could be tuned for the translocation of compounds such as proteins 
either across endothelial barriers or within endothelial cells by controlling surface 
information.  Specifically, a composite surface, PSS-PLL-Heparin, when coated on fSLN 
by simple layer-by-layer assembly, facilitated transendothelial transport across 
endothelial barriers, whereas PEG blocked transport completely.  Interestingly, the PSS 
coating facilitated intracellular transport, prompting the subsequent study of this fSLN 
formulation in Chapter VI.  This chapter expands upon the potential of multimodal fSLN 
by describing the construction of various fSLN-PSS formulations, including multimodal 
fSLN bearing both QD and SPIO, and begins the elucidation of the fSLN-PSS 
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intracellular transport mechanism.  Future work relevant to Aim 2 is directed toward the 
in vivo investigation of fSLN-PSS-PLL-Heparin, in the context of transendothelial barrier 
delivery of imaging agents and therapeutics.  Should this formulation be capable of 
blood-brain barrier translocation, this would be a significant result in the field of 
nanomedicine as this barrier complicates effective treatment.  Furthermore, the studies of 
Chapter VI will be continued to generate statistically-robust data relating to fSLN 
internalization and the generation of magnetic resonance and optical contrast by these 
probes.  In future work, alternative SPIO will be selected, as the commercially-available 
SPIO (Micromod GmbH) purchased for this study were degraded in the organic solvents 
used for encapsulating fSLN.  Several methods for the synthesis of magnetite for 
solubility in both organic and aqueous phases have been reported, specifically those 
involving oleic acid as a surfactant.  These SPIO will likely be evaluated in future 
applications due to enhanced solubility in both phases, which should translate toward 
higher encapsulation efficiencies.  In order to evaluate fSLN as an effective drug carrier, 
extensive studies must be performed to determine therapeutic efficacy, encapsulation 
efficiency via HPLC, and evaluation of release profiles.     
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APPENDIX A 
 
ANIMAL SUBJECTS 
 
 This appendix details the rat and mouse models used for studies in Aim 1, as well 
as relevant experimental details for each animal.  All acquired video sequences have been 
archived on DVD and catalogued by date, corresponding to the dates of animal 
experimentation.   
 
I. STZ-induced diabetic rat model and wild-type controls 
All species are male, Long-Evans (Blue Spruce) rats from Harlan Sprague Dawley, Inc. 
    
STZ treatment = 65 mg/kg intraperitoneally 
QD-Mab injections included a QD565 isotype control Mab injection 
    
Date Age (Days) STZ Measurements 
9/22/2004 111+ 8/4/2004 Fluorescein/dextran angiography, acridine orange fluorography, PS/F quantitation 
3/2/2005 111+ N acridine orange fluorography 
3/21/2005 111+ 11/22/2004 QD-VCAM-1/ICAM-1/RP-1/PECAM-1 
3/22/2005 111+ 11/22/2004 QD-VCAM-1/ICAM-1/RP-1/PECAM-1 
3/23/2005 111+ 11/22/2004 QD-VCAM-1/ICAM-1/RP-1/PECAM-1 
4/5/2005 111+  3/2/2005 QD-RP-1; nontargeted QD circulation kinetics 
4/5/2005 111+ N  QD-VCAM-1/ICAM-1/RP-1/PECAM-1 
4/14/2005 111+ 11/23/2004 QD-CD45; flow cytometric analysis; leukostasis; rolling velocities 
5/17/2005 111+ 4/6/2005 QD-VCAM-1/ICAM-1/RP-1/PECAM-1 
6/14/2005 111+ N QD-VCAM-1/ICAM-1/RP-1/PECAM-1 
7/6/2005 111+ 6/21/2005 QD-VCAM-1/ICAM-1/RP-1/PECAM-1 
7/13/2005 111+ 6/21/2005 QD-VCAM-1/ICAM-1/RP-1/PECAM-1 
8/1/2005 111+ N QD-VCAM-1/ICAM-1/RP-1/PECAM-1 
1/31/2006 111+ N QD-VCAM-1/ICAM-1/RP-1/PECAM-1 
2/28/2006 111+ N QD-VCAM-1/ICAM-1/RP-1/PECAM-1 
3/7/2006 111+ 1/30/2006 QD-VCAM-1/ICAM-1/RP-1/PECAM-1 
3/8/2006 111+ N QD-VCAM-1/ICAM-1/RP-1/PECAM-1 
3/29/2006 111+ 1/30/2006 QD-VCAM-1/ICAM-1/RP-1/PECAM-1 
4/14/2006 111+ 1/30/2006 QD-VCAM-1/ICAM-1/PECAM-1 
4/18/2006 111+ N QD-VCAM-1/ICAM-1/RP-1/PECAM-1 
10/4/2006 111+ N FC BLOCKADE EXPERIMENT  
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II. Endotoxin-induced uveitis (EIU) rat model of ocular inflammation 
LPS treatment = 200 ug LPS intraperitoneally 
All species are male, Long-Evans (Blue Spruce) rats from Harlan Sprague Dawley, Inc. 
Date Age (Days) LPS Measurements 
10/24/2006 111+ 10/23/2006 QD-CD45/RP-1 
10/24/2006 111+ 10/23/2006 QD-CD45 
10/24/2006 111+ N QD-CD45 
3/6/2007 91-100 3/6/2007 CD3, CD45, monocytes, dendritic cells 
3/8/2007 91-100 3/6/2007 CD45, monocytes, dendritic cells 
3/19/2007 91-100 N CD45 
4/30/2007 111+ N CD45 
5/1/2007 50-57 5/1/2007 CD45, RP-1, natural killer cells 
5/3/2007 50-57 5/1/2007 RP-1, CD45, monocytes, natural killer cells 
 
III. ApoE -/- mouse model of atherosclerosis 
 
Path ID Animal Type Age (mos.) Injections/Measurements
7885 Apo E -/- 7 QD/CD11b- 5 X 10^6 cells
7886 Apo E -/- 7 QD/CD11b- 5 X 10^6 cells
7887 Apo E -/- 7 QD/CD11b+ 300,000 cells
7931 Apo E -/- 12 QD/TCR+ and QD/CD11b+ 1 X 10^6 cells
7932 Apo E -/- 12 QD/CD11b+ 1 X 10^6 cells
7983 Apo E -/- 12 QD/CD11b+ 1 X 10^6 cells
7984 Apo E -/- 12 QD/CD11b+ 1 X 10^6 cells
8035 C57/BL6 12 QD/TCR+ and QD/CD11b+ 1 X 10^6 cells IVIS imaging
8036 Apo E -/- 12 QD/TCR+ and QD/CD11b+ 1 X 10^6 cells IVIS imaging
8037 C57/BL6 12 QD/TCR+ and QD/CD11b+ 1 X 10^6 cells IVIS imaging
8038 Apo E -/- 12 QD/TCR+ and QD/CD11b+ 1 X 10^6 cells IVIS imaging
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APPENDIX B 
 
IN VIVO IMAGING OF LEUKOCYTES IN ENDOTOXIN-INDUCED UVEITIS 
 
 Using the methods described in detail in Chapter III, quantum dots emitting at 
spectrally-distinct wavelengths were conjugated to antibodies against neutrophils (RP-1), 
dendritic cells, natural killer cells, and monocytes (mouse anti-rat, BD Biosciences).    
Endotoxin-induced uveitis was initiated by intraperitoneal injection of 200 µg of 
lipopolysaccharide in 50 and 90 day old Long-Evans male rats and imaged 24-48 hrs. 
post-injection.  In addition, peripheral blood was drawn from a 90 day old wild-type rat 
for flow cytometric analysis.  During in vivo imaging, RP-1 labeled neutrophils were 
identified in the retinal circulation as hyperfluorescent cells rolling along vessels, 
characteristic of EIU.  Using spatial calibration based on the size of the rat optic disk, 
rolling velocities were determined for 10 neutrophils within 2 optic disc diameters and 
compared to literature values.  The mean rolling velocity of QD-labeled neutrophils was 
57.7 ± 7.3 µm/sec.  This is somewhat close to the values of neutrophil rolling in EIU 
post-injection (24 hrs.) recorded by Miyamoto et al. (1), which was 46.6 µm/sec.  In 
future work, a greater sample size and wider range of animals will be employed to 
generate statistically-significant data.  The in vivo findings suggest that QD-RP-1 can be 
used to quantify leukocyte rolling in vessels without significantly perturbing function.   
 As previously reported, RP-1 is upregulated on rat neutrophils in proportion to 
activation state.  However, its role in inflammation has not been defined.  QD-RP-1 was 
incubated at 100 nM doses to 1 X 106 Percoll density gradient-isolated neutrophils with 
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or without 100 ng/mL LPS pre-treatment.  As shown by FACS below (Figure 1), QD-
RP-1 labeling was observed to be proportional to activation time.  QD can therefore be 
harnessed as a biosensor to probe not just the presence or absence of a single cell type, 
but also cell function.  In vivo imaging of QD-RP-1 labeled neutrophils at increasing 
intervals post-LPS injection were consistent with in vitro observations (Figure 1).   
 
                    
            
Figure 1. Top: QD655-RP-1 labeled neutrophils at 1 (red), 2 (green), and 3 (blue) 
hrs. post-LPS treatment.  Brown – unlabeled cells.  Fluorescence intensity was 
found to increase with increasing post-treatment times.  Bottom:  In vivo imaging 
of neutrophil 1 hr. (left) and 6 hrs. (right) post-LPS treatment.  Greater intensity 
of labeled cells was qualitatively-apparent, particularly in slow-moving or 
stagnant neutrophils. 
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Using the in vivo imaging strategy outlined in Chapter III, other cell types were 
also imaged in EIU, including monocytes, dendritic cells, and natural killer cells.  In 2 
90-day old mice, it was observed that the 3-6 hr. post-injection timepoint featured a 
transient monocytic infiltrate, whereas 48 hrs. post-injection, dendritic cells appeared to 
be primarily recruited (Figure 2).  These observations, while preliminary, underscore the 
need to characterize individual components of the immune response using multispectral 
imaging.  Such observations may have a profound impact on the development of timely 
therapeutic interventions in inflammatory disease. 
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Figure 2. Left: Monocyte infiltrate at 3-6 hrs. post-LPS treatment in an EIU rat model.  
Right: Dendritic cell infiltrate 48 hrs. post-injection. 
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Abstract 
 
Solid Lipid Nanoparticles (SLN) bear significant potential as drug delivery 
systems and diagnostic probes.  They constitute a promising alternative to 
polymeric and liposomal nanoparticulate formulations due to their efficient loading 
and stabilization of poorly soluble or instable compounds, high biocompatibility, and 
potential for scaling up production processes for pharmaceutical applications.  To 
enhance the scope of their biomedical application, methods which enable 
simultaneous drug/probe entrapment and presentation of surface functionalities are 
desired.  We have developed a process for the single-step formulation of 
functionalized polymeric nanoparticles with tunable size and narrow polydispersity 
(1).  By incorporation of a polyelectrolyte or polymer within the aqueous phase, 
our process enables the surface engineering of diverse surface moieties upon a 
non-functionalized polymer backbone within a binary solvent system, via a phase 
inversion process.  By substitution of a biocompatible coco-glyceride for the 
non-functionalized polymer in the organic phase, we have applied this strategy 
toward the formulation of surface functionalized SLN capable of entrapping 
physicochemically-diverse cargoes.  We investigated the effect of process 
parameters on nanoparticle size, surface charge, and compound entrapment 
efficiency.  Species to be encapsulated included fluorescent dyes, semiconducting 
nanocrystals, and paramagnetic nanoparticles.  Surface moieties incorporated in the 
aqueous phase included PEG, amine groups and carboxyl groups for the 
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bioconjugation of targeting ligands.  Nanoparticles were characterized by laser 
light scattering, x-ray photoelectron spectroscopy (XPS), fluorescence 
spectrophotometry, electron microscopy, and fluorescence microscopy.  Our studies 
demonstrate that the solvent composition can be varied to control nanoparticle 
hydrodynamic radius while maintaining a narrow polydispersity.  Both hydrophilic 
and hydrophobic species can be efficiently entrapped within the lipid matrix to 
create targeted and stable high signal intensity diagnostic probes or concentrated 
drug carriers for biomedical applications.  We anticipate the application of SLN 
toward magnetic resonance and fluorescence imaging, targeted chemotherapy, as 
well as the surface modification of biomaterials for tissue engineering strategies.              
 
Introduction 
  
Nanoparticulate delivery systems generally aim to safely and efficiently deliver 
therapeutic or diagnostic compounds to specific tissue sites, without degradation of 
the cargo that would limit its efficacy.  Nanoparticles with solid lipid matrices, or 
solid lipid nanoparticles, (SLN) exhibit several key features which make them 
promising agents for the delivery of diagnostic probes or therapies in vivo.  Among 
these are their capacity to entrap poorly water-soluble compounds, physical stability 
(remaining solid at physiologic temperatures and/or during storage), and 
biocompatibility (2-4).  They are not limited by some of the challenges associated 
with current nanoparticulate drug delivery systems in research and clinical 
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administration stages, including poly-lactide-co-glycolide nanoparticles (PLGA NP) 
and liposomes, which have been associated with acidic degradation of protein 
cargoes (5) and potentially low cargo loading and stability (6), respectively.   
In order to expand the capabilities of SLN in medical imaging and drug delivery 
and to facilitate their clinical implementation, further work is warranted in the 
continued adaptation of laboratory-scale production processes for the 
pharmaceutical-scale, and the modifications of process parameters to control 
efficiency-critical properties of SLN, such as size and loading capacity.  
Furthermore, it is important that SLN be capable of bearing surface functionalities 
and/or functionally-diverse cargoes such as contrast agents and drugs, regardless of 
their physicochemical properties (e.g. hydrophilicity, size).  Such a versatile carrier 
technology at the nanometer scale of biology would provide a template for the 
manufacture of a broad spectrum of drugs and imaging agents which work at the 
scale of biology.   
 We have developed a single-step process for the rapid synthesis of 
functionalized polymeric nanoparticles based on the polymers PLGA and poly-lactic 
acid (PLA) (1).  The solvation core of this non-functionalized polymer backbone is 
specifically engineered such that addition of a polyelectrolyte or polymer-containing 
aqueous phase results in the instantaneous formation of a nanoparticle, the surface of 
which bears the aqueous moiety.  We have adapted this process toward the surface 
engineering of SLN capable of entrapping various types of cargoes while at the same 
time bearing different surface functionalities.  Our process obviates the need for 
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surfactants, emulsifiers, and melting/cooling steps which are often involved in other 
nanoparticle synthesis methods.  Tailoring of the solvent composition and presence 
of aqueous phase moieties in the process was found to have profound effects on the 
surface engineering and encapsulation features of the nanoparticulate system.  We 
discuss the synthesis and characterization of polymeric and solid lipid NP and 
implications for biomedical applications such as drug delivery, imaging, and tissue 
engineering.        
 
Materials and Methods 
 
Materials 
Poly (dl-lactide-co-glycolide) (PLGA, RG 503, MW=30,000) and poly 
(L-lactide) (PLA) MW = 70,000, inherent viscosity 1.20 dL/g in CHCl3) were 
purchased from Birmingham Polymers.  PLGA and PLA were prepared for use by 
precipitation from methylene chloride (MeCl) in methanol. Tetrahydrofuran (THF), 
Toluene, MeCl, Acetone, and 1-Methyl-2-pyrrolidinone (NMP) were purchased from 
Sigma or Fisher Scientific in HPLC grades.  HCl, NaOH, Fluorescein 
isothiocyanate-bovine serum albumin conjugate (FITC-BSA), Poly (styrene-4 
sodium sulfonate) (PSS, MW = 70,000), poly (acrylic acid) (PAA, MW = 2000), 
poly (L-lysine hydrochloride) (PLL, MW=22,100), Fluorescein isothiocyanate PLL 
(FITC-PLL, avg. MW = 30,000) and poly (ethylene glycol) (PEG, MW=10,000) 
were purchased from Sigma.  4',6-diamidino-2-phenylindole (DAPI) in the form of 
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VECTASHIELD, an aqueous mixture of DAPI in a glycerol-containing suspension, 
was purchased from Vector Labs.  Trypan Blue was purchased from Gibco.  
Softisan 100 was a gift from Sasol GmbH.  Water soluble, 50nm silica magnetite 
nanoparticles were purchased from Micromod GmbH as a 10 mg/mL suspension in 
PBS. Cadmium Selenide-Zinc Sulfide (CdSe) semiconducting nanocrystals (EviDots) 
in toluene were purchased from Evident Technologies.  10K MWCO regenerated 
cellulose (RC) and 100K MWCO cellulose ester (CE) 6 mL capacity floating 
dialysis columns (Float-a-Lyzer) were purchased from Spectrum Laboratories and 
dialyzed overnight against 4L double distilled water (Millipore) to remove sodium 
azide preservative prior to use.     
 
Methods 
Polymeric Nanoparticle Synthesis 
To prepare polymeric NP, an aqueous phase was added to an equal volume of 
PLGA or PLA polymer dissolved in a binary solvent system. THF:Acetone, 
MeCl:Acetone and MeCl:THF were selected as the binary solvent systems for 
polymeric NP synthesis. The volumetric ratio of the solvent pair was varied to 
investigate the effect of solvent polarity on nanoparticle formation. When surface 
functionalization was desired, the aqueous phase was supplemented with either a 
polyelectrolyte or a water-soluble polymer such as PEG, at a 0.5% concentration.  
Alternatively, the fluorescent dye DAPI was added to the aqueous phase at a 100 
ug/mL concentration prior to phase inversion, after which the polymeric NP were 
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dialyzed on 10K MWCO Float-a-Lyzers against double distilled water to remove 
non-entrapped dye. 
Solid Lipid Nanoparticle Synthesis 
 To prepare SLN, Softisan 100 was dissolved in an anhydrous 80:20 mixture of 
NMP:Acetone as the binary solvent system at a concentration of 1%.  To synthesize 
SLN bearing quantum dots (QD), 1 uL of a 1 mg/mL suspension of CdSe QD in 
toluene was added to the NMP/Acetone/Softisan mixture in a nitrogen-purged glove 
bag.  An aqueous phase containing 1% PSS in ultrapure (100nm filtered) 
double-distilled water was prepared.  To synthesize SLN bearing 
FITC-BSA/magnetite, the PSS-based aqueous phase was supplemented with 0.1% 
FITC-BSA and 100ug of paramagnetic, silica-capped iron oxide nanoparticles.  The 
organic phase was rapidly infused into a scintillation vial containing the aqueous 
phase using a syringe accompanied by gentle shaking.  Organic solvents were 
removed by dialysis against 4L ddH2O in 10K MWCO RC Float-a-Lyzers in a 
low-speed stirring beaker for 2 hours.  Next, excess polymer and FITC-BSA was 
removed by overnight dialysis against 4L ddH2O in 100K MWCO CE 
Float-a-Lyzers with a complete change of dialysis buffer every 4 hours.  For further 
surface functionalization of PLL, FITC-PLL was incubated at 4°C overnight with 
SLN-QD-PSS at a concentration of 1%, and dialysis against 4L ddH2O using 
100,000 MWCO CE Float-a-Lyzer was performed the following day to remove 
excess FITC-PLL.    
Measurement of Polymeric and Solid Lipid Nanoparticle Hydrodynamic Radius and 
Zeta Potential  
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 Polymeric NP were diluted by a factor of 15 in ddH2O and adjusted to the 
desired pH for zetasizing analysis using either HCl and NaOH.  Measurements of 
zeta potential and hydrodynamic radius were conducted in automatic mode on a 
Malvern Instruments Zetasizer 3000HS.   
SLN were diluted by a factor of 50 in ddH2O and adjusted to an acidic pH using 
HCl.  Measurement of hydrodynamic radius and zeta potential was conducted using 
a Beckman-Coulter 440SX Zetasizer.   
Fluorescence and Electron Microscopy of Polymeric and Solid Lipid Nanoparticles 
Fluorescence microscopy of DAPI (VECTASHIELD)-loaded PLGA NP 
mounted in PBS, pH=7.4, was conducted on a Zeiss Axiophot equipped with 
bandpass excitation and emission filters specific for the dye.  Digital photographs 
were acquired at optically- and digitally-enhanced 400X magnification and analyzed 
using Zeiss-supplied software.  SLN-QD, SLN-QD with FITC-PLL surface 
functionalization, and SLN bearing FITC-BSA-iron oxide NP were mounted in 
borate buffer, pH = 8, and analyzed using a Nikon TE-2000U fluorescence 
microscope equipped with bandpass excitation and emission settings of 380/45ex, 
585/40em for SLN-QD, and a standard FITC configuration to visualize 
dye-conjugated PLL on the SLN surface or entrapped FITC-BSA, at digitally and 
optically-enhanced magnification of up to 500X.  For microscopy of 
FITC-BSA/iron oxide bearing SLN, the solution was supplemented with 0.5% 
Trypan Blue to quench non-encapsulated FITC-BSA fluorescence.  A 1.5T static 
magnet was placed on the right edge of the microscope slide to induce coordinated 
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movement of FITC-BSA/iron oxide SLN in response to the applied field.  Images 
were analyzed using Image Pro Plus 5.1 software (Media Cybernetics). 
 SLN-QD were prepared for electron microscopy by mounting on Formvar grids 
with 50:50 EtOH:phosphotungstic acid solution to visualize solid lipid in negative 
relief using a Philips CM-12 electron microscope.  Electron density of encapsulated 
QD enabled facile visualization.     
X-ray Photoelectron Spectroscopy (XPS) of Polymeric NP 
Polymeric NP were prepared for XPS surface analysis by dialysis of a 5 mL NP 
suspension against 500 mL 50% EtOH, flash freezing of NP in liquid nitrogen, 
followed by lyophilization for 48 hrs.  The NP powder surface composition was 
analyzed using a Kratos Axis-Ultra X-ray photoelectron spectrometer equipped with a 
monochromatic Al Kα (1486eV) x-ray source, configured at at 315W (25mA).  Data 
was collected using a pass-energy of 40eV with 0.05eV steps.  Elemental composition 
was determined using CasaXPS software. 
Fluorescence Spectrophotometry of Solid Lipid NP 
 SLN-QD-PSS and SLN-QD-PSS-FITC/PLL were diluted 10-fold in borate 
buffer, pH=8.  2 uL of each suspension was then analyzed on a Nanodrop ND-3300 
spectrofluorimeter configured for UV LED excitation and automatic sensitivity 
adjustment, with fluorescence emission intensity analyzed in the visible spectrum. 
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Results and Discussion 
 
Control of Polymeric Nanoparticle Size and Polydispersity 
 We hypothesized that judicious selection of an appropriate organic solvent 
composition for dissolution of the non-functionalized polymer (i.e., PLGA or PLA), 
by alteration of solvent polarity, would have significant effect on NP size by 
modulating the rate of polymer chain collapse into a nanoparticle upon the rapid 
addition of water.  By varying both the choice of solvent pairs and the relative 
solvent volumetric ratios, the process yielded polymeric NP diameters ranging from 
70-400nm, with narrow PDI.  Representative results are shown in Table 1.  It is 
likely that the primary determinant of NP size in our system is solvent composition.  
Specifically, a highly-polar solvent system with dissolved PLGA or PLA, upon 
addition of water, collapses rapidly into small NP, whereas a less polar solvent 
system would support slower polymer chain collapse upon interaction with water, to 
yield larger NP.       
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Table 1. Typical NP diameter and polydispersity index (PDI) 
measured for different combinations of polymer, polyelectrolyte 
(aqueous), and binary solvent systems. 
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Surface Engineering of Polymeric Nanoparticles  
The presence of a polyelectrolyte in the aqueous phase prior to organic-aqueous 
phase mixture provided a mechanism for spontaneous surface functionalization of 
the solidifying non-functionalized polymer core.  We hypothesized that by utilizing 
polyelectrolytes for surface functionalization with high affinities for water, 
preferential accumulation of the surface moieties would occur at the NP-water 
interface following phase inversion.  Zeta potential analysis of polymeric NP 
supports our hypothesis.  Figure 1 shows the surface charge variation as a function 
of pH for non-functionalized (PLGA) and functionalized (PLGA-PSS, PLGA-PLL) 
nanoparticles.  As shown, the isoelectric point of the nanoparticulate formulation is 
associated closely with the pKa of the ionizable group (PLGA = -COOH, PSS = 
SO3H, PLL = NH2).     
XPS analysis also confirms our hypothesis, as polymeric NP surface 
compositions were abundant with the desired functionality (Table 2).  It is 
important to note that PSS, despite its charge profile to PLGA, is effectively 
entrapped on the PLGA NP surface using our approach (66%).  Additionally, the 
ability to functionalize NP surfaces with PLL enables the potential bioconjugation of 
ligands via amide linkages to the NP surface for in vivo targeting applications.  
Thus we are able to rapidly produce PLGA NP of defined size ranges and narrow 
PDI, with the added benefit of customizing NP surface information.    
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Figure 1. Zeta potential as a function of pH for non-functionalized and 
functionalized PLGA NP.  Isoelectric points of NP correlate with the pKa 
of the PLGA or polyelectrolyte functional groups. 
 
 
 
 
 
 
    Table 2. Surface composition of PLGA NP as analyzed by XPS (C1S). 
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Encapsulation of Small Molecules by Polymeric NP                
Our single-step process for the surface engineering of polymeric NP does not 
appear to preclude the encapsulation of compounds for drug delivery or imaging 
purposes.  Fluorescence microscopy of DAPI-loaded PLGA-PSS NP reveals that 
the water-soluble dye is efficiently and homogenously entrapped within the NP core 
(Figure 2).  In other work, we have entrapped other fluorescent dyes, proteins, and 
synthetic drugs within polymeric NP.  Thus, our process appears to be a versatile 
approach for packaging structurally and functionally-diverse cargoes within 
well-defined (tight size range and PDI) and surface functionalized NP.    
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 Figure 2. Fluorescence micrograph (400X) of DAPI-loaded PLGA NP. 
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Control of Solid Lipid Nanoparticle Size and Loading Efficiency 
  
An adaptation of our procedure for synthesizing functionalized polymeric NP 
for the entrapment and targeted delivery of small therapeutic and diagnostic agents 
enabled us to develop a similar process for the rapid single-step production of 
functionalized SLN.  After considerable investigation we found the binary solvent 
system NMP:Acetone to provide effective size control of SLN while also providing 
for excellent solubility of the coco-glyceride.  High ratios of NMP:Acetone are 
associated with rapid lipid packing upon exposure to water, due to the high 
miscibility of NMP with water.  Lower ratios result in slower lipid packing, 
resulting in larger SLN.  Quantum dots, which without commercial modifications 
are highly hydrophobic, were selected as a candidate for encapsulation, as it has a 
high molecular weight and has emerged as a fluorescent probe with superior optical 
properties for bioimaging applications (7).  By varying the volumetric ratio of 
NMP:Acetone from 40:60 to 80:20, SLN bearing quantum dots ranging from 
75nm-790nm were synthesized.  Furthermore, by varying the SLN diameter 
through solvent composition, we were able to concurrently modulate SLN loading 
efficiency of QD (Figure 3).  Larger SLN diameters, or larger lipid matrix cores, 
allow for more incorporation of QD as they partition into the lipid phase upon 
exposure to water.  The high loading capacity of 100nm SLN, for example 
(100-150 QD avg. per SLN (n=10) as determined by TEM), allows for the creation 
of nanoparticulate probes with significantly enhanced signal intensity compared to 
single nanoparticles (Figure 3).  This feature could be useful in many biomedical 
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applications, including the magnetic resonance (e.g., CLIO-NP) or 
fluorescence-based (e.g., QD) signal amplification of low levels of antigens on cell 
surfaces, or the delivery of large payloads of drug into cells.   
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Figure 3. Transmission electron microscopy and fluorescence microscopy of 
SLN-QD.  First row: A.) Transmission electron micrograph (175000X at 80keV, 
scale bar 100nm) showing 2.4nm 580nm-emitting CdSe/ZnS quantum dots (red 
arrow) within a lipid matrix (white background of QD) against phosphotungstic acid 
negative lipid stain (green arrow).  B.) TEM (66000X at 80 keV) of same SLN-QD 
sample, showing dispersion and narrow size range of SLN-QD (outlined in blue). 
Second row: Fluorescence micrographs (40X) of large-diameter (C) and 
small-diameter (D) SLN-QD. 
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Surface Engineering of SLN 
 By incorporation of polyelectrolytes into the aqueous phase prior to the 
lipid-packing phase inversion step, we efficiently loaded the desired surface 
functionality upon the SLN surface in a manner analogous to that seen for polymeric 
NP.  Functionalization of negative charges upon SLN (SLN-PSS) was confirmed by 
zeta potential analysis (Figure 4).  As shown in Figure 5, fluorescence microscopy 
and spectrophotometry were indicative of efficient surface incorporation of 
dye-labeled PLL.  PLL was readily functionalized upon SLN surfaces by 
layer-by-layer assembly.  By first synthesizing SLN initially coated with the 
negatively-charged PSS, which effectively incorporates within the lipid while 
remaining preferentially at the NP-water interface (due to the sulfonic acid group), 
the positively-charged PLL can be layered electrostatically.  Other surface 
functionalities presented on SLN surfaces to date include polyethylene glycol (PEG) 
for evasion of the mononuclear phagocyte system in vivo (8), polyacrylic acid (PAA), 
which has been utilized to incorporate mucoadhesive properties (9), and streptavidin 
for biotin-based immunofluorescence applications (10).  Thus, our process enables 
the encapsulation of functionally-diverse nanoparticles (i.e. dye, contrast agent, 
therapeutic) within solid lipid matrices capable of bearing different types of surface 
information.         
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Figure 4. Zeta potential analysis of SLN-QD-PSS as a function of pH.  The 
isoelectric point of the sample correlates with the pKa of the sulfonic acid 
group of PSS, thus indicating effective surface functionalization. 
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Figure 5. Top Row: Fluorescence microscopy of QD entrapped within 
PSS-FITC/PLL-functionalized SLN, in the QD 580 emission (left) and FITC 
emission channels (right).  The core of the SLN exhibits high QD fluorescence 
due to effective entrapment of hydrophobic QD within the lipid matrix, whereas 
FITC-PLL is adsorbed upon previously incorporated PSS at the NP-water 
interface, thus providing an amine template for further bioconjugation.  Bottom 
Row: Fluorescence spectrophotometry of QD-PSS (orange) and 
QD-PSS-FITC/PLL (green) SLN.  Surface functionalization of PLL (initial 
FITC peak as indicated) does not significantly affect native QD fluorescence 
(580nm emission peak, as indicated).  Mean diameter 550 nm. 
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Multimodal SLN for Biomedical Applications 
 In order to demonstrate the potential of SLN as multimodal carriers, we 
co-encapsulated 50nm silica-capped paramagnetic iron oxide NP and FITC-BSA 
within PSS-functionalized lipid matrices by incorporation of both species within the 
aqueous phase prior to phase inversion.  FITC-BSA/iron oxide NP SLN coated with 
PSS were incubated in a solution containing 0.5% trypan blue and analyzed by 
fluorescence microscopy (Figure 6).  Trypan Blue is an effective quenching agent 
for reducing extracellular FITC as part of phagocytosis assays (11).  We therefore 
utilized trypan blue to quench unencapsulated FITC-BSA to confirm that only 
FITC-BSA within SLN was visualized.  Upon application of a magnetic field using 
a static magnet (1.5 T), FITC-BSA nanoparticles shown in Figure 6 were observed 
to move in response to magnet polar orientation. Fluorescent nanoparticles were 
highly sensitive to rapid changes in the external field while control nanoparticles 
consisting of FITC-BSA mixed with iron oxide NP in distilled water without lipid 
did not move in response to changes in magnetic fields. These data suggest that 
FITC-BSA was co-encapsulated with iron oxide NP, and that the native 
magnetization properties of the NP are not affected by encapsulation. We have in 
effect created a technique applicable to the development of magnetooptical probes 
which employ fluorophores (e.g. quantum dots or fluorescently-labeled proteins) and 
iron oxide nanoparticles, which would have applications for in vivo imaging using 
MRI and fluorescence imaging techniques such as multiphoton excitation 
microscopy.  Further work is directed toward the co-encapsulation of QD and iron 
oxide NP to develop high-intensity magnetooptical probes for bioimaging 
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Figure 6. Fluorescence microscopy of SLN bearing FITC-BSA and iron oxide 
NP in a solution of 0.5% Trypan Blue.  Encapsulated FITC-BSA not 
accessible to Trypan Blue in mounting medium is evident, and all SLN were 
observed to move toward the pole of an externally applied magnet, indicating 
successful co-encapsulation of FITC-BSA with iron oxide NP. 
applications, as well as drug-QD conjugates for pharmacokinetic/pharmacodynamic 
studies of chemotherapeutics.      
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applications, as well as drug-QD conjugates for pharmacokinetic/pharmacodynamic 
studies of chemotherapeutics.      
 
Conclusion 
 
We have demonstrated a technique for the rapid synthesis of functionalized 
polymeric NP, and an analogous procedure for producing functionalized solid lipid 
nanoparticles.  Our process provides for the simultaneous, efficient entrapment of 
compounds of varying physicochemical properties, so that combinative imaging and 
therapeutic strategies can be harnessed.  Mechanical dispersion, the addition of 
emulsifying agents, or temperature-dependent steps are not required.  The lipid 
utilized in SLN is derived from cosmetic formulations, and all solvents used in 
synthesis are removed, thus ensuring biocompatibility.  Furthermore, the process 
can be easily scaled-up for the mass production of pharmaceuticals and SLN are 
highly-stable in storage.  Future work is directed toward with the applications of 
multimodal SLN for the simultaneous utilization of multiple imaging modalities as 
well as combined drug delivery/gene therapy approaches.  
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Abstract 
 
Free radical species generated through fluorescence photobleaching have been 
reported to effectively couple a water-soluble species to surfaces containing electron-rich 
sites (1).  In this report, we expand upon this strategy to control the patterned attachment 
of antibodies and peptides to surfaces for biosensing and tissue engineering applications.  
In the first application, we compare hydrophobic attachment and photobleaching methods 
to immobilize FITC-labeled anti-M13K07 bacteriophage antibody to the SiO2 layer of a 
differential capacitive biosensor and to the polyester filament of a feedback-controlled 
filament array.  On both surfaces, antibody attachment and function were superior to 
previously employed hydrophobic attachment.  Furthermore, a laser scanning confocal 
microscope could be used for automated, software-guided photoattachment chemistry.  In 
a second application, the cell adhesion peptide RGDS was site-specifically photocoupled 
to glass coated with fluorescein-conjugated polyethylene glycol. RGDS attachment and 
bioactivity were characterized by a fibroblast adhesion assay.  Cell adhesion was limited 
to sites of RGDS photocoupling.  These examples illustrate that fluorophore-based 
photopatterning can be achieved by both solution-phase fluorophores or surface adhered 
fluorophores.  The coupling preserves the bioactivity of the patterned species, is 
amenable to a variety of surfaces, and is readily accessible to laboratories with 
fluorescence imaging equipment.  The flexibility offered by visible light patterning will 
likely have many useful applications in bioscreening and tissue engineering where the 
controlled placement of biomolecules and cells is critical, and should be considered as an 
alternative to chemical coupling methods. 
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Introduction 
 
Strategies for the directed patterning of biomolecules at specific sites on diverse 
material surfaces are highly desired for multiplexed, array-based screening paradigms (2) 
as well as technologies such as tissue engineering, which rely on micro- or nanoscale 
cell-protein interactions (3).  Recently, a fluorophore-based immobilization technique 
was described for the high-resolution, site-specific patterning of proteins such as enzymes 
within microfluidic channels (1, 4).  This method utilizes photobleaching, a singlet 
oxygen-dependent immobilization mechanism, to couple dye-labeled proteins to glass 
and polydimethylsiloxane (PDMS) surfaces.  Visible light patterning has two main 
advantages over other biomolecular patterning strategies.  Non-damaging wavelengths, 
such as those used in aryl azide and benzophenone chemistries (5, 6), are avoided.  
Secondly, the reaction can be rapidly carried out in aqueous, neutral buffers preserving 
protein functionality.   
In order to facilitate the implementation of photoattachment chemistry in the 
development biomolecular and/or cellular arrays, further studies are necessary to expand 
upon the scope of materials which can be surface engineered using this process, namely 
polymer surfaces. Also, efforts to facilitate photopatterning, such as implementation with 
laser scanning confocal microscopes and software-driven, automated bleach parameters, 
are relatively unexplored.  In addition, a reverse-coupling technique would be desirable. 
In this case, instead of labeling the soluble protein with a dye, the target surface is 
conjugated to a fluorophore.   This has several advantages.  Dye-labeling of proteins is 
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not required, and in this scenario, one photoactivable surface could be employed for the 
patterning of multiple biomolecules.   
In this study, we explored the utility of visible light-guided surface engineering 
for site-specific antibody immobilization on a differential capacitance-based viral 
biosensor (7) as well as a polyester filament-based fluorescence detection platform (8-
10).  We then extended this photopatterning technique to couple the cell adhesion peptide 
RGDS (11) to a surface layer of polyethylene glycol-fluorescein (PEG-FITC) with the 
intent of developing a substrate for site-specific biomolecular and cellular patterning.  
This latter example also features low nonspecific adsorption, a limitation not addressed in 
previous visible-light photopatterning techniques (4).  In these initial studies, we 
observed that a variety of surfaces are amenable to photopatterning, and that the 
simplicity of these techniques makes automated surface patterning readily accessible to 
biological laboratories with access to a laser scanning confocal microscope.  This method 
may have broad applicability in the field of biosensors which rely on an a priori pattern 
of binding partners as well as tissue engineering applications which rely on spatial 
control of cells in their construction.  Photocoupling can also be used to functionalize 
nanoparticles and other bioconjugates bearing amine or PEG-FITC moieties.   
 
Experimental Procedures 
 
Antibodies were photocoupled onto silicon dioxide and polyester surfaces for 
sandwich immunoassays.  In the third portion of this report, peptides were 
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photoimmobilized on PEG-FITC coated capture substrates in order to modulate cell 
attachment.   
 
Photopatterning of capture antibody on capacitive M13K07 sensor  
 A previously-characterized, capacitive sensor for the detection of M13K07 
bacteriophage (7) was prepared for use under dry argon at 25ºC with three rinses of 
anhydrous acetone (Sigma, St. Louis, MO).  The surface was then immersed in a 4% 
solution of 3-aminopropyltriethoxysilane (United Chemical Technologies, Bristol, PA) in 
anhydrous acetone for 10 minutes, followed by 5 minute immersions in anhydrous 
acetone and ultrapure water, and stored at 25ºC in a desiccator.  Successful silanation of 
capacitor surfaces was verified by comparing the adsorption of fluorescein-conjugated 
bovine serum albumin (1 mg/mL in borate pH = 8.5) on treated and untreated chips.  
Immediately prior to use, the silicon dioxide surface was layered by micropipette with 
100 μL of a 100 μg/mL FITC-anti-M13K07 monoclonal antibody ((mAb), 2.8 mol 
FITC/mol IgG) in 100 mM sodium bicarbonate buffer, pH = 8.5.    
 The FITC-labeled capture mAb (anti-M13K07 Ms IgG1, GE Healthcare) was 
immobilized onto the biosensor surface using an upright laser scanning confocal 
microscope (LSM 510, Carl Zeiss).  The timed bleach function provided in the 
microscope manufacturer’s software package, as used for fluorescence recovery after 
photobleaching (FRAP) studies (12), was used to control the laser intensity of the 488 nm 
line of a 30 mW Argon laser, as well as the number of scanning iterations.  A 4X, 0.1 NA 
objective was used to scan the 200 μm2 capacitor surface.  Two capacitors were each 
bleached using different bleach iterations (50 vs. 10, using 100% laser intensity).  Using 
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the manufacturer’s software, the laser was rastered in parallel with the plates of the 
capacitor, and the bleaching time was less than three minutes.  The surface was rinsed 
three times with PBS, pH = 7.4 for 1 minute each.  Next, the capacitors were coated with 
the same amount and concentration of FITC-mouse IgG1 isotype control mAb (3 mol 
FITC/mol IgG), and bleached at 100% intensity for 50 iterations.   
The functionality of the photoimmobilized surface was ascertained by sandwich 
immunoassay.  The surface was rinsed with PBS, and exposed to a solution of 100 μL of 
M13K07 bacteriophage (3.3 X 1011 virions/mL) for 30 min at 25ºC.  The surface was 
rinsed with PBS and incubated with 100 μL of Cy5-conjugated anti-M13K07 mAb (1.72 
mol Cy5/mol IgG, 50 μg/mL in PBS) for 30 min at 25ºC.  The chip was rinsed with PBS 
and imaged immediately on a Nikon TE2000U inverted fluorescence microscope 
equipped with a Cy5 fluorescence cube, an Exfo X-Cite 120 metal halide excitation light 
source, and a C7780 Hamamatsu cooled CCD camera.  Mean fluorescence intensities 
were measured by analyzing ROIs defined along capacitor boundaries using Image Pro 
Plus 5.0 (Media Cybernetics), with data plotted using SigmaPlot 9.0 (SYSTAT).   
 
Photopatterning of antibody on polyester filament-based M13K07 sensing array  
 We investigated the utility of photoattachment chemistry in the development of 
high-throughput biomolecular screening.  A previously described polyester 
monofilament-based system for viral detection based on hydrophobically-immobilized 
capture mAb for multiplexed sandwich immunoassays (9) was adapted for the detection 
of M13K07 bacteriophage, a test virus, based on photopatterned capture mAb.  All 
procedures were carried out at 25°C.  A 120 μm polyester monofilament (Sulky Corp.) 
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was wrapped around a PhastGel sample applicator (GE Healthcare) and inlaid within the 
concave teeth as previously described (9).  The filament/comb apparatus was rinsed in 
successive washes of 70% ethanol, 10% HCl, Milli-Q water, and dried overnight prior to 
use.  0.75 μL of solution containing 100 μg/mL of anti-M13K07 mAb or mouse IgG1 
isotype control mAb in 100 mM borate buffer, pH = 8.5 was pipetted on each loading 
tooth for either timed passive incubations or photobleaching sessions.  The distance 
between neighboring teeth is 0.5 cm.  For photobleaching, the comb was inverted and 
suspended within a humidified 60 mm petri dish upon the Nikon TE2000U microscope 
stage.  For photobleaching, the X-Cite 120 metal halide light source was used in 
conjunction with a FITC cube and 4X objective at full lamp intensity (1.4 W from 
microscope emission port, as determined by the manufacturer) for specific durations.  
Bleaching was monitored by measuring filament mean fluorescence using Image Pro Plus 
5.0.   
To test the functionality of the passively-adsorbed and photopatterned surfaces, 
combs were was rinsed three times in PBS, immersed in a multichannel pipette basin 
containing 3.3 X 1011 virions/mL M13K07 in PBS for 30 min, and rinsed three times 
with PBS.  The combs were subsequently immersed in a basin containing 50 μg/mL Cy5-
anti-M13K07 mAb for 30 min and rinsed in PBS.   
 Filaments were immediately fastened to a standard, pre-cleaned microscope slide 
with tape, and the fluorescence measured using a Genepix 4000B microarray scanner 
(Axon Instruments) equipped with a 635 nm laser line as previously-described (9).  Mean 
fluorescence intensity of ROIs defined along discrete filament spots was measured by 
Image Pro Plus on grayscale 16-bit images, and plotted using SigmaPlot.  
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Photopatterning of poly-D-lysine coated glass substrate with PEG-RGDS 
Poly-D-lysine-coated 35 mm glass-bottom dishes with no. 1 borosilicate 
coverglass (MatTek Corp.) were coated with a heterobifunctional PEG spacer (MW = 
3400) containing an N-hydroxysuccinimide ester (NHS) amine-reactive group and a 
fluorescein isothiocyanate moiety (NHS-PEG-FITC, Nektar Therapeutics) by incubating 
the surface with 0.2 mg of NHS-PEG-FITC in 100 mM borate buffer, pH = 8.5 for 1 hr. 
followed by three rinses in borate buffer. Unreacted amine groups were quenched by 20 
min. incubation with 1 mg of sulfo-NHS-acetate (Pierce Chemical) in borate buffer. This 
acetylation reaction rendered the remaining amines unreactive. The glass dish was then 
incubated with with 100 μg/mL of the fibronectin-derived cell adhesion peptide RGDS (> 
95% purity, Genscript Corp.) in borate buffer. Photobleaching of 1 mm rectangular areas 
delineated by taped foil photomasks was achieved using a 10X objective with the 
aforementioned inverted fluorescence microscope and light source for timed intervals, 
with mean fluorescence levels monitored to confirm photobleaching. Typically, the time 
necessary to reduce intensity levels 20% of initial fluorescence was less than 5 minutes.  
Photobleaching and RGDS passive adsorptions were followed by three rinses in borate.  
RGDS presence on the glass substrate was qualitatively assessed using fluorescamine.  
Since RGDS has been demonstrated to promote fibroblast adhesion and spreading 
(DeLong et al. 2005), we evaluated the bioactivity of the coupled RGDS using a 
fibroblast adhesion assay. 3T3 fibroblasts (ATCC) were cultured to 70% confluency in 
DMEM containing 10% bovine calf serum under incubation at 37°C, 5% CO2. The cells 
were then seeded in each dish at a concentration of 1000 cells/mL and incubated 
overnight under the same culture conditions. The next day, dishes were rinsed three times 
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with PBS, and fixed for 20 min. at 25°C in 4% paraformaldehyde in PBS. Dishes were 
incubated with 0.5% trypan blue prior to the fixation step to ascertain cell viability via 
dye exclusion. The dishes were then rinsed in PBS containing 100 mM glycine and 
imaged by phase-contrast.   
 
Comparison of antibody chemical crosslinking and photoattachment on PEG-FITC and 
PEG-maleimide-coated glass substrates 
 
Poly-D-lysine-coated MatTek dishes were coated with 0.2 mg of NHS-PEG-FITC 
or thiol-reactive NHS-PEG-Maleimide (NHS-PEG-MAL, MW = 3400, Nektar) and 
acetylated as described in 2.3.  To generate sulfhydryl groups for covalent coupling of 
mAb to NHS-PEG-MAL, 5 mg of anti-M13K07 mAb in 1 mL PBS-EDTA, pH = 7.4 was 
reacted with a 10-fold molar excess of 2-iminothiolane (Traut’s reagent, Sigma) for 30 
min. at 25°C.  Excess Traut’s reagent was removed by 3 centrifugation cycles of 
mAb/Traut’s reagent on an Amicon-4 Ultra 100K MWCO spin column filtration device 
(Millipore) using PBS-EDTA as the rinse and resuspension buffer.  For chemical 
crosslinking, 200 μg of mAb in 200 μL PBS-EDTA was pipetted onto the PEG-MAL 
surface and was reacted overnight at 4°C.  For photocrosslinking, 200 μg of purified mAb 
in a 200 μL solution of PBS-EDTA was pipetted on the PEG-FITC surface.  The 
microwell of the dish was then photobleached using the X-Cite 120 light source (1.4 W) 
using a 2X objective for 10 min.  Following both reactions, the dishes were rinsed 3X 
with PBS, saving the initial aspirate.  Aspirate was collected from 20 MatTek dishes 
bearing either the PEG-FITC or PEG-MAL attachment linker.  Protein concentration was 
determined using the Coomassie Plus assay (Pierce) according to manufacturer 
instructions.         
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Results and Discussion 
 
Our studies suggest that photobleaching can be used to pattern proteins and 
peptides on SiO2, polyester, and glass surfaces.  Photopatterning of anti-M13K07 mAb to 
capacitor surfaces was site-specific, with an achieved spatial resolution below 10 μm 
(Figure 1a-b).  No signal was detected due to photopatterned IgG1 control mAb capture 
of virus, or nonspecific binding of the virus itself, as indicated by mean fluorescence 
output (Figure 1c).  In addition, no secondary antibody fluorescence was detected 
beyond the capacitor regions of the chip, indicating that diffusion of the bleached 
fluorophore did not interfere significantly with site-specific coupling, and that 
nonspecific adsorption was not significant.  Specifically, the average fluorescence from 
10 different non-capacitor regions of the chip was 237 ± 67, which was similar to control 
capacitor values (Figure 1c). 
The fluorescence signal from sandwich immunoassay generated from filament-
coupled anti-M13K07 mAb using photoattachment chemistry was two to three-fold 
higher than signal generated by passively-adsorbed antibodies (Figure 2). The enhanced 
signal could be due to either a.) an initially-higher coupling efficiency using the 
photobleaching technique, and/or b.) greater preservation of bioactivity of photocoupled 
mAb. Although further studies would be required to differentiate between these two 
possibilities, we did observe that photocoupled antibodies appeared to be more tightly-
coupled since successive washes of filament was associated with loss of passively-
adsorbed antibodies but with low loss of photocoupled antibody (data not shown). 
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Figure 1. Light (A) and fluorescence (B) micrographs of a multiplexed capacitive 
biosensor photopatterned with anti-M13K07 monoclonal antibodies and isotype controls, 
with measured fluorescence intensities shown in (C).  Parameters and reagents used for 
photoattachment using a confocal microscope: Cap 1: 30 mW, 50 bleach iterations, anti-
M13K07 photopatterned, Cap 2: 30 mW, 50 bleach iterations, anti-Ms IgG 
photopatterned, Cap 3: 30 mW, 10 bleach iterations, anti-M13K07 photopatterned, Cap 
4: No patterned antibody. (C) Fluorescence intensity measurements of Cy5-anti-
M13K07-incubated sensors, reported as mean ± S.D., n = 3. Bar = 10 μm  
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Figure 2. Schematic of a strategy for photocoupling of antibody to polyester filament (A) 
and resulting sandwich immunoassay Cy5-anti-M13K07 intensities (B). A representative 
filament is overlaid on the graph in (B).   
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Our studies also demonstrated that cell adhesion peptides can be site-specifically 
coupled on tissue culture substratum (Figure 3).  Irradiated PEG-FITC regions (Figure 
3a) promoted fibroblast attachment similar in density and morphology observed on the 
native poly-D-lysine-coated MatTek surface (Figure 3e).  Non-irradiated PEG-FITC 
regions on the same were resistant to cell adhesion (Figure 3b).  The lack of cell 
adhesion in nonirradiated regions was most likely due to the PEG-coating on the surface 
which blocks adsorption of RGDS (Figure 3c) as well as the fibroblasts themselves 
(Figure 3f).  The PEGylation of the surface was found to be important for controlling cell 
attachment, as acetylation of the surface alone was not sufficient (Figure 3d).  Complete 
photobleaching of the entire PEG-FITC surface (from 1 to 3 hours of continuous lamp 
illumination) did not result in cell attachment (Figure 3g-h).  In a separate experiment, 
we demonstrated that attachment of 3T3 cells to PEG-RGDS was most likely due to 
specific peptide-integrin interactions, since competitive inhibition experiments (addition 
of 2 mM soluble RGDS peptide) reduced cell attachment by 82% (Figure 4).     
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Figure 3. Representative micrographs of 3T3 fibroblast attachment on surface engineered 
poly-d-lysine MatTek dishes from 3 trials using PEG-FITC based photoattachment 
diagrammed in (I). Experimental conditions for each substrate: (A) PEG-FITC and 
acetylation, RGDS photopatterned; (B) Same as in (A), but in an area where RGDS was 
not photopatterned; (C) PEG-FITC and acetylation, RGDS passively adsorbed; (D) No 
PEG-FITC, acetylation, RGDS passively adsorbed (cells are rounded); (E) No PEG-
FITC, no RGDS (native surface); (F) PEG-FITC, no acetylation, no RGDS; (G) PEG-
FITC and acetylation, bleached 1 hr prior to cell adsorption, no RGDS; (H) PEG-FITC 
and acetylation, bleached 3 hrs. prior to cell adsorption, no RGDS. Cells in (A) and (E) 
showed similar viability of seeded cells as indicated by trypan blue exclusion (not 
shown). (50X magnification) 
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Figure 4. Competitive inhibition of 3T3 attachment to PEG-RGDS-coated MatTek glass 
bottom dishes.  3T3 cells at a concentration of 1000 cells/mL were incubated with 1 μM 
calcein-AM (Invitrogen) in serum-free DMEM for 20 min. at 37°C and seeded on PEG-
RGDS-coated surfaces in the presence or absence of 2 mM soluble RGDS.  Cells were 
incubated for 4 hrs. at 37°C, 5% CO2, rinsed 3X with Hank’s Balanced Salt Solution, and 
immediately imaged via fluorescence microscopy under FITC imaging settings to analyze 
attached cells.  Viable cells as ascertained by calcein-AM fluorescence were counted in 
10X fields (n = 4) using Image Pro Plus 5.1.Representative 10X fields show a.) 3T3 
attachment onto PEG-RGDS-coated borosilicate glass, and b.) 3T3 attachment in the 
presence of 2 mM soluble RGDS.  Shown on each panel is the mean ± S.D. of calcein-
AM positive 3T3 cells counted within each 10X field, for each experimental condition. 
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The mAb coupling efficiency of photoattachment and chemical crosslinking was 
compared and found to be similar.  The efficiency of photocoupling was measured to be 
3.3 pmol / cm2.  Thiol-maleimide crosslinking, a technique which has long been utilized 
for efficient, facile conjugation of proteins to material surfaces (13), resulted in a higher 
mAb coupling efficiency (4.2 pmol / cm2).  Although the chemical crosslinking technique 
was capable of immobilizing a higher quantity of mAb, further optimization of 
experimental conditions may produce higher yields for visible light photoconjugation, 
such as buffer strength, reaction volume, PEG molecular weight, and reagent 
concentrations.  Furthermore, photopatterning offers control over site specificity of 
coupling, which in itself may warrant its future implementation. 
The light patterning properties of the confocal microscope facilitated the efficient 
photoattachment of antibodies on the biosensor surface.  With a fixed laser intensity (full 
output), the number of bleach iterations within the FRAP software module controlled the 
coupling efficiency of FITC-mAb.  Furthermore, the ROI can be readily defined within 
the software to pattern microscale regions.  The patterning of antibodies upon groups of 
four capacitors was achieved within five minutes, and real-time fluorescence intensity 
measurements within the software confirmed successful photobleaching.  The confocal 
microscope should facilitate the implementation of photoattachment methods in various 
laboratories in biological and biomedical sciences, where they are readily available.  
Since these laboratories often do not have access to cleanroom facilities needed for 
photolithography, photoattachment chemistry may constitute a viable alternative to the 
in-house development of custom molecular and cellular arrays as diagnostic or biological 
study tools.   
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 In addition to extending techniques related to the coupling of dye-conjugated 
biomolecules on surfaces, we also hypothesized that biomaterial substrates could be 
engineered to bear the photoreactive groups, thus obviating the need for bioconjugating 
proteins, a step which can often compromise native function.  Polyethylene glycol (PEG) 
has long been utilized for reducing protein adsorption to biomaterial surfaces, is 
biocompatible, and is amenable to the grafting of functional groups (14).  NHS-PEG-
FITC is a commercially-available heterobifunctional reagent used to detect PEGylation 
efficiency in bioconjugate chemistry, and combines the properties of PEG with the 
bioconjugation moiety NHS (amine-reactive) for immobilization on a variety of 
substrates, as well as a FITC dye, to enable detection of the PEGylated species in vitro or 
ex vivo.  We observed that pipetting an RGDS peptide solution over the PEG-FITC-
functionalized glass substrate, followed by photobleaching of the dye groups, resulted in 
site-specific immobilization of the adhesion peptide, as indicated by fibroblast binding 
exclusively on regions of irradiation (Figure 3a).  Therefore, the use of this reagent in the 
development of biosensor arrays affords the resistance of the coating to nonspecific 
adsorption of proteins.  
 Dye photobleaching generally involves the energy transfer from the dye in the 
excited state to molecular oxygen in the ground state (15-17).  As a result of 
photobleaching, singlet molecular oxygen is produced, leaving the fluorophore with an 
unpaired electron.  While the process of visible light coupling of dye-conjugated species 
has not been completely elucidated, it is possible that the unpaired electron on the dye 
serves as a binding site to an electron-rich substrate.  Our data provide further evidence 
that the photobleached fluorophore as the coupling moiety.  When including 1 mg/mL 
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sodium fluorescein (NaFl) as a free dye in the initial mAb coupling solution, we observed 
a decrease in fluorescence signal from the virus-associated Cy5 secondary antibody, 
indicating that the coupling technique was associated with fluorophore photobleaching 
(Figure 2b).  In previous work, oxygen depletion in the coupling medium was associated 
with significantly-lower photoattachment efficiency (1), which is consistent with our 
report that photobleaching chemistry is essential for the coupling reaction.  Provided that 
photobleaching events drive the coupling of biomolecules onto the surfaces tested in this 
work, it is important to take necessary precautions when carrying out individual 
reactions.  Samples were only exposed to ambient lab light for durations < 5 min., to 
minimize premature photobleaching due to the photolability of fluorescein.   
This work expands upon previous approaches to achieve photopatterning of 
biomolecules, through adapting a confocal microscope to perform automated patterning 
of microscale regions, and by expanding the scope of surfaces which are candidate 
substrates for this technique.  Future work will focus on the controlled 
orientation/deposition of cells on adhesion peptide-patterned surfaces.  Such a feature 
would be useful in the development of arrays which incorporate cells as biosensors, or in 
the synthesis of 3-D tissue constructs, in which hierarchical organization of cells and 
proteins elicit specific cell functions (18).  Our technique features the microscale 
resolution necessary to construct such devices, and nanoscale resolution is potentially 
achievable with this technique, when used in conjunction with techniques to overcome 
diffraction barriers, such as stimulated emission depletion fluorescence microscopy 
(STED) (19, 20).  While fluorescein was used as the coupling moiety in this work, it has 
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been demonstrated that photottachment strategies can be extended toward the patterning 
of multiple dye-labeled species, such as Alexa Fluor-labeled proteins (1).    
 
Conclusion 
 
Our studies have extended the utility of visible light photoattachment chemistry in 
creating biomolecular and/or cellular arrays in well-defined microscale regions on diverse 
substrates.  The method is rapid and can be easily controlled on a spatial and temporal 
scale.  Furthermore, protein activity is retained, and the high-efficiency conjugation of 
proteins using light patterning may facilitate the development of high-sensitivity 
screening platforms.  Additionally, we have shown that a photoreactive substrate can be 
the mediator for photocoupling, eliminating the need for bioconjugation of species prior 
to patterning.  In forthcoming applications which utilize cells as biosensors, this 
technique may be useful for controlling cell orientation and spreading.  This rapid, 
flexible technique is readily accessible and can be implemented in a number of 
biomedical applications.   
 
Acknowledgements 
 
This work was supported in part by the National Institutes of Health (EB003516 
(FRH), T32EY07135 (Jeff Schall, PI) (AJ)) and the Vanderbilt University Discovery 
Grant program.  Confocal microscope-assisted patterning experiments were performed in 
198
  
part through the use of the VUMC Cell Imaging Shared Resource.  We thank Ray 
Mernaugh for helpful discussions. 
 
References 
 
(1) Holden, M. A., and Cremer, P. S. (2003) Light activated patterning of dye-labeled 
molecules on surfaces. J Am Chem Soc 125, 8074-5. 
(2) Sumerel, J., Lewis, J., Doraiswamy, A., Deravi, L. F., Sewell, S. L., Gerdon, A. 
E., Wright, D. W., and Narayan, R. J. (2006) Piezoelectric ink jet processing of 
materials for medical and biological applications. Biotechnol J 1, 976-87. 
(3) Stevens, M. M., and George, J. H. (2005) Exploring and engineering the cell 
surface interface. Science 310, 1135-8. 
(4) Holden, M. A., Jung, S. Y., and Cremer, P. S. (2004) Patterning enzymes inside 
microfluidic channels via photoattachment chemistry. Anal Chem 76, 1838-43. 
(5) Blawas, A. S., and Reichert, W. M. (1998) Protein patterning. Biomaterials 19, 
595-609. 
(6) Clemence, J. F., Ranieri, J. P., Aebischer, P., and Sigrist, H. (1995) 
Photoimmobilization of a bioactive laminin fragment and pattern-guided selective 
neuronal cell attachment. Bioconjug Chem 6, 411-7. 
(7) Balasubramanian, A., Bhuva, B., Mernaugh, R., and Haselton, F. R. (2005) Si-
based sensor for virus detection. Ieee Sensors Journal 5, 340-344. 
(8) Stone, G. P., Lin, K. S., and Haselton, F. R. (2006) Adaptive virus detection using 
filament-coupled antibodies. Journal of Biomedical Optics 11, -. 
(9) Stone, G. P., Mernaugh, R., and Haselton, F. R. (2005) Virus detection using 
filament-coupled antibodies. Biotechnology and Bioengineering 91, 699-706. 
199
  
(10) Stone, G. P., Wetzel, J. D., Russ, P. K., Dermody, T. S., and Haselton, F. R. 
(2006) Autonomous reovirus strain classification using filament-coupled 
antibodies. Annals of Biomedical Engineering 34, 1778-1785. 
(11) DeLong, S. A., Gobin, A. S., and West, J. L. (2005) Covalent immobilization of 
RGDS on hydrogel surfaces to direct cell alignment and migration. J Control 
Release 109, 139-48. 
(12) Wu, Y. X., Masison, D. C., Eisenberg, E., and Greene, L. E. (2006) Application 
of photobleaching for measuring diffusion of prion proteins in cytosol of yeast 
cells. Methods 39, 43-49. 
(13) Hermanson, G. T. (1996) Bioconjugate techniques, Academic Press, San Diego. 
(14) Tessmar, J. K., and Gopferich, A. M. (2007) Customized PEG-derived 
copolymers for tissue-engineering applications. Macromol Biosci 7, 23-39. 
(15) Gaigalas, A. K., Wang, L., Cole, K. D., and Humphries, E. (2004) 
Photodegradation of fluorescein in solutions containing n-propyl gallate. Journal 
of Physical Chemistry A 108, 4378-4384. 
(16) Song, L., Hennink, E. J., Young, I. T., and Tanke, H. J. (1995) Photobleaching 
kinetics of fluorescein in quantitative fluorescence microscopy. Biophys J 68, 
2588-600. 
(17) Song, L., Varma, C. A., Verhoeven, J. W., and Tanke, H. J. (1996) Influence of 
the triplet excited state on the photobleaching kinetics of fluorescein in 
microscopy. Biophys J 70, 2959-68. 
(18) Albrecht, D. R., Underhill, G. H., Mendelson, A., and Bhatia, S. N. (2007) 
Multiphase electropatterning of cells and biomaterials. Lab Chip 7, 702-9. 
(19) Willig, K. I., Harke, B., Medda, R., and Hell, S. W. (2007) STED microscopy 
with continuous wave beams. Nat Methods. 
(20) Willig, K. I., Kellner, R. R., Medda, R., Hein, B., Jakobs, S., and Hell, S. W. 
(2006) Nanoscale resolution in GFP-based microscopy. Nat Methods 3, 721-3. 
 
 
200
